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Class Switch Recombination (CSR) is the mechanism responsible for antibody isotype 
differentiation in mature B-lymphocytes and it is required for the establishment of an 
efficient immune response. CSR is a deletional somatic reaction that replaces the gene 
encoding for the  constant region (donor) of the immunoglobulin heavy chain (Igh) with 
one of the several downstream constant genes (acceptor) within the same locus. 
Consequently, a B cell switches from expressing an antibody molecule of the IgM class 
to one of the other isotypes (IgG, IgE or IgA), which have the same antigen specificity 
but different effector function. At the molecular level, CSR occurs between donor and 
acceptor repetitive DNA elements, the so-called switch (S) regions that precede each 
constant gene. Upon antigen encountering, B cells proliferate and undergo cytokine 
stimulation that induces germ-line transcription (GLT) at the Igh locus. This process 
leads to non-coding transcripts and the exposure of single strand stretches of DNA, 
which are the substrate for the B cell specific enzyme AID (activation-induced cytidine 
deaminase). AID enzymatic activity generates U:G mismatches that are eventually 
converted into DNA double-strand breaks (DSBs). DSBs in donor and acceptor S regions 
are then directly ligated by the classical non-homologous end-joining pathway (c-NHEJ), 
leading to antibody isotype differentiation. Structurally, the Igh locus comprises 250 kb 
and contains two enhancers, E and the 3’RR (3’ Regulatory Region). While E is 
essential during early stages of B cell development, the 3’RR controls antibody isotype 
differentiation. Altogether, CSR is a complex physiological process that involves the 
formation and repair of DSBs through different molecular mechanisms that have not 
been fully elucidated yet. For example, it has been shown that the 3’RR is required for 
GLT and therefore CSR but how the enhancer activity is regulated is still unknown. 
Therefore, the aim of this study was to identify and characterize novel CSR factors that 
play a role in any of these mechanisms, contributing to the establishment of an efficient 
immune response. To do so, a functional loss-of-CSR screen was set-up and performed 
in the CH12 lymphoma B cell line that can undergo antibody isotype differentiation to IgA 
in vitro with high efficiency. Specifically, potential 53BP1 and RIF1 interactors were 
somatically targeted by CRISPR/Cas9, since these two factors play a key role during 
CSR. In this study, the chromatin reader ZMYND8 was found to regulate GLT and CSR 
by binding and modulating the transcriptional activity of the 3’RR at the Igh locus. 
Moreover, PDAP1 was independently identified as a novel factor required for efficient 
CSR by modulating Aicda (AID) mRNA levels. Conclusively, the results of this thesis 
contributed to further understand the processes regulating antibody isotype 




Als Klassenwechsel (class switch recombination, CSR) bezeichnet man den 
Mechanismus der Antikörper-Isotyp-Differenzierung in ausgereiften B-Lymphozyten. Er 
wird für den Aufbau einer effizienten Immunantwort benötigt. CSR ist eine löschende, 
somatische Reaktion, welche das Gen für die konstante Domäne  (Spender) der 
schweren Kette des Immunoglobulins (immunoglobulin heavy chain, Igh) ersetzt. Dabei 
erfolgt der Austausch mit einem von mehreren, strangabwärts gelegenen Genen 
(Akzeptor) im selben Lokus. Dadurch wechselt eine B-Zelle von der Expression eines 
Antikörpermoleküls der IgM-Klasse zu einer der anderen Isotypen (IgG, IgE oder IgA). 
Diese haben dieselbe Spezifität, jedoch eine andere Effektorfunktion.  
Auf molekularer Ebene findet der Klassenwechsel zwischen Spender und Akzeptor 
repetitiver DNS-Elemente statt. Diese befinden sich in der Switch-Region (S), welchen 
sämtlichen konstanten Genen vorangeht. Wenn B-Zellen auf Antikörper treffen, 
vermehren sie sich und es erfolgt eine Stimulation durch Zytokine, welches eine 
Transkription der Keimbahn (germline transcription, GLT) am IgH Lokus hervorruft. Dies 
führt zu nicht-kodierenden Transkripten und dem Offenlegen von Einzelsträngen der 
DNS. Diese sind die Bindestellen für das B-Zellen-spezifische Enzym AID (activation-
induced cytidine deaminase). 
AID Enzymaktivität erzeugt U: G Basenpaarfehler, welche zu DNS-Doppelstrangbrüche 
(DNA double-strand breaks, DSBs) umgewandelt werden. DSBs in Spender und 
Akzeptor S-Regionen werden direkt durch den klassischen non-homologous end-joining 
(c-NHEJ) Pfad repariert, welcher zur Differenzierung der Antikörper-Isotypen führt. 
Strukturell besteht der Igh-Lokus aus 250 kB und enthält zwei Enhancer, E und 3'RR 
(3' regulatorische Region). Während E essentiell für die frühen Phasen der B-
Zellenentwicklung, kontrolliert 3'RR die Differenzierung der Antikörper-Isotypen. 
Zusammengenommen ist CSR ein komplexer, physiologischer Prozess, welcher die 
Formation und Reparatur von DSBs umfasst. Die verschiedenen molekularen 
Mechanismen, welche daran beteiligt sind, sind noch nicht vollständig verstanden. 
Beispielsweise wurde gezeigt, dass 3'RR benötigt wird für GLT und dadurch CSR. Wie 
diese Enhancer-Aktivität reguliert wird, ist jedoch noch unbekannt. Daher war das Ziel 
dieser Studie die Identifikation und Charakterisierung neuer CSR-Faktoren, welche 
diese Mechanismen beeinflussen und zum Aufbau einer effizienten Immunantwort 
beitragen. 
Dafür wurde ein Testverfahren für einen funktionalen Verlust von CSR aufgebaut und 
durchgeführt in CH12 Lymphoma B-Zellen welche die Differenzierung von Antikörper-
Isotypen nach IgA in-vitro mit hoher Effizienz vollziehen können. Insbesondere wurden 
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potentielle 53BP1 und RIF1 Interaktoren somatisch untersucht durch CRISPR/Cas9, da 
diese beiden Faktoren eine Schlüsselrolle während CSR spielen. In dieser Studie wurde 
herausgefunden, das ZMYND8 GLT und CSR reguliert, indem es 3'RR am IgH bindet 
und moduliert. Außerdem wurde PDAP1 unabhängig als neuer Faktor, welcher für 
effiziente CSR benötigt wird durch Modulierung von Aicda (AID) mRNA-Leveln.  
Zusammenfassend tragen die Ergebnisse dieser Arbeit zum weiteren Verständnis der 





















1.1 The immune system 
 
Mammals have evolved a highly complex and effective immune system in order to 
protect their organism against foreign pathogens, allergens and toxins. Specifically, the 
immune system presents innate and adaptive mechanisms to elicit a response. The 
innate immune system is the first line of defense against antigens and it is characterized 
by the presence of germline encoded membrane-bound receptors and cytoplasmic 
proteins that recognize common microbial patterns, known as pathogen-associated 
molecular patterns (PAMPs)1. On the other hand, the adaptive immune system is 
constituted by lymphocytes (B and T cells) bearing antigen specific receptors generated 
by somatic recombination or gene rearrangement2. These antigen specific cells can 
persist in the body in order to mount a rapid and robust immune response upon future 
infection with the same pathogen, a process called immunological memory3. Importantly, 
the two systems are coordinated: while the innate system is rapidly activated upon 
pathogen encountering, the adaptive system is effective at a later stage because it 
requires time to generate and expand antigen specific cells that can effectively neutralize 
it. Moreover, components of the innate response contribute to the activation of 
lymphocytes, which can in turn make use of the innate mechanisms to mediate their 
effector function. Importantly, the innate and adaptive systems are tightly regulated in 
order not to recognize self-antigens that would lead to autoimmune diseases upon 
degradation4. Therefore, the function, modulation and synchronization of adaptive and 
innate mechanisms are crucial for the establishment of effective immune responses.         
 
1.2 B-lymphocytes and antibody structure 
 
B cells are a central component of the Adaptive Immune System due to their potential to 
produce antigen-specific antibodies with effector function. Immunoglobulins (Igs) are 
roughly Y-shaped molecules composed of two identically heavy (IgH) and two identical 
light (IgL) polypeptide chains bound by disulfide bridges. Each of these chains present a 
variable region that is responsible for recognizing and binding the antigen, and a constant 
part (Figure 1.1)5,6. The variable region is codified by variable (V), diversity (D) and 
joining (J) genes that get rearranged through a process called V(D)J recombination 
during B cell development to generate functional antibodies with different antigen 
specificities. This process is mediated by recombination activating genes-1 and -2 
(RAG1 and RAG2) that recognize specific sequences called recombination signals 
(RSS). Rearrangements always occur in between two gene segments flanked by RSS7. 
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In humans, V(D)J recombination has been reported to produce at least 1016 antibody 
variants8. Igs further diversify over the course of an immune response due to 
physiological point mutations of the variable regions by somatic hypermutation (SHM), 
leading to the full antibody repertoire. On the other hand, the constant part of the heavy 
chain (CH) determines isotype of the Ig, conferring diverse effector properties like 
activation of the complement (group of plasma proteins that are part of the innate system 
and participate in the immune response)  or binding to Fc receptors5,6. Initial studies of 
the antibody structure described different fragments that were observed upon IgG1 
digestion with the enzyme papain:  Fab or antigen binding fragment, comprising IgL and 
the variable region plus the first constant domain of IgH, and Fc or crystallizable fragment 
that includes the rest of CH and can be easily crystalized (Figure 1.1)9.  
 
Figure 1.1. Antibody structure.  
Schematic representation of the antibody structure as a monomer. The heavy chain (shown in 
green) and the light chain (colored in blue) are bound by disulfide bridges, indicated in red (S). 
Both chains exhibit a variable region (VL and VH) that determines the antigen specificity and a 
constant (CL and CH) part, which confers effector functions. Fab (antigen binding fragment) and 
Fc (crystallizable fragment) are indicated. 
 
Importantly, humans and mice present five isotype classes: IgM, IgD, IgG, IgA and IgE. 
Moreover, IgG is divided in four subclasses that are different in both species, as human 
IgGs are IgG1, IgG2, IgG3 and IgG4 and murine IgGs are IgG1, IgG2a, IgG2b and IgG3. 
IgA can be found as IgA1 or IgA2 in humans. The vast majority of B-lymphocytes initially 
co-express IgM and IgD in their plasma membrane but antigen exposure leads to 
antibody isotype differentiation to IgG, IgA or IgE by a process called class switch 
recombination (CSR)10,11. At the molecular level, this change occurs at the constant 
region of the IgH and, therefore, antigen specificity remains the same upon isotype 
switching. IgM is the first Ig expressed as a monomer on the surface of 
naïve/unstimulated B cells and it is secreted as a pentamer during an immune response 
to opsonize the antigen and to activate the complement. IgD is also present in naïve B-
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lymphocytes and its effector function is mostly unknown. Monomeric IgG is the most 
abundant isotype found in the body, constituting 75% of the serum Igs. Although the 
different subclasses exhibit distinctive functional affinities and exist in different ratios, 
they are all important to fix the complement and to neutralize virus and toxins. IgA is 
majorly found in mucosal areas of the body as a dimer, where it prevents bacterial and 
viral infection. Lastly, IgE is the least abundant Ig but has a strong effector function in 
allergic reactions and during worm parasite invasions5,11.  
Conclusively, before antigen encountering IgM/IgD B-lymphocytes present a pre-
immune repertoire generated by V(D)J recombination. During an immune response, the 
secondary diversification mechanisms SHM and CSR lead to the formation of antibodies 
with increased antigen affinity and different effector functions, respectively. 
 
1.2.1 Murine immunoglobulin heavy chain 
The IgH is codified by the Immunoglobulin heavy chain locus, Igh, that expands over 28 
Mb within the chromosome 12 in mice. Mature B cells express only one of the two Igh 
alleles on their surface, by a process known as allelic exclusion that prevents from 
showing two heavy chains with different antigen specificity within the same cell12. 
Moreover, B-lymphocytes exhibit a variable region resulting from the rearrangement of 
one VH, one DH and one JH gene segments. Mice have 195 VH gene segments classified 
in 16 families based on their sequence homology. Downstream VH, twelve DH and four 
JH gene segments can be found13,14. Specifically, one DH and one JH gene segments are 
rearranged first during VDJ recombination in both Igh alleles. Next, a VH gene segment 
is joined to the recombined DH-JH sequence in one of the alleles, exclusively. If the newly 
formed VH-DH-JH exon is non-functional the second allele gets recombined15. Following 
the variable region in the Igh locus, there is an enhancer element called Eμ that is crucial 
for supporting efficient Igh expression, VDJ recombination and early B cell 
development16–19.  Then, the constant part (CH) follows, consisting of seven different 
transcription units conformed by a cytokine-inducible promoter, an intervening exon (I-
exon), an highly repetitive intronic switch (S) region and a constant gene segment (C) 
(Figure 1.2)20. Importantly, IgD results from alternative splicing of a long primary 
transcript containing both Cμ and Cδ genes21. Additionally, the 3’ regulatory region 
(3’RR) is a super-enhancer localized downstream Cα, the last constant gene. This 
element is conformed of four DNase I hypersensitive sites (hs) and is required for late B 
cell differentiation, CSR and SHM22–27 (see section 1.6). The 3’RR is followed by 
additional hs regions (hs5-8) (Figure 1.2). Lastly, a putative enhancer element, E, has 
been identified in between Cγ1 and Sγ2b in developing B cells28–30. Although its function 
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in mature B cells has not been characterized yet, recent literature showed that this 
enhancer is required for efficient Igh transcription and CSR to some isotypes31. 
 
 
Figure 1.2. The murine immunoglobulin heavy chain locus (Igh). 
Scheme representing the structure of the murine Igh locus (not in scale). The variable region 
comprises VH, DH and JH gene segments. The constant region has independent transcription units 
(shown in black) that consist on an intervening exon (I), a highly repetitive element (switch region, 
S) and a constant gene (Cμ, Cδ, Cγ3, Cγ1, Cγ2b, Cγ2a, Cε, Cα). The Igh locus exhibits two 
enhancer elements, Eμ and the 3’ Regulatory Region (3’RR), shown in dark grey. The 3’RR is 
followed by additional DNase I hypersensitivity sites (hs 5-8). 
 
1.2.2 Murine immunoglobulin light chain 
Whereas IgH is codified by a single locus, IgL can result from two independent loci, the 
kappa (Igκ) or the lambda (Igλ) locus. As in the case of the Igh locus, allelic exclusion 
leads to the expression of only one allele of either Igκ or Igλ on the surface of mature B-
lymphocytes15. Of note, human and murine B cells greatly differ in their expression of Igκ 
versus Igλ, as humans present a ratio of 1.5:1 of Igκ to Igλ and mice have a ratio of 
19:132. 
 
The murine Igκ locus (chromosome 6) has a variable region with more than 100 Vκ 
segments that, as in the case of VH, can be classified in different families. Directly 
downstream, there are five Jκ regions followed by one Cκ that is located in between two 
enhancer regions: Eiκ (intronic kappa enhancer) and 3’Eκ (3’ kappa enhancer) (Figure 
1.3). Importantly, several of the Vκ murine genes can be found in opposite transcriptional 
orientation to their associated Jκ-Cκ segments33. As a consequence of this orientational 
structure of the κ locus, a primary rearrangement of one Vκ with a Jκ does not result in 
the deletion of the gene segments that are in between. If this first recombination is 
unproductive or results in a self-reactive B cell receptor (BCR), further rearrangements 
can take place, since there are additional Vκ segments available. When all recombination 
possibilities are exhausted, the other κ locus in the second chromosome gets rearranged 
and, upon failure, the λ chain gets ultimately recombined. Moreover, another element in 
the κ locus, the recombining segment (RS), plays an important role in this sequential 
rearrangement. Specifically, it recombines with sequences bearing a specific motif that 
is present within the Jκ-Cκ intron and in the RSS (recombination signal sequences 
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recognized by RAG) located at the 3’ of Vκ. As a consequence of this recombination, the 
first κ locus is discarded and rearrangement starts in the other locus15,33. 
 
 
Figure 1.3. The murine immunoglobulin light chain loci (Igκ and Igλ). 
Schematic diagram of the murine Igκ (up) and Igλ (down) loci. The Igκ locus has a variable region 
followed by a constant part that includes one constant gene segment (Cκ, black) surrounded by 
two enhancer regions, Eiκ and 3’Eκ (dark grey). RS (recombination segment). The Igλ locus is 
configured in two Vλ-Jλ-Cλ clusters. Constant gene segments are depicted in black. There are two 
enhancer elements, located downstream each cluster (Eλ2-4 and Eλ3-1, dark grey).  
 
In mice, the Igλ locus is found in chromosome 16 and in the case of C57BL/6 it is 
organized in two Vλ-Jλ-Cλ clusters that present the same transcription orientation. 
Specifically, two Vλ gene segments associate with two functional Jλ-Cλ gene pairs and 
the third Vλ gene is joined to a second Jλ-Cλ cluster consisting of two Jλ and two Cλ 
(Figure 1.3). Rearrangement happens within the clusters and not in between them and 
each cluster is flanked by a downstream enhancer (Eλ2-4 and Eλ3-1, lambda 2-4 and 
lambda 3-1 enhancers, respectively)33. 
 
1.3 Murine B cell development 
 
B-lymphocytes derive from hematopoietic stem cells (HSCs) that are self-renewing and 
multipotent cells found in the fetal liver and in the bone marrow (BM) after birth. There 
are two distinct B cell populations: B-1 and conventional B-2 lymphocytes. B-1 cells 
mainly originate from the fetal liver and are involved in protecting the organism against 
self-antigens. On the other hand, B-2 cells principally derive from the BM and participate 
in the adaptive immune response34.  In the BM, these B-2 lymphocytes can be induced 
to differentiate into multipotent progenitor cells (MMPs), which lack the self-renewing 
capability but can still give rise to all lineages of a tissue or organ. Next, MMPs generate 
common lymphoid (CLPs) and common myeloid (CMPs) progenitor cells. CMPs are the 
precursors of erythrocytes, megakaryocytes, granulocytes and macrophages and CLPs 
lead to B and T lymphocytes and natural killer (NK) cells35. Specifically, during B cell 
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maturation, CLPs differentiate into pre-progenitor B cells (pre-pro-B cells), which are 
characterized by the expression of the markers CD45R/B220 and CD43 on their surface 
and have germline Ig genes. Next, progenitor B cells (pro-B) cells express the marker 
CD19 together with CD45R/B220 and present rearranged DH-JH gene segments in their 
Igh loci that express a μ chain. Pro-B cells also express immunoglobulin-α, -β and 
calnexin proteins, which are signaling components that associate with the BCR in mature 
B cells. At the precursor stage, pre-B cells become CD43- and finalize VH-DH-JH 
recombination in one of the Igh alleles, which associates with the so called “surrogate 
light chain” (SLC)36–38. Therefore, expression of Igμ and its binding to the SLC, Igα and 
Igβ lead to the generation of the pre-BCR (pre-B cell receptor) that is presented on the 
surface of pre-B cells. If the newly recombined IgH chain successfully pairs with the SLC, 
pre-B cells continue to rearrange the V and J gene segments of their IgL chains, leading 
to the replacement of the SLC with an Igκ or Igλ chain and assembly of the pre-BCR. 
When this pre-BCR results non-functional or autoreactive, further recombination events 
can occur to substitute it and this process is known as receptor editing. Upon failure to 
rearrange and express a productive pre-BCR, autoreacting pre-B cells undergo 
apoptosis and are negatively selected. On the other hand, when recombination and 
pairing of Igh and Igl chains are successful, an IgM antibody is expressed on the surface 
of B cells that are known as immature B-lymphocytes37,38. Importantly, the newly formed 
non-autoreactive BCR expressed in immature B cells needs to achieve a signaling 
threshold in order for differentiation to continue. This process is known as positive 
selection, determines the survival of B-lymphocytes in the periphery and it is mainly 
mediated by the binding of BAFF (B-cell activator of the TNF-α family) to its receptor 
(BAFF-R)12,15,36. Immature B-lymphocytes exit the BM and migrate to the spleen, where 
they develop in a stepwise manner. Consequently, 3 independent populations known as 
transitional 1, 2 and 3 (T1, T2 and T3) can be distinguished based on their surface 
expression of CD23 and IgM: T1 are IgMhigh and CD23-, T2 are IgMhigh and CD23+ and 
T3 are IgMlow and CD23+. Importantly, IgD is co-expressed with IgM during late 
transitional stages as a result of alternative splicing of the Igh transcript. Immature B cells 
express high levels of IgM, while mature naïve B cells present increased IgD and 
reduced IgM levels39. In the spleen, immature transitional B-lymphocytes differentiate 
into naïve follicular (FO) or marginal zone (MZ) B cells which can be phenotypically 
distinguished by their surface expression of IgD, CD21 and CD23: MZ are IgDlow CD21+ 
CD23- and FO are IgDhigh CD21- CD23+. Splenic MZ B-lymphocytes rapidly participate in 
the immune response upon infection independently of their interaction with T cells by 
secreting IgM molecules and ultimately differentiating into short-lived plasma cells 
(SLPCs)40–42. Within the follicles of secondary lymphoid organs, mature naïve B cells can 
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mediate a T cell dependent response to pathogenic infection. Specifically, they can be 
found in anatomically distinguishable functional compartments known as germinal 
centers (GCs) that are formed roughly 1 week after antigen encountering43. There, B 
cells undergo SHM to further diversify the B cell repertoire, cell proliferation, and affinity 
maturation, which is a process that mediates the selection of clones that present the 
highest affinity for the antigen. Moreover, GC is the place where CSR takes place and 
GC murine B cells are phenotypically characterized by the expression of CD95/Fas and 
the downregulation of CD38. Highly antigen-specific class-switched B-lymphocytes exit 
the GC as plasmablasts (PB) that are the precursors of antibody-secreting plasma cells. 
Importantly, commitment to the plasma cell lineage takes place already in the GC, when 
B cells express BLIMP-1 (B-lymphocyte-induced maturation protein-1, codified by Prdm1 
gene) that acts as a transcriptional repressor controlling B cell identity. Memory B-
lymphocytes also result from a GC reaction and will rapidly differentiate into long-lived 
plasma cells (LLPCs) or re-enter the GC for further diversification upon re-encountering 
the same antigen. Finally, these non-dividing long-lived plasma cells migrate back to the 
BM, where they locate in specialized niches (Figure 1.4)40,43,44. 
 
 
Figure 1.4. Murine B cell development. 
Diagram depicting the different stages of B cell maturation in the bone marrow (up) and in the 
spleen (bottom). HSC, hematopoietic stem cell; MMP, multipotent progenitor; CLP, common 
lymphoid progenitor; pre-pro-B, pre-progenitor B cell; pro-B, progenitor B cell; pre-B, precursor B 
cell; SLC, surrogate light chain; pre-BCR, pre-B cell receptor imm. IgM+, immature IgM positive; 
T1, T2, T3, transitional B cell populations; FO, follicular; MZ, marginal zone; SLPC, short-lived 
plasma cell; GC B, germinal center B cell; SHM, somatic hypermutation; CSR, class switch 
recombination; mem. B, memory B cell; PB, plasmablast; LLPC, long-lived plasma cell. IgM and 
IgD antibody molecules are shown in blue and green, respectively. Surface markers are indicated 





1.4 Somatic hypermutation (SHM) 
 
In order to increase antigen specificity, GC B cells undergo SHM, a process that 
generates single base mutations as well as stochastic base insertions or deletions in the 
variable regions of IgH and IgL chains. SHM occurs at a frequency of 10-5 to 10-3 per bp 
per generation in mice and can be detected from 150-200 bp downstream the IgV 
promoter up to 1.5-2 kb in the rearranged variable region, including the 3’ intron before 
the C part45. Mutations do not happen in a random manner, as there is a preferential 
“hotspot” or conserved sequence RGYW/WRCY (W = A/T, R = A/G, Y = C/T) that is 
recognized by the enzyme AID (activation-induced deaminase)46–49. AID is exclusively 
expressed in activated B-lymphocytes and deaminates cytosine (C) to uracil (U) bases 
in single-stranded DNA (ssDNA)47,50–52 (Figure 1.5). Although AID functions during CSR 




Figure 1.5. Somatic hypermutation. 
SHM occurs within the V(D)J region of the heavy and light chains. AID (shown in yellow) 
enzymatic activity leads to the deamination of cytosine (C) to uracil (U). U:G mismatches are then 
processed by DNA replication or base excision repair (BER) and mismatch repair (MMR) 
pathways, leading to transition (C:G to T:A) and transversion (C:G to G:C or A:T) mutations. 
 
Specifically, during SHM there are three possible processes that can happen. First, U 
may remain in the DNA and act as a template for the incorporation of adenine (A) in the 
newly synthetized strand during DNA replication, leading to a transition mutation from 
C:G (guanine) to T (timine):A. Alternatively, U can be recognized by UNG (uracil DNA-
glycosilase) or by MSH2/MSH6 (homologue of bacterial MutS 2/6) proteins54–57. UNG 
activity catalyzes the removal of U, which generates an abasic site that is recognized by 
APE2 (apurinic/apyrimidinic endonuclease 2) and subsequently repaired by the BER 
(base excision repair) pathway. However, mutagenic repair often happens following 
UNG activity in AID target spots where the removal of U leads to a non-template site that 
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can be filled in by polymerases. During SHM, REV1 and polη mediate DNA synthesis 
and catalyze transversion (from C:G to G:C and A:T) or transition mutations (from C:G 
to T:A), respectively. Of note, most A:T mutations happening in SHM are dependent on 
MSH2/MSH6 and EXO1 (exonuclease 1) proteins, which are part of the MMR (mismatch 
repair) pathway. As in the case of BER, a non-canonical version of this MMR pathway 
functions upon AID targeting, and EXO1 activity resects the DNA generating a gap, 
which is filled by polη and other low-fidelity polymerases that ultimately introduce 
mutations54–57. The reason why mutagenic versions of these physiological DNA repair 
mechanisms function during SHM is yet to be discovered. Moreover, the factors and 
molecular processes regulating AID targeting are still being investigated.  
 
1.5 Class switch recombination (CSR) 
 
CSR is a deletional somatic recombination process that replaces the constant μ region 
(Cμ), which is expressed in mature naïve B cells, with one of the downstream constant 
genes, thus altering the antibody molecule’s effector function without affecting its 
specificity. At the molecular level, CSR occurs between internally repetitive DNA 
elements that precede each constant gene, the so-called switch (S) regions. CSR is 
initiated by cytokine stimulation that promotes cell proliferation and germline transcription 
(GLT) across the switch regions and constant genes. This process creates stretches of 
ssDNA that are ideal substrates for the B cell specific enzyme AID. As in SHM, AID 
activity generates U:G mismatches. However, during CSR, these mismatches eventually 
lead to double-strand breaks (DSBs) formation within the switch regions during the G1 
phase of the cell cycle. DNA damage response (DDR) factors are then recruited to 
mediate the productive ligation of DSBs in Sμ and one of the downstream S regions by 
classical non-homologous end-joining (c-NHEJ), a DSB repair process that directly 
ligates broken ends after minimal DNA end processing (Figure 1.6). Therefore, CSR is 
a multistep process that involves the formation and repair of DSBs at the Igh locus. 
These steps are explained in detail below. 
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Figure 1.6. Class switch recombination steps. 
Diagram of antibody isotype differentiation to IgG1. anti-CD40 or LPS and IL-4 cytokine 
stimulation induces germline transcription across donor (Sμ) and acceptor (Sγ1) switch regions. 
As a result, Aicda gene gets transcribed and AID is recruited to the S regions through RNA 
polymerase II and SPT5, generating U:G mismatches that are eventually converted into DSBs. 
DSBs in the donor and acceptor S regions are repaired by classical non-homologous end-joining 
(c-NHEJ), leading to CSR to IgG1. Intervening sequence is looped out as a circular 
extrachromosomal DNA (excised circle). 
 
1.5.1 Germline transcription (GLT) 
GLT defines the process of transcription across the individual units that are present in 
the C part of the Igh locus, from the cytokine-inducible promoter located 5’ of the I-exon, 
through the repetitive S region until the 3’ of the constant gene. As a result, unprocessed 
germline transcripts (GLTs) are generated, which are then spliced and polyadenylated, 
leading to processed/mature products. Transcription happens constitutively across Sμ, 
also known as the “donor” region and it is induced in a cytokine-dependent manner in 
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the “acceptor” elements (Sγ1, Sγ3, Sγ2a, Sγ2b, Sε, Sα).  Importantly, GLTs do not code 
for any protein, but their induction in the acceptor region is directly related to antibody 
differentiation to specific isotypes20,58. In vivo, CSR can occur in a T cell-dependent (TD) 
or -independent manner (TI). TD CSR is mediated by the interaction of CD40, which is 
present on the surface of B-lymphocytes, with CD40 ligand (CD40L) that is expressed 
by T cells. On the other hand, TI CSR is induced by bacterial or viral antigens that 
crosslink the BCR and stimulate toll-like receptors (TLRs) in B cells. Both TD and TI 
responses can be mimicked in vitro by treatment with anti-CD40 antibodies or with 
bacterial lipopolysaccharide (LPS), respectively. Specifically, LPS can bind to TLR4 
through its lipid A moiety and to the BCR through its polysaccharidic domain. 
Furthermore, in vitro B cell culturing with different cytokines’ combinations recruit 
transcription factors and induce GLT in specific acceptor regions that result in CSR to 
particular isotypes, mimicking TI and TD responses59. Consequently, LPS leads to Sγ2b 
and Sγ3 transcription and subsequent CSR to IgG2b and IgG3, respectively. LPS or anti-
CD40 and IL-4 (interleukin-4) stimulate Sγ1 and Sε GLT and expression of IgG1 and IgE 
on the surface of B-lymphocytes60–63 TGFβ (transforming growth factor β) activates 
downstream target proteins that bind the promoter of Sα and Sγ2b, regulating antibody 
isotype differentiation to IgA and IgG2b64–66. IL-5 (interleukin-5) has been shown to 
increase IgA switching together with LPS and TGFβ67,68. Importantly, IL-4 and IL-5 are 
cytokines secreted by T cells that activate tyrosine kinase cascades, controlling gene 
expression, viability and proliferation. Similarly, IFN-γ (interferon-γ) is produced by T 
cells and binds to its receptor to induce signaling and transcription, stimulating the 
production of Sγ2a and IgG2a isotype differentiation69. Lastly, BAFF (B cell activating 
factor of the TNF-f family) supports proliferation and intracellular signaling and has been 
reported to enhance CSR to IgA and IgG2b67.  
 
1.5.2 AID function in CSR 
Importantly, cytokines are not only required to induce GLT during CSR, but also Aicda 
gene transcription that peaks at around 48 h post-activation (see section 1.8.2)10. 
Although S regions differ in sequence in length (1-12 kb), they are G-rich and contain 
recurring DNA motifs including hotspots for AID targeting, leading to multiple deaminated 
U bases in both DNA strands57,70,71. These hotspots are enriched in the central part of S 
regions and become infrequent in the 5’ and 3’ extremes. As in SHM, U residues are 
removed from the DNA by UNG, generating an abasic site. During CSR, this abasic site 
is recognized by the apurinic/apyrimidinic endonuclease-1 APE1, which generates a nick 
or single strand break (SSB). The formation of a proximal additional nick on the opposite 
strand leads to a DSB. Since AID hotspots are less frequent outside the core of S 
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regions, there is a decreased probability of forming DBSs and mainly SSBs are present. 
In this case, MSH2/MSH6 bind U:G mismatches that are neighboring those SSBs and 
recruit the exonuclease EXO1 that excises the DNA from the closest 5’ SSB to the 
mismatch, leading to the formation of a DSB with a 5’ overhang. Importantly, most of the 
DSBs created within the S regions contain overhangs, which should be processed into 
blunt ends in order to allow for efficient ligation of two independent regions. This can be 
done by exo- or endo-nucleases that resect ssDNA and the subsequent activity of 
polymerases that fill-in the gap10,20,71.   
 
1.5.3 AID targeting to S regions 
Although the precise molecular mechanism by which AID access the S regions is still not 
fully elucidated, there are several hypotheses described in literature and there is a clear 
link in between GLT and AID targeting. First, transcription across the S regions exposes 
stretches of ssDNA, which are the substrates of AID. Moreover, GLTs are G-rich and 
can form a R-loop (RNA:DNA hybrid) with the non-template strand. As a consequence, 
the top/template strand of the DNA becomes accessible for AID targeting. Importantly, 
AID has been shown to equally deaminate both strands in vivo but transcription across 
the S regions has only been observed in one direction, creating controversy in these 
models70,72. However, recent data uncovered a novel role for the core RNA exosome 
complex, which associates with AID during CSR and degrades the transcript RNA 
associated to the template strand, resulting in the exposure of stretches of ssDNA73. 
Furthermore, although GLT splicing is essential for efficient CSR to happen, the reason 
for this is yet to be discovered. Since splicing happens co-transcriptionally, it is possible 
that the splicing machinery contributes to AID targeting or that it is required for R-loop 
formation74. Moreover, AID has been shown to bind G-quadruplex-like RNA structures, 
formation of which depends on the nucleotide sequence. Interestingly, the spliced-out 
intronic S region of GLTs that is G-rich can fold into a G-quadruplex configuration, which 
interact with soluble AID. AID-RNA complexes can bind the S regions because of the 
complementarity of the G-quadruplex and its template strand. Alternatively, and 
considering the existence of R-loops due to GLT, it is also possible that transcripts are 
processed and released but part of the spliced-out intronic S region remains conforming 
the DNA:RNA hybrid. These parts that do not anneal with the DNA could then form G-
quadruplex structures that recruit AID58,75. 
Additionally, RNA polymerase II (RNAPII) is stalled at S regions, possibly due to R-loop 
formation. Stalled RNA polymerase II (RNAPII) interacts with SPT5 (suppressor of Ty 5 
homolog), which also associates with AID in B cells undergoing CSR. Induction of Us 
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resulting from AID function are enriched within the 5’ end of S regions, leading to the 
conclusion that AID is recruited to RNAPII during transcription initiation or early 
elongation76. Interestingly, AID phosphorylation at serine-38 (S38) supports its 
interaction with APE1, which is recruited to the DNA and amplifies the density of DSBs77. 
This AID post-translational modification also mediates its association with RPA, which 
binds to and stabilizes stretches of ssDNA, favoring AID targeting and the recruitment of 
DSB repair factors78–80.  
An additional requirement for AID targeting is DNA accessibility, which is determined by 
specific histone modifications at the Igh locus. Sμ donor region has a constitutively 
poised state, exposing H3K4me3 and H3K9ac marks that increase upon B cell 
activation. Contrary, constant and acceptor S regions are inaccessible, exhibiting 
repressive chromatin modifications like H3K36me3 and H4K20me1 (constant regions) 
H3K9me3 and H3K27ac (acceptor S regions)81–84. Cytokine stimulation determines 
which specific acceptor S region will be transcribed, promoting the removal of these 
repressive marks and inducing H3K9ac, H3K14ac, H3K27ac, H4K8ac and H3K4me3. A 
major regulator in this process is PTIP (pax interaction with transcription-activation 
domain protein-1), a component of the mixed-lineage leukemia-like (MLL) 
complexes85,86. Specifically, PTIP recruits histone methyltransferases that catalyze the 
formation of H3K4me3. Moreover, R-loops generated during CSR accumulate 
combinatorial H3K9ac and H2S10 phosphorylation (H3K9AcS10ph), which can be 
recognized by 14-3-3 adaptor proteins. Importantly, 14-3-3 factors show scaffold 
functions and have been shown to recruit AID to the S regions87. AID targeting is 
additionally supported by the H3K9me3 mark, which is present in naïve B cells and is 
retained at low levels in Sμ region upon stimulation. Although this histone modification 
is characteristic of a repressive sate, it tethers the KAP1-HP1γ (KRAB domain-
associated protein 1 and heterochromatin protein 1, respectively) complex that binds AID 
and facilitates its targeting within the donor region88. 
1.5.4 DSB repair during CSR 
Mammalian cells can undergo DSB repair through two main pathways: c-NHEJ and 
homologous recombination (HR). Whereas the former is active throughout the cell cycle 
and directly joins the broken ends of a DSB, the latter requires the presence of long 
stretches of sequence homology in the sister chromatid generated upon replication to 
copy the information89–91. AID-induced DSBs in donor and acceptor S regions at the Igh 
locus are majorly repaired by c-NHEJ, leading to the deletion of the intervening sequence 
as an extrachromosomal circular DNA and the generation of a newly switched heavy 
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chain (Figure 1.6). The different S regions junctions show limited sequence homology 
among them and isotype differentiation majorly happens during the G1 and early S 
phases of the cell cycle, when the sister chromatid is not available for HR92,93. DSBs 
present in S regions are rapidly recognized by the MRN complex, which is composed of 
MRE11 (meiotic recombination 11 homolog A), RAD50 and NBS1 (Nijmegen breakage 
syndrome 1). Apart from the MRN complex, DSBs are also recognized by the 
heterodimer Ku70-Ku80, which is a core component of c-NHEJ and forms a ring that 
encircles the DNA, preventing the access of nucleases and supporting the recruitment 
of DNA-PK catalytic subunit (DNA-PKcs)70–72,94,95. DNA-PKcs phosphorylates and 
activates the LIG4-XRCC4-XLF complex, which is composed of essential c-NHEJ factors 
(DNA ligase IV – X-ray repair cross complementing 4 – XRCC4-like factor) for the ligation 
of DNA ends and S-S synapsis. NSB1 activates the kinase ATM (ataxia telangiectasia 
mutated), which phosphorylates threonine and serine residues of several factors 
involved in the DDR and initiates the G1/S cell cycle checkpoint until breaks are repaired. 
Specifically, ATM phosphorylates H2AX (H2A histone family member X, a H2A variant) 
and this modification, known as γH2AX, spreads in the surroundings of a DSB. 
Furthermore, 53BP1 (p53-binding protein 1) is an ATM downstream target crucial for c-
NHEJ repair and CSR that binds γH2AX, forming foci (focal accumulation) upon DSB 
formation. During c-NHEJ, phosphorylated 53BP1 protects DNA ends from resection by 
recruiting its downstream target RIF1 (replication timing regulatory factor 1), favoring S-
S efficient synapsis (see section 1.7)96–100.  
Furthermore, DSBs can also be repaired by an additional mechanism called alternative 
non-homologous end-joining (alt-NHEJ) that favors the use of microhomologies at S-S 
junctions. Consequently, the S-S junctions of B-lymphocytes deficient in c-NHEJ 
components and factors mediating DNA end protection show increased length of 
microhomologies, mainly due to DNA end resection of DSBs94,95,98,101,102. Since S regions 
contain internally repetitive sequences but different from each other, there is a high 
possibility of finding stretches of microhomology within the same S region. This results 
in “intra-switch” recombination and reduced S donor – S acceptor synapsis, leading to 
decreased efficiency of antibody isotype differentiation71.  
1.5.5 Cell cycle progression 
It is widely accepted that antibody isotype differentiation is linked to cell cycle progression 
and undivided B cells are CSR-deficient103–106. Several studies have shown that DSBs 
preferentially happen in the G1 phase of the cell cycle. This observation is supported by 
the fact that both, AID and UNG also predominantly function in this step and also that 
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unresolved DNA breaks would not scape the G1/S cell cycle checkpoint. Furthermore, 
AID expression has been linked to cell division107. However, there is an additional level 
of complexity, since further investigations revealed that efficient CSR requires S phase 
entry, and, possibly the initiation of DNA replication92,93,108–111. Recently, it has been 
shown that activation of replication origins support CSR112, which is completed in early 
S phase before the sister chromatid is generated and used for HR92,113.  
 
1.5.6 Chromatin organization 
The Igh locus presents a three-dimensional spatial organization that is required for 
efficient antibody isotype differentiation. Specifically, mature resting B-lymphocytes 
show intra-chromosomal interaction between the 5’Eμ and the 3’RR enhancer elements 
(separated by 220 kb) that form a chromatin loop. Upon B cell activation, specific GLT 
promoters are recruited to the Eμ-3’RR contact region in a cytokine dependent manner, 
resulting in efficient transcription of targeted acceptor S regions114,115. Although the full 
plethora of factors modulating this spatial organization has yet to be discovered, PTIP 
has been shown to be required for maintaining the interaction in between the 3’RR and 
acceptor S regions85,86. Additionally, the Igh chromatin architectural disposition brings Sμ 
donor (located immediately downstream Eμ) and acceptor regions in close proximity, 
allowing synapsis115,116. In order for productive CSR to happen, this S-S synapsis are 
generated in a specific orientation that supports deletional donor-acceptor joining117. In 
this context 53BP1 has been described to support Igh architectural structure118,119, Eμ-
3’RR looping and productive orientational joining of AID-induced breaks117. 
 
1.6 Igh 3’ regulatory region (3’RR) 
 
The murine 3’RR is a super-enhancer of 28 kb composed of 4 DNase I hypersensitive 
sites (hs) or core enhancers that can be divided in two structurally distinctive modules. 
First, hs1,2 is located at the center of a palindromic region flanked by two inverted copies 
of hs3 (hs3a and hs3b). Secondly, hs4 is found downstream hs3b and is referred as the 
distal core enhancer120–127. Importantly, the DNA sequence that joins these enhancers 
supports the 3’RR function, most likely by contributing to its architectural configuration128. 
Several mouse models with partial or full deletions of the 3’RR have been generated in 
the past, showing that the activity of this super-enhancer is crucial for efficient B cell 
development, CSR and SHM (Figure 1.7)22,23,25–27,128–135 . Furthermore, although some 
factors have been shown to bind the 3’RR, the precise molecular mechanism of how this 




Figure 1.7. The murine Igh 3’ regulatory region (3’RR). 
Scheme representing the 3’RR genomic structure in a wild-type murine B cell (top) and the 
different mutants that have been described in literature. White arrows depict transcriptional 
orientation. Deleted regions (Δ) are shown with a red cross. Neo indicates the insertion of a 
neomycin cassette.  
 
1.6.1 3’RR role in B cell development 
The 3’RR is required for late B cell maturation, at the pre-B cell stage and at the transition 
from immature to mature B cells. Specifically, this super-enhancer supports IgM BCR 
expression and differentiation towards marginal zone B cells22–24. Previously published 
data indicate that the core enhancer hs4 supports 3’RR activity throughout B cell 
development. Firstly, hs4 was found to be constitutively active during B cell maturation, 
while hs3a, hs1,2 and hs3b activity was only detected at late B cell stages136. Secondly, 
single or combined deletion of the core enhancer hs4 together with hs3b (Δhs4, Δhs3b-
hs4) lead to decreased number of IgM+ bone marrow and resting B cells in the spleen, 
suggesting that this distal module is required for efficient Ig expression25,129,132. Finally, 
Δhs3a-hs1,2-hs3b mice present WT (wild-type) levels of IgM expression in the bone 
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marrow and spleen as well as unaffected transition of B cells to the marginal and follicular 
zone129. 
 
1.6.2 3’RR function during SHM 
The 3’RR supports efficient SHM of the Igh locus, exclusively. Accordingly, Δ3’RR 
splenocytes show a nearly complete abrogation in the number of mutations present in 
the heavy chain, while the light chain remains unaffected131. Initial studies proved that 
deletion of individual 3’RR core enhancers does not affect SHM26,132,133. Interestingly, 
further research clarified that the generation of mutations at the Igh locus is dependent 
on the presence of the proximal 3’RR modules (hs3a, hs1,2 and hs3b), their palindromic 
structure and also their surrounding sequence of DNA, as core3’RR and ΔIRIS mutants 
are SHM-deficient128,129,135. 
 
1.6.3 3’RR function during CSR 
The 3’RR regulates CSR during the steps that precede DSB formation at the Igh locus, 
but it is dispensable for repair pathway choice between c-NHEJ and alt-NHEJ and 
subsequent synapsis of donor-acceptor S regions. Specifically, the 3’RR is required for 
efficient binding and pausing of RNAPII and transcription of acceptor S regions. 
Accordingly, 3’RR-deficient cells show decreased R-loop formation and AID targeting 
upon cytokine stimulation. These cells also display reduced density of H3K4me3 and 
H3K9ac histone marks, which reflect an open chromatin state134. Furthermore, the Igh 
architectural configuration has been shown to be modulated by the 3’RR, as combined 
deletion of core enhancers hs3b and hs4 impairs Eμ-3’RR loop formation115. 
 
1.7 53BP1 and RIF1 role in CSR  
 
DSB repair by c-NHEJ is a crucial step for efficient CSR to happen. This pathway relays 
on the presence of blunt or nearly blunt DNA ends, as limited resection and exposure of 
microhomology sequences within the S regions skew the repair process towards alt-
NHEJ and result in intra-switch recombination94. Therefore, factors involved in regulating 
DNA end processing play a major role in pathway choice between c-NHEJ and alt-NHEJ 
and productive CSR. 53BP1 is a key modulator of this process since its phosphorylation 
by ATM upon DNA damage promotes its interaction with RIF1 to prevent DNA end 
resection by CtIP96,97,100,137,138. Recently, two novel complexes, REV7-shieldin (SHLD1, 
SHLD2, SHLD3) and CST (CTC1-STN1-TEN1), have been identified and suggested to 
act downstream RIF1 to protect the DNA ends (Figure 1.8)139–146. Deletion of any of 
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these factors provides access to proteins mediating DNA end resection and lead to 
defects in CSR96,100,137,142,144,146. 
 
 
Figure 1.8. DSB DNA end protection. 
Diagram representing proteins implicated in DNA end protection. Upon DSB formation, 
phosphorylated (P) 53BP1 is recruited to damaged sites (marked by γH2AX) through its 
association to H2AK15ub and H4K20me2. RIF1 interacts with phosphorylated 53BP1 and recruits 
downstream components (REV7-shieldin and CST complexes) to prevent DNA end resection, 
ensuring c-NHEJ. Histones are indicated with grey cylinders, that are surrounded by DNA (black 
line).   
 
1.7.1 53BP1 
53BP1 is a large protein of 1972 amino acids. It presents a N-terminal region containing 
28 SQ/TQ sites (a serine or a threonine followed by a glutamine residue) that can be 
phosphorylated by ATM in response to DNA damage98,99,147,148. The phosphorylation of 
these motifs mediates 53BP1 interaction with RIF1 and therefore its function during DNA 
repair. Accordingly, mutation of these 28 SQ/TQ motifs leads to a decrease in DNA end 
protection and CSR. Moreover, the N-terminal region of 53BP1 is necessary for 
chromatin mobility upon DNA damage, although this function is dispensable for antibody 
isotype differentiation. Next, an oligomerization domain follows, which has been also 
shown to be required for the focal accumulation of 53BP1 when DSBs are formed and 
for CSR. Furthermore, 53BP1 is recruited to damaged chromatin via the interaction of its 
Tudor and UDR (ubiquitination-dependent recruitment) domains with H4K20me2 and 
H2AK15ub. Both, Tudor and UDR are necessary for DNA damage induced 53BP1 focal 
accumulation and for preventing DNA end resection of DSBs. During the DDR, ATM also 
phosphorylates H2A and MDC1 (mediator of DNA damage checkpoint 1) that interact. 
MDC1 then mediates the recruitment of the ubiquitin ligases RNF8 and RNF168 (ring 
finger protein 8 and 168, respectively). Lastly, RNF168 catalyzes the formation of the 
histone mark H2AK15ub and, therefore, supports the association of 53BP1 with the 
damaged chromatin. The C-terminal part of 53BP1 is characterized by the presence of 
the BRCT domain, which is dispensable for the focal accumulation of the protein and for 
CSR99,147,148.  
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Apart for supporting DNA end protection, 53BP1 promotes long range S-S synapsis 
during antibody isotype differentiation. This can be at least partly explained by the facts 
that 53BP1 is required for efficient chromatin looping of the Igh locus and for the correct 
deletional orientation of S-S junctions during CSR115,117,118.  
 
1.7.2 RIF1 
The mechanism by which 53BP1 mediates DNA end protection upon DSB formation has 
been studied for many years. Hypothetically, 53BP1 could be preventing the access of 
nucleases and/or recruiting downstream effectors that actively protect the broken DNA. 
In this context, RIF1 has been identified as a phospho-dependent 53BP1 interactor that 
is recruited to DSBs and inhibits DNA end resection. Consequently, RIF1 is required for 
efficient NHEJ during CSR96,97,100,137,138. Furthermore, recent studies have shown that 
REV7/MAD2L2 (mitotic arrest deficient-like 2) is recruited downstream 53BP1 and RIF1 
to counteract DNA end resection upon DSB formation149,150. Likewise, the shieldin and 
CST complexes mediate DNA end protection and are required for efficient CSR. These 
complexes have been suggested to function downstream 53BP1 and RIF1, but the 
precise relationship in between all these factors is yet to be defined139–146. Although 
53BP1 and RIF1 exert common functions in DNA repair, RIF1 is likely to have additional 
roles because Rif1 deletion is lethal whereas Trp53bp1 is not151. Indeed, RIF1 has been 
shown to play a role in transcriptional silencing152–155, replication origin firing156,157, repair 
of stalled forks151,158, resolution of ultrafine DNA bridges in anaphase159, and to slow 
down DNA synthesis upon DNA damage160. Murine RIF1 is a protein of 2426 amino acids 
with a large N-terminal domain containing HEAT repeats that are required for its DSB-
dependent interaction with phosphorylated 53BP1 and focal accumulation. The vast 
majority of the protein is conformed of an intrinsically disordered region followed by a C-
terminal domain that is necessary for RIF1 oligomerization and counteract BRCA1 
(breast cancer 1; HR factor) activity in the G1 phase of the cell cycle137. Importantly, the 
contribution of these individual domains to CSR is unknown.  
 
1.8 Physiological relevance of Ig diversification 
 
SHM and CSR are physiological processes necessary for the generation of antigen-
specific antibodies with effector properties during an effective adaptive immune 
response. Consequently, defects in any of these processes can lead to immune 
defects161. Moreover, AID is a B cell specific enzyme induced upon stimulation that is 
responsible for the generation of mutations and DSBs that are necessary for SHM and 
CSR to happen, respectively. AID recognizes specific sequence motifs within the 
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immunoglobulin variable segments and also within the S regions at the Igh locus. 
However, these motifs are also present elsewhere in the genome. Consequently, AID 
can be targeted to other loci and its mutagenic activity may lead to oncogenic 
chromosomal translocations or undesired mutations. To prevent this, there are several 
molecular mechanisms that control AID functionality at the level of transcription, post-
transcription, post-translation and subcellular localization. Furthermore, AID-induced 
DSBs in donor and acceptor S regions are repaired by c-NHEJ during productive CSR 
events. However, inefficient repair may increase the load of DBSs and alt-NHEJ can 
make use of sequences microhomologies to fuse DNA ends together. As a result and 
considering that AID targeting is not exclusive to the S regions, abnormal joining can 
happen, contributing to translocation events162–164.  Conclusively, there is a tight 
modulation at the molecular level of the physiological processes that ensure 
immunoglobulin diversification while preventing malignant transformation during an 
adaptive immune response.  
 
1.8.1 Primary antibody deficiencies caused by defects in CSR/SHM 
Primary antibody deficiencies (PADs) are considered a group of rare diseases 
characterized by the inability to support an efficient immune response165,166. They are 
majorly caused by B cell-intrinsic defects, although they can also result from the loss of 
function of other immune cell types, like T-lymphocytes. Regarding B-lymphocytes, there 
are syndromes associated to deficiencies in B cell development, survival, proliferation 
signaling and Ig diversification. Specifically, defects in CSR (often referred as hyper-IgM 
syndromes) lead to normal or increased IgM levels and reduced IgG, IgA and IgE 
concentrations in serum. They are usually diagnosed during childhood and they curse 
with recurrent bacterial and opportunistic infections. Depending on the molecular cause, 
deficiencies in CSR can be accompanied with defects in SHM. For example, CD40L 
(expressed in activated T cells) interaction with CD40 (constitutively present in B cells 
and other immune cell types) is required for GC formation. Mutations in CD40 result in 
both, CSR and SHM defects and they lead to a rare autosomal-recessive syndrome. 
Mutations in CD40L (expressed by activated T cells) cause the X-linked form of the 
disease. Defects in AID abolish CSR and SHM, resulting in autosomal-recessive AID 
deficiency. Importantly, mutations in the C-terminal region of AID completely abrogate 
CSR but do not affect SHM. Furthermore, alterations in the nuclear export of AID cause 
an autosomal-dominant CSR defect, which is clinically less severe than the autosomal-
recessive form. Lack of UNG leads to a rare autosomal-recessive CSR deficiency that 
courses with defects in SHM. Furthermore, inefficient DSB repair can also cause CSR 
deficiency. For example, functional impairment of the MMR pathway has been linked to 
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reduced antibody isotype differentiation to IgA and IgG. Likewise, mutations in the DNA 
damage response and repair factors ATM, RNF168 and MRE11 have been shown impair 
CSR161,166,167. Importantly, there are many patients that present defects in Ig 
diversification, but the genetic cause is still unknown. Therefore, the identification and 
molecular characterization of novel players that support CSR and SHM during an 
adaptive immune response are crucial for the diagnosis and treatment of these patients. 
 
1.8.2 Regulation of AID activity 
The Aicda gene is encoded in chromosome 6 in mice. It presents four distinctive and 
conserved DNA regions that are the binding sites for several transcription factors that 
regulate its expression in B-lymphocytes: Region I functions as a promoter; region II 
contains silencer elements bound by repressors in memory B cells and non-B cells that 
restrict AID expression; region III has been shown to support physiological levels of AID 
expression; region IV and region II present enhancer elements that overcome the 
silencing of Aicda transcription during B cell activation (Figure 1.9)168. Both, TD and TI 
signals promote CD40 engagement or dual TLR-BCR crosslinking, leading to activation 
of the canonical (CD40 and TLR) and non-canonical (CD40 and BCR) NF-κB (nuclear 
factor kappa beta) signaling cascades. The non-canonical NF-κB p52 subunit binds to 
the Aicda promoter and the canonical NF-κB p65 subunit associates with an upstream 
enhancer region. LPS binds to TLR4 and the BCR, activating both NF-κB pathways that 
initiate and sustain Aicda expression. Furthermore, IL-4, TGFβ and IFN-γ activate 
transcription factors that bind and support the induction of Aicda gene and that inhibit the 
activity of silencers restricting Aicda expression10. 
 
Additionally, AID transcription is also dependent on histone modifications of the locus. 
Specifically, the Aicda locus of naïve B-lymphocytes presents low levels of histone H3 
acetylation and a hypermethylated promoter. During stimulation, the promoter is 
demethylated and the locus shows H3K4me3, H3K9ac and H3K14ac modifications. 
Moreover, Aicda transcription elongation is supported by H3K36me3. Therefore, both 
epigenetic marks and the induction of transcription factors participate in the expression 




Figure 1.9. Mechanisms of AID regulation. 
Diagram depicting the different levels of regulation of AID activity. NLS, nuclear localization signal; 
NES, nuclear export signal. Representations of the different regions of the Aicda locus, the AID 
protein domains and the four alternative splicing forms are adapted from previous 
publications168,169. 
 
Once transcription is completed, Aicda mRNA can be negatively regulated by miRNA 
species (Figure 1.9). miRNAs are small (21-23 nt) non-coding evolutionary conserved 
RNAs that bind target mRNAs to promote their degradation and inhibit their translation. 
Specifically, miR-155, miR-181b and miR-361 have been shown associate with the 
3’UTR (untranslated region) of Aicda transcript to limit its expression83. Among all, miR-
155 is the most characterized and abundant non-coding RNA that is induced together 
with AID in activated B cells undergoing CSR. Mutation of the miR-155 binding site in 
the Aicda mRNA leads to an increase in AID protein translation, antibody isotype 
differentiation and c-myc/Igh translocations170,171. Therefore, the post-transcriptional 
regulation of Aicda by miRNAs represents a mechanism of control of malignant 
transformation in B cells. 
 
Aicda transcript can be alternatively spliced, leading to the generation of four different 
AID isoforms in addition to the full-length (FL) with distinctive exon organization. 
Although these isoforms have been identified in physiological conditions, they have been 
shown to be important in patients with B cell malignancies172,173. Specifically, AID protein 
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is organized in 5 functional domains: the N-terminal region codified by exon 1 and part 
of exon 2 that is required for SHM and contains a nuclear localization signal; a 
dimerization signal, which corresponds to the rest of exon 2; the functional deaminase 
activity domain, transcribed from a portion of exon 3; a linker region that is partly codified 
by exon 3 and also exon 4; and the C-terminal domain, which supports CSR and 
presents a nuclear export signal (exon 5) (Figure 1.9)168. The AID-ΔE4a isoform lacks a 
portion of the linker. The AID-ΔE4 and AID-ivs3 variants present a stop codon after exon 
3 and, therefore, the linker and the CSR domain are spliced out. Lastly, AID-ΔE3E4 
retains the CSR region but lacks the deaminase domain169. Of note, some of these 
isoforms were initially described to be catalytically active169, but later reports showed that 
although Aicda undergoes alternative splicing, the resulting isoforms do not code for a 
functional AID protein174,175. Taking all results into consideration, Aicda splicing is a 
critical step for the generation of a functional protein with physiological roles in SHM and 
CSR.  
 
Furthermore, AID activity is also regulated by post-translational modifications that involve 
serine and threonine phosphorylation (Figure 1.9). Specifically, serine-3 
phosphorylation of AID (S3) suppresses its activity in vivo. Consequently, S3 mutation 
results in increased CSR and c-myc/Igh translocations, whereas induction of S3 
phosphorylation decreases antibody isotype differentiation176. On the other hand, 
phosphorylation of serine-38 (S38) or threonine-140 (T140) positively modulate AID 
function80. S38 is the best characterized AID post-translational modification and it 
supports AID targeting to the V and S regions during SHM and CSR, respectively. 
Interestingly, supra-physiological levels of S38 phosphorylation result in increased c-
myc/Igh translocations but not CSR, suggesting that AID function can be differentially 
regulated by post-translational modifications177.  
 
Lastly, AID function is tightly modulated by its subcellular localization (Figure 1.9). 
Indeed, AID is mainly retained in the cytoplasm and its accessibility to the nucleus is 
restricted in order to minimize undesired off-target deamination. A combination of 
mechanisms that mediate cytoplasm retention, degradation of nuclear AID as well as 
active nuclear import and export ensure that only the necessary amount of protein is 
targeted to the DNA178–180 
 
1.8.3 Implications of AID off-targeting and dysregulation   
Chromosome translocations result from the joining of DSBs present in non-homologous 
chromosomes that are in close proximity. These translocations can lead to malignant 
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transformation when involving proto-oncogenes or tumor suppressor genes. Indeed, 
many types of B cell lymphomas are caused by translocations that activate proto-
oncogenes as a consequence of their binding to the Igh locus, which is actively 
transcribed. For example, the coding region of the proto-oncogene c-myc is fused to the 
Igh locus in Burkitt lymphoma, which originates from GC B cells. AID has been shown to 
target several non-Ig genes, including the proto-oncogenes c-myc, Pax5, Pim1, Bcl6 and 
RhoH and deregulated AID expression causes B cell lymphomagenesis163,181. 
Importantly the repair of AID-induced on- and off-target DSBs breaks also plays a role in 
chromosomal translocations. The absence of c-NHEJ components can lead to the 
persistence of unrepaired DSBs that can be processed and aberrantly joined by alt-
NHEJ. Accordingly, there is an increase in the level of translocations in Ku-, XRCC4-, 
LIG4- or DNA-PKcs-deficient B cells. However, despite the higher number in 
chromosomal translocations, these defects in c-NHEJ factors do not result in tumor onset 
because cells undergo apoptosis182–184.  
Furthermore, AID activity in chronic myeloid leukemia promotes genomic instability, 
chemotherapy resistance and progress into blast crisis (incurable and fatal phase of the 
disease)185. Interestingly, AID upregulation has been observed in solid tumors. For 
instance, AID activity results in point mutations and copy alterations of tumor suppressor 
genes in gastric cancer186. Additionally, Helicobacter pylori, which is involved in gastric 
carcinogenesis, has been shown to induce aberrant AID expression in gastric epithelial 





















2. GOAL AND SPECIFIC AIMS  
 
CSR is a complex physiological process that involves the formation and repair of DSBs 
through different molecular mechanisms that have not been fully elucidated yet. 
Therefore, the aim of this study was to identify novel CSR factors, and characterize their 
role(s) in the reaction. This was achieved as detailed in the specific aims below:  
 
2.1 Set-up and perform a functional loss-of-CSR screen  
To identify novel factors regulating CSR, a functional loss-of-CSR screen by 
CRISPR/Cas9 somatic targeting was established in the B cell lymphoma line 
CH12F3, which can undergo CSR to IgA in vitro. 53BP1 is a key factor involved in 
various steps in CSR but the precise molecular mechanisms by which it exerts its 
functions is still unknown. When this study started, RIF1 had just been identified as a 
53BP1 downstream effector in CSR by a mass-spectrometry based approach96. 
Therefore, this list of potential 53BP1 interactors was available and was used to select 
candidates for the loss-of-CSR assay. Moreover, a similar experimental approach 
was employed to define the RIF1 interactome in B-lymphocytes activated to undergo 
CSR, and to test the involvement of the newly identified associating proteins in 
antibody isotype differentiation.   
 
2.2 Molecular characterization of the newly identified CSR effectors 
CSR is a physiological process that is dependent on B cell proliferation and cell cycle 
progression, efficient AID expression and targeting, DSB formation, chromatin 
remodeling and DSB repair. Considering that the newly identified effectors could be 
playing a role in any of these processes, several experimental approaches and 
functional assays were employed to characterize their functions in CSR.  
 
Therefore, the identification and characterization of novel CSR factors aimed to further 
define the molecular mechanisms ensuring antibody isotype differentiation and the 









3. MATERIALS AND METHODS 
 
3.1 Materials  
 
Mouse lines 
Line Company/Reference Cat. No. 
C57BL6 (wt)  The Jackson 
Laboratory 
664 
Rif1FH/FH 156 N/A 
AID-/- 53 N/A 
Zmynd8tm1a(EUCOMM)Wtsi European Mouse 
Mutant Archive 
05720 
Rosa26Flpo The Jackson 
Laboratory 
007844 
Cd19Cre/+ 188 N/A 
Zmynd8F/F This study N/A 
Zmynd8F/FCd19Cre/+ This study N/A 
Pdap1F/F This study N/A 
Pdap1F/FCd19Cre/+ This study N/A 
Cell lines 
Line Company/Reference Cat. No. 
CH12 (CH12F3) (wt, parental) 189 N/A 
WTc CH12 (clonal derivative) This study 
Daniel B. Rosen 
N/A 
Aicda-/- CH12  Kerafast  ESP013 
Lig4-/- CH12 190 N/A 




Rif1-/- CH12 This study 
Matteo Andreani 
N/A 
Zmynd8-KO1 CH12 This study 
Daniel B. Rosen 
N/A 
Zmynd8-KO2 CH12 This study 
Daniel B. Rosen 
N/A 




iMEFs (wt, parental) 98 N/A 












Brca1-/- iMEFs 192 N/A 





BOSC23 (wt) 191 N/A 
Antibodies 
Name Company/Reference Cat. No. 
Donkey anti-goat (HRP) Gift from Claus 
Schreidereit’s lab 
N/A 
Goat anti-IgA-PE Southern Biotech 1040-09 
Goat anti-IgG1, Human ads-
BIOT 
Southern Biotech 1070-08 
Goat anti-IgM, Human ads-BIOT Southern Biotech 1020-08 
Goat anti-Kappa-UNLB Southern Biotech 1050-01 
Goat anti-Lamda-UNLB Southern Biotech 1060-01 
Goat anti-mouse Alexa488 ThermoFisher Scientific A-11029 
Goat anti-mouse Lc (HRP) Jackson 
ImmunoResearch 
115-035-174 
Goat anti-rabbit Alexa546 ThermoFisher Scientific A-11035 
Hamster anti-CD95/Fas-FITC 
Clone Jo2 
BD Biosciences 554257 
Hamster anti-CD95/Fas-PE 
Clone Jo2 
BD Biosciences 561985 
Mouse anti-53BP1 Clone BP18 Millipore/Merck 05-725 
Mouse anti-Flag M2  Sigma-Aldrich F3165 
Mouse anti-Flag M2 (HRP 
conjugated)  
Sigma-Aldrich A8592 
Mouse anti-rabbit Lc (HRP) Jackson 
ImmunoResearch 
211-032-171 
Mouse anti-RNA polymerase II 
CTD repeat YSPTSPS (phospho 
S5) Clone 4H8 
Abcam ab5408 
Mouse anti-βActin Clone AC-15 Sigma-Aldrich A5441 
Mouse anti-γH2AX (Ser139) 
Clone JBW301  
Millipore 05-636 
Mouse IgG1-UNLB Clone 15H6 Southern Biotech 0102-01 
Mouse IgM-UNLB Clone 11E10 Southern Biotech 0101-01 
Rabbit anti-PDAP1 Sigma-Aldrich HPA050294 
Rabbit anti-Rif1 96 N/A 
Rabbit anti-ZMYND8  Sigma-Aldrich HPA020949 







Rat anti-B220/CD45R-PE  
Clone RA3-6B2 
BioLegend 103207 
Rat anti-CD180 (RP/14) BD Biosciences 552128 
Rat anti-CD19-Alexa700  
Clone 6D5 
BioLegend 115527 
Rat anti-CD19-APC Clone 6D5 BioLegend 115512 





BD Biosciences 561769 
Rat anti-CD23-PE Clone B3B4 BioLegend 101607 
Rat anti-CD3-PE Clone 17A2 BioLegend 100206 
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Rat anti-CD38-Alexa700 Clone 
90 
ThermoFisher 56-0381-82 
Rat anti-CD40 Clone 1C10 BioLegend 102810 
Rat anti-CD43-PE Clone S7 BD Biosciences 561857 
Rat anti-IgD-FITC Clone 11-
26c.2a 
BD Biosciences 562022 
Rat anti-IgG1-APC Clone X56 BD Biosciences 550874 
Rat anti-IgG2b-PE Clone 
RMG2b-1 
BioLegend 406707 
Rat anti-IgG3-BIOT Clone R40-
82 
BD Biosciences 553401 
Rat anti-IgM-FITC Clone II/41 BD Biosciences 553437 
Rat anti-IgM-PE Clone R6-60.2 BD Biosciences 553409 
Secondary rat Gift from Fritz Rathjen’s 
lab 
N/A 
Streptavidin-AP Conjugate Sigma-Aldrich 11089161001 
Streptavidin-APC BD Biosciences 554067 
TruStain fcX Rat anti-CD16/32 
Clone 93 
BioLegend 101320 
Chemical, peptides, recombinant proteins and commercial kits 
Reagent Company/Reference Cat. No. 
13C6 L-arginine Cambridge Isotope 
Laboratories 
CLM-2265-H-PK-1 
13C6 L-lysine Cambridge Isotope 
Laboratories 
CLM-2247-H-PK-1 
1X PBS ThermoFisher Scientific 10010031 
2-Mercaptoethanol ThermoFisher Scientific 21985023 
3XFlag peptide Sigma-Aldrich F4799 
4-hydroxytamoxifen (4-HT) Sigma-Aldrich H7904 
4-nitrophenyl phosphate Sigma-Aldrich N2765 
Acetic acid Roth 6755.1 
ACK lysis buffer ThermoFisher Scientific A1049201 
Actinomycin D Sigma-Aldrich A9415 
Agarose Roth 2267.4 
AllPrep DNA/RNA Mini Kit Qiagen 80204 
Alum KAI(SO4)2 Sigma-Aldrich 31242  
Antibiotic Antimycotic ThermoFisher Scientific 15240062 
BAFF (human recombinant) PeproTech 310-13 
Benzonase Sigma-Aldrich E1014 
Bradford reagent Bio-Rad 500-0006 
BSA  NEB B900S 
BSA (Albumin, IgG-free) Roth 3737 
Carboxyfluorescein succinimidyl 
ester (CFSE) 
ThermoFisher Scientific 65-0850-84 
CellTrace Violet (CTV) ThermoFisher Scientific C34557 
Colcemid Sigma-Aldrich 10295892001 
Complete EDTA-free protease 
inhibitor cocktail  
Roche 11873580001 
Crystal Violet Sigma-Aldrich C0775 
Dialyzed fetal bovine serum ThermoFisher Scientific 26400-044 
Diethanolamine Roth 0332 
DirectPCR Ear Lysis reagent VWR 402-E 
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DMEM ThermoFisher Scientific 41965062 
DTT ThermoFisher Scientific R0862 
Dynabeads M-270 Epoxy ThermoFisher Scientific 14301 
Dynabeads Protein A ThermoFisher Scientific 10001D 
ECL PerkinElmer NEL104001EA 
EDTA Roth 8043.2 
Ethanol Roth P075.1 
FBS Sigma-Aldrich F7524 
FuGENE HD Reagent Promega E2312 
Gel loading dye (6X) NEB B70245 
Gentamicin Lonza 17-519 
Gibson Assembly master mix BioLabs E2611S 
Glutaraldehyde Sigma-Aldrich 340855 
Glycine Roth 3908 
Glycogen Roth HP51.3 
Gurr Buffer Tablets ThermoFisher Scientific 10582013 
H3BO3 Roth 6943 
HEPES ThermoFisher Scientific 15630056 
High Sensitivity D1000 Ladder Agilent 5067-5587 
High Sensitivity D1000 Sample 
Buffer 
Agilent 5067-5603 
High Sensitivity D1000 
ScreenTape 
Agilent 5067-5584 
HotStarTaq DNA Polymerase Qiagen 203205 
Igepal CA-630 Sigma-Aldrich I8896 
IL-4 (mouse recombinant) Sigma-Aldrich I1020 
Immobilen PVDF membrane Millipore IPVH00010 
Isofluran CP-Pharma G81G17A 
KaryoMAX Giemsa Stain 
Solution 
ThermoFisher Scientific 10092013 
KCl Roth 6781 
L-Glutamine ThermoFisher Scientific 25030024 
LPS Sigma-Aldrich L2630 
Luna Universal qPCR Mastermix NEB M3003 
Methanol Chemsolute 143.2511 
MgCl2 Sigma-Aldrich M8266 
NaCl Roth 3957.1 
NaOH Roth 6771 
Neon Transfection System, 
100μl Kit 
ThermoFisher Scientific MPK10025 
non-labeled L-arginine Sigma-Aldrich A8094 
non-labeled L-lysine Sigma-Aldrich L8662 
NP-CGG16  Biosearch Technologies N5055B 
NP-IgG1 Gift from Klaus 
Rajewsky’s lab 
N/A 
NP-IgM Gift from Klaus 
Rajewsky’s lab 
N/A 
NP22-BSA Gift from Klaus 
Rajewsky’s lab 
N/A 
NucleoSpin DNA Purification Kit Macherey-Nagel 740499 
NucleoSpin Gel and PCR Clean-




NuPAGE 3-8% Tris-Acetate 
Protein Gel 
ThermoFisher Scientific EA03752BOX 
NuPAGE 4-12% Bis-Tris Protein 
Gel 
ThermoFisher Scientific NP0322BOX 
 
NuPage LDS Sample buffer ThermoFisher Scientific NP0008 
NuPage MES SDS Running 
Buffer 
ThermoFisher Scientific NP0002 
NuPage MOPS SDS Running 
Buffer 
ThermoFisher Scientific NP0001 
NuPage Tris-Acetate SDS 
Running Buffer 
ThermoFisher Scientific LA0041 
One Shot Stbl3 chemically 




One Shot TOP10 chemically 




Opti-MEM medium ThermoFisher Scientific 31985062 








Phosphatase inhibitor cocktail 
tablets 
Roche 04906837001 






Pierce 16% Formaldehyde 
Methanol-free 
ThermoFisher Scientific 28906 
Pierce complete protease 
inhibitor mini tablets 
ThermoFisher Scientific A32953 
Polyvinylpyrrolidone Sigma-Aldrich PVP40 
Prolong Gold Antifade Mountant ThermoFisher Scientific P36930 
Proteinase K Peqlab 3375501 
PureLink HiPure Plasmid 
Midiprep Kit 
ThermoFisher Scientific K210005 
Qubit dsDNA HS Assay Kit ThermoFisher Scientific Q32851 
Qubit RNA HS Assay Kit ThermoFisher Scientific Q32852 
 
RapidOut DNA Removal Kit ThermoFisher Scientific K2981 
Rat anti-CD43 (Ly-48) 
Microbeads 
Miltenyi Biotec 130-049-801 
recombinant murine IL-5 Peprotech 215-15 
Ribo-Zero Gold rRNA Removal 
Kit  
Illumina MRZG12324 
RIPA buffer Sigma-Aldrich R0278 
RNeasy Mini Kit Qiagen 74104 
RPMI 1640 ThermoFisher Scientific 21875091 
SDS Roth EN30.2 
SeeBlue Plus2 Pre-stained 
Protein Standard 
ThermoFisher Scientific LC5925 
 
SILAC-RPMI ThermoFisher Scientific 88421 
Sodium Acetate Sigma-Aldrich 52889 
Sodium Pyruvate ThermoFisher Scientific 11360039 
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SuperScript VILO cDNA 
Synthesis Kit 
ThermoFisher Scientific 11754250  
TE buffer ThermoFisher Scientific 12090015 
TGF-1 (mouse recombinant) R&D Systems 7666-MB-005/CF 
TOPO TA Cloning Kit  ThermoFisher Scientific 450641 
Tris Roth AE15.3 
TRIzol LS Reagent Invitrogen  10296028 
TruSeq Stranded Total RNA 
Library Prep Kit  
Illumina 20020597 
TruSeq Stranded Total RNA 
Library Prep Kit Gold   
llumina 20020598 
 
Trypan Blue ThermoFisher Scientific 15250061 
Tween Sigma-Aldrich P7949 
Materials and Equipment 
Name Company/Reference Cat. No. 
0.45 μM filter GE Healthcare 10462100 
0.50 μM filter CellTrics 04-0042-2317 
0.70 μM cell strainer Falcon 352350 
1 ml syringe Braun 9161496V 
1.5 ml tubes Sarstedt 72.690.001 
10 cm dishes (cell culture) Sarstedt 83.3902 
10 ml pipettes Sarstedt 86.1254.001 
10 ml syringe Braun 4606198V 
12-well plates (cell culture) Greiner 665180 
15 ml tubes Falcon 352096 
25 cm dishes (cell culture) Sarstedt 83.3903 
25 ml pipettes Sarstedt 86.1685.001 
3 ml syringe Braun 4616025V 
4200 ScreenTape System Agilent G2991AA 
5 cm dishes (cell culture) Corning 403196 
5 ml pipettes Sarstedt 86.1253.025 
50 ml pipettes Sarstedt 86.1256.001 
50 ml syringe BD Plastipak 300865 
50 ml tubes Falcon 352070 
6-well plates (cell culture) Sarstedt 83.3920 
96-well plates (high binding) 
(ELISA) 
Greiner 675061 
96-well plates (RT-qPCR) Applied Biosystems 4346907 
96-well plates F bottom (cell 
culture) 
Greiner 655083 
96-well plates lids (qRT-PCR) Applied Biosystems 4311971 
96-well plates U bottom (cell 
culture) 
Greiner 650180 
Automated Metaphase Finder 
System Metafer4 
MetaSystems N/A 
Biophotometer Eppendorf 6133000001 
Cell sorter BD Biosciences Aria 
Centrifuge  Eppendorf 5810R 
Cover glass VWR 631-0149 
Cuvettes  Roth XK20.1 
Developer machine Protec OPTIMAX 2010 
Films VWR 28906839 
Flow cytometer BD Biosciences LSR Fortessa 
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Flow Cytometry tubes Starstedt 55.1579 
Flow Cytometry tubes (filter cap) Falcon 352235 
HiSeq 4000 Illumina N/A 
LSM700 laser scanning confocal 
microscope 
Zeiss N/A 
MACS MS columns Miltenyi Biotech 130-042-201 
Microscope slides Corning 2947 
Mini trans blot cell Bio-Rad 153BR107517 
Nanodrop Peqlab ND1000 
Neon Transfection System ThermoFisher Scientific MPK5000 
Neubauer chamber Marienfeld 0640010 
NextSeq High Output 75 SR Illumina N/A 
Novex Xcell sure lock ThermoFisher Scientific EI0001 
OctoMACS manual separator Miltenyi Biotech 130-042-109 
Pasteur pipette Sigma-Aldrich 7331759 
PCR Machine Applied Biosystems 4484073 
Phase Lock Gel tubes VWR 2302820 
Planetary Ball Mill PM 100 Retsch N/A 
Qubit ThermoFisher Scientific Q33238 
S220 Focused Ultrasonicator Covaris N/A 
SpectraMAX 340PC microplate 
reader 
Marshall Scientific N/A 
StepOnePlus Real-Time PCR 
System 
Applied Biosystems 4376600 
Thermomixer Eppendorf 5382000015 
Plasmids 
Construct Company/Reference Cat. No. 
pMX-IRES-GFP 200 N/A 
pMX-AIDER-IRES-GFP Gift from M. Nussenzweig 
lab 
N/A 
pX458 (pSpCas9(BB)-2A-GFP) Addgene 48138 
pX330 expressing GFP Gift from K. Rajewsky lab Modified version of 
42230 
pX458 expressing Cas9D10A This study N/A 
pX330-GFP expressing 
Cas9D10A 
This study N/A 
Softwares and Algorithms 
Software/Algorithm Company/Reference Cat. No. 
www.crispr.mit.edu  194 N/A 
CRISPRGold 195 N/A 
kallisto v0.43.0 204 N/A 
R package tximport 205 N/A 
DESeq2 206 N/A 
MaxQuant software (version 
1.2.2.5) 
212 N/A 
Burrows-Wheeler Alignment tool 213 N/A 
HOMER ChIP-Seq program 214 N/A 









Rif1FH/FH (Rif1FLAG-HA2/FLAG-HA2, C57BL/6 background)156 , Cd19Cre/+ (Cd19tm1(cre)Cgn, 
C57BL/6 background)188  and Aicda-/- (Aicdatm1Hon/tm1Hon C57BL/6 background)53 were 
previously generated and described. The conditional Zmynd8F allele presents two LoxP 
sites flaking exon 4 (ENSMUSE00001273891) for Cre-mediated recombination. It was 
generated by crossing the knockout first allele with conditional potential 
Zmynd8tm1a(EUCOMM)Wtsi (purchased at the European Mouse Mutant Archive, C57BL/6 
background, EMMA #05720) with the Rosa26Flpo deleter strain (purchased at The 
Jackson Laboratory, 129S4/Sv background [agouti]), which is a flippase-expressing 
mouse line. Germline transmission was confirmed by backcrossing progeny to a 
C57BL/6 mouse. Positive Zmynd8F/+ heterozygous pups were intercrossed to get a 
homozygous Zmynd8F/F allele. Finally, these mice were bred with Cd19Cre/+ mice to 
generate the Zmynd8F/F Cd19Cre/+ mouse model (mixed C57BL/6 129S4/Sv background). 
The conditional Pdap1F allele bears LoxP sites flanking Exon 2 
(ENSMUST00000031627.8) and was generated by CRISPR/Cas9-mediated knock-in 
microinjection of single cell embryos transferred to a C57BL/6 female. Germline 
transmission was confirmed by backcrossing progeny to a C57BL/6 mouse. Positive 
Pdap1F/+ heterozygous pups were intercrossed to get a homozygous Pdap1F/F allele. 
Finally, these mice were bred with Cd19Cre/+ mice to generate the Pdap1F/FCd19Cre/+ 
mouse model (C57BL/6 background). Mice were maintained in a specific pathogen-
free (SPF) barrier facility under standardized conditions (20+/-2 °C temperature; 
55%±15% humidity) on a 12 h light/12 h dark cycle. Male and female mice 7 to 31 weeks 
old were used in age-matched groups for the experiments. All experiments were 
performed in compliance with EU Directive 2010/63/EU, and in agreement with protocols 
approved by Landesamt für Gesundheit und Soziales (LAGeSo, Berlin). 
 
3.2.2 Cell lines 
WT CH12 (CH12F3, murine)189 and clonal derivative cell lines (Aicda-/-, purchased from 
Kerafast; Rif1-/-, generated by Matteo Andreani; Trp53bp1-/-, generated by Devakumar 
Sundaravinayagam; Lig4-/-, previously described190; Zmynd8-/- and Random generated 
by Daniel B. Rosen and Verónica Delgado-Benito targeting exon 4 or exon 5 
(ENSMUST00000109269.7); and Pdap1-/-, generated by Verónica Delgado-Benito 
targeting exon 4 (ENSMUST0000031627.8)) were cultured in RPMI 1640 medium 
(ThermoFisher Scientific) supplemented with 10% FBS (fetal bovine serum; Sigma-
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Aldrich), 10 mM HEPES, 1 mM Sodium Pyruvate, 1X Antibiotic Antimycotic, 2 mM L-
Glutamine and 50 μM 2-Mercaptoethanol (ThermoFisher Scientific).  
WT BOSC23 (human)191, WT iMEFs (immortalized mouse embryonic fibroblasts)98 and 
clonal derivative cell lines (Brca1-/-, previously described192 and Zmynd8-/- and Random, 
generated by Verónica Delgado-Benito) were cultured in DMEM medium supplemented 
with 10% FBS, 2 mM L-Glutamine, and 1X Penicillin-Streptomycin (ThermoFisher 
Scientific). All cells were grown in sterile incubators at 37 ºC and with 5% CO2 levels. 
 
3.2.3 Genotyping 
Mice ear punches were incubated overnight with DirectPCR Ear Lysis reagent (VWR) 
containing 0.1 mg/ml of Proteinase K (Peqlab) at 55 ºC. Proteinase K was inactivated by 
incubating samples at 85 ºC for 45 min and 0.2 μl of sample was used for PCR. 
Amplification was performed with HotStarTaq DNA Polymerase (Qiagen). Primers used 
for Zmynd8F, Pdap1F and Cd19Cre/+ genotyping listed in Table 1193. 
Regarding cell lines in culture, genomic DNA (gDNA) was extracted from at least 1x106 
pelleted cells that were subsequently incubated overnight with 0.1 mg/ml of Proteinase 
K diluted in proteinase K buffer (100 mM Tris pH 8, 0.2% SDS, 200 mM NaCl, 5 mM 
EDTA) at 55 ºC. Samples were transferred to 2 mL Phase Lock Gel tubes (VWR) and 
the same volume of Phenol:Chloroform:Isoamyl alcohol (Roth) was added. After 
centrifugation (13000 rpm for 20 min at RT), the upper aqueous phase was transferred 
to a new 1.5 ml tube and the same procedure was repeated once. The aqueous phase 
was then mixed with 1/10 volume of 3 M Sodium Acetate pH 5.2, 2.5X volumes of 100% 
ethanol and 1 mg/ml of glycogen (Roth). After 30 min incubation at -20 ºC, samples were 
centrifuged (13000 rpm for 15 min at 4 ºC) and precipitated gDNA was washed twice in 
70% ethanol. Air-dried pellets were finally resuspended in of pre-warmed TE buffer 
(ThermoFisher Scientific). gDNA of Zmynd8- and Pdap1-KO clonal derivatives was 
amplified with HotStarTaq DNA Polymerase (Qiagen) by PCR. Primers are listed in table 
Table 1. 
 
3.2.4 CRISPR/Cas9 loss-of-CSR screen 
For the functional loss-of-CSR of potential RIF1-interacting factors, 3 - 6 gRNAs per 
candidate were cloned into the U6 cassette of pX458 plasmid (pSpCas9(BB)-2A-GFP, 
Addgene #48138). gRNAs were designed by using a bioinformatic tool available on-line 
developed by the Zhang’s lab (www.crispr.mit.edu)194. To somatically target the selected 
putative phospho-53BP1 interactors, 3 gRNAs per candidate were cloned into the U6 
cassette of a modified version of the pX330 vector that encodes for GFP (kind gift from 
Klaus Rajewsky’s lab; T2A-GFP was cloned into pX330-U6-Chimeric_BB-Cbh-hspCas9, 
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Addgene #42230). gRNAs were designed with CrispRGold by Robin Graf (Klaus 
Rajewsky’s lab) before this bioinformatic tool was published195. As a negative control for 
both loss-of-CSR screens, CH12 cells were transfected with empty pX458 or pX330 
vectors or including gRNAs against random sequences not present in the mouse 
genome (GeCKO library196). gRNAs sequences are listed in Table 2. In all cases, cloning 
was performed following a previously described protocol from Zhang’s lab197. Stbl3 
bacteria were transformed with cloned plasmids and DNA was purified (PureLink HiPure 
Plasmid Midiprep Kit, ThermoFisher Scientific). All constructs were verified by 
sequencing and diagnostic digestion. 1x106 bulk WT CH12 cells were electroporated with 
10 μg of the Cas9-gRNAs expressing constructs (either individually or in a pooled 
equimolar format) by using the Neon Transfection System (ThermoFisher Scientific) and 
subsequently seeded in complete RPMI lacking antibiotics. Electroporating conditions 
were: 1600 volts, 20 milliseconds and 1 pulse. Following 40 h of incubation, nucleofected 
cells were collected, resuspended in PBS/FBS, filtered and sorted in bulk based on their 
GFP-positive expression. Samples were then resuspended at a concentration of 3x104 
cells/ml in complete RPMI additionally supplemented with gentamicin (0.01 mg/ml). After 
72 h of recovery, cells were activated for CSR and IgA levels were determined by flow 
cytometry after two days (see CSR ex vivo and in vitro). 
 
3.2.5 CRISPR/Cas9-mediated generation of KO clonal derivatives 
For the generation of Zmynd8-KO CH12 and iMEFs clonal derivatives, either single 
gRNAs were cloned into pX458 (WT Cas9), or paired gRNAs were introduced into 
tandem U6 cassettes in a modified version of pX458 expressing a mutated form of Cas9 
(Nickase Cas9, Cas9D10A) to reduce possible off-target effects. To generate Pdap1-
deficient CH12 single clones, 3 gRNA pairs were cloned into tandem U6 cassettes in a 
modified version of pX330-GFP encoding for Cas9D10A (Nickase-a/c). In all cases, cloning 
was performed using Gibson Assembly master mix (BioLabs). gRNAs sequences are 
listed in Table 2. Stbl3 bacteria were transformed with cloned plasmids and DNA was 
purified (PureLink HiPure Plasmid Midiprep Kit, ThermoFisher Scientific). All constructs 
were verified by sequencing and diagnostic digestion. Bulk CH12 and iMEFs cells were 
electroporated with the Cas9-gRNAs expressing constructs by using the Neon 
Transfection System (ThermoFisher Scientific) and subsequently seeded in 
supplemented RPMI (CH12) or DMEM (iMEFs) lacking antibiotics. Electroporating 
conditions for iMEFs were: 10 μg DNA per 5x105 cells; 2500 volts, 10 milliseconds and 
1 pulse. Following 40 h of incubation, electroporated cells were collected, resuspended 
in PBS/FBS, filtered and single cell sorted in 96-well plates based on their GFP-positive 
expression. CH12 clones were allowed to grow for 12 days in complete medium 
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supplemented with gentamicin (0.01 mg/ml) and subsequently re-arrayed in 3 replica 96-
well plates: one plate was used for CSR activation and measuring the percentage of IgA-
positive cells by flow cytometry; another plate was kept in culture to expand selected 
clones based on their viability and CSR levels determined by FACS; and the last plate 
was frozen at -80 ºC. Following 17 days of culture post-sorting, iMEFs clones were 
expanded. CH12 and iMEFs clonal derivatives were validated at the level of genomic 
scar and protein expression. Negative controls included WT cultures (non-
electroporated), WT clonal derivatives and clones resulting from targeting CH12/iMEFs 
bulk cultures with random sequences not present in the mouse genome (GeCKO 
library196). 
 
3.2.6 CRISPR/Cas9-mediated CSR 
In order to induce CSR in CH12 independently of cytokine addition, Sμ and Sα regions 
were targeted by CRISPR/Cas9198. Single gRNAs complementary to these two regions 
were cloned in a modified version of the pX458 vector containing two tandem U6 
cassettes. Control construct was generated by cloning two random sequences not 
present in the mouse genome on the same plasmid. CH12 cells were subsequently 
electroporated using the same conditions described above and the Neon Transfection 
System (ThermoFisher Scientific). Following 12 h of incubation, samples were collected, 
stained with fluorochrome labeled anti-IgA-PE antibody (1:400 v/v; Southern Biotech), 
washed, resuspended in PBS/FBS and acquired by flow cytometry.  
 
3.2.7 Primary B cell isolation and culture 
Primary B cells were isolated from the murine spleen, which was mashed with the 
plunger of a 3 ml syringe, resuspended in 10 ml of cold PBS/FBS (1X PBS– 3% FBS) 
and filtered through a 0.70 μM cell strainer. Following centrifugation, pellets were 
resuspended in 1 – 3 ml of ACK (ammonium-chloride-potassium) lysis buffer 
(ThermoFisher Scientific) in order to lyse the erythrocytes. The reaction was stopped 
after 3 min by adding 10 – 12 ml of cold PBS/FBS and samples were centrifuged at 1200 
rpm for 5 min at 4 ºC. Each sample was resuspended in 900 μl of cold PBS/FBS and 
100 μl of anti-CD43 (Ly-48) microbeads (Miltenyi Biotec). After incubation in a turning 
wheel at 4 ºC for 20 – 30 min, samples were diluted in 10 ml of cold PBS/FBS and filtered 
through a 0.45 μM mesh into a new tube. Centrifugation was carried out at 1200 rpm for 
5 min at 4 ºC and pellets resuspended in 1 ml of cold PBS/FBS were transferred to 
previously equilibrated magnetic MACS MS columns that were attached to an 
OctoMACS manual separator (Miltenyi Biotec). Columns were washed with 1 extra ml of 
cold PBS/FBS and samples containing mature naïve B cells were eluted in 8 ml of cold 
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PBS/FBS. Following centrifugation (1200 rpm for 5 min at 4 ºC), pellets were 
resuspended in 10 – 12 ml of cold complete RPMI 1640 (10% FBS, 10 mM HEPES, 
1mM Sodium Pyruvate, 2 mM L-Glutamine, 1X Antibiotic Antimycotic, 50 μM 2-
Mercaptoethanol). An aliquot of cells was stained with Trypan Blue (ThermoFisher 
Scientific) and live mature naïve B-lymphocytes were manually counted with a Neubauer 
chamber. Cells were seeded at a concentration of 1.25 – 2.5x105 cells/ml in 6-well, 10 
cm or 25cm plates and activated with different cytokines mixes (see CSR ex vivo and in 
vitro). 
 
3.2.8 CSR ex vivo and in vitro  
Primary B cells were cultured for 96 h with a combination of cytokines to induce CSR to 
different isotypes: 5 – 25 μg/ml LPS and 5 ng/mL of mouse recombinant IL-4 (Sigma-
Aldrich) (IgG1); 5 – 25 μg/mL LPS (IgG3); ; 5 μg/ml LPS, 10 ng/ml BAFF 
(PeproTech) and 2 ng/ml TGF (R&D Systems) (IgG2b); 5 μg/ml LPS, 10 
ng/ml BAFF, 2 ng/ml TGF and 1.5 ng/ml recombinant murine IL-5 (PeproTech) for 
(IgA). Cell suspensions were stained with fluorochrome-conjugated antibodies in 
PBS/FBS for 20 min at 4 ºC: anti-IgG1-APC (BD Biosciences), anti-IgG2b-PE 
(BioLegend), anti-IgG3-biotin and Streptavidin-APC (BD Biosciences), anti-IgA-PE 
(Southern Biotech) (1400 v/v). Cells were washed, resuspended in PBS/FBS and the 
percentage of switching cells was measured by flow cytometry. 
CH12 cells were seeded at a concentration of 3 – 5x104 cells/ml in complete RPMI 1640 
containing 1 – 5 μg/ml of anti-CD40 (BioLegend), 5 ng/ml TGF and 5 ng/ml IL-4 to 
induce CSR to IgA. Following 48 h of activation, cell suspensions were collected and 
stained with anti-IgA-PE (1:400 v/v) in PBS/FBS for 20 min at 4 °C. Cells were then 
washed, resuspended in PBS/FBS and CSR levels were assessed by flow cytometry. 
 
3.2.9 Cell proliferation analysis and cell counting 
Isolated naïve mature CD43- B-lymphocytes were resuspended in a 1X PBS solution 
containing 5 μM of CTV (cell trace violet) or in incomplete RPMI supplemented with 2 
μM of CFSE (carboxyfluorescein succinimidyl ester) (ThermoFisher Scientific) at a 
concentration of 2x106 cells/ml (CTV) or 10x106 cells/ml (CFSE). Splenocytes were 
stained for 10 min at 37 ºC in the dark and subsequently washed with complete RPMI. 
Cells were seeded at a concentration of 1.25 – 2.5x105 cells/ml in complete RPMI and 
different cytokine mixes were added to induce CSR to different isotypes (see CSR ex 
vivo and in vitro). Once the staining was completed, stained samples plus an unstained 
control were acquired by flow cytometry to determine that 1) the staining worked and 2) 
all samples were stained equally. On the following days (48, 72 and 96 h post-seeding), 
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cells were collected, washed and resuspended in PBS/FBS. Proliferation profiles were 
compared by flow cytometry.  
In order to track differences among samples in cell growth, isolated primary B-
lymphocytes were seeded at a concentration of 1.25 – 2.5x105 cells/ml in complete RPMI 
and activated with LPS and IL-4 (IgG1). Following 48, 72 and 96 h post-activation, cells 
were stained with Trypan Blue and manually counted with a Neubauer chamber. 
 
3.2.10 Immunization and blood serum collection 
In order to induce a T cell-dependent immune reaction, 9-18 weeks-old mice were 
injected intraperitoneally with 100 μg of NP16-CGG (4-Hydroxy-3-nitrophenylacetyl 
hapten conjugated to chicken gamma globulin, ratio 16; ThermoFisher Scientific) 
previously precipitated in alum199. The conjugation ratio refers to the molar ratio of hapten 
groups (NP) to protein (CGG) present, so in this case 16 NP haptens were conjugated 
to each CGG molecule. For NP16-CGG precipitation, a PBS-alum solution (100 mg/ml) 
was freshly prepared by dissolving 1 g of KAI(SO4)2 (Sigma-Aldrich) in 10 ml of 1X PBS. 
NP16-CGG was resuspended in sterile 1X PBS at a concentration of 1 mg/ml and 
subsequently mixed at a 1:1 ratio in the alum solution. pH was adjusted to 6.5 – 7 by 
adding NaOH and, as a consequence, NP16-CGG and alum precipitated together. This 
precipitate was washed 3 times with sterile 1X PBS by centrifugation at 5000 rpm for 15 
sec. Pellet was resuspended in sterile 1X PBS to get a final NP16-CGG concentration of 
0.5 μg/μl and a final alum concentration of 50 μg/μl. 200 μl of this alum-precipitated NP16-
CGG solution were injected per mouse. 
Blood was collected from the tail of animals on the same day before immunization and 
after 7 and 20 days. In order to obtain serum from blood, samples were first incubated 
in a shaking block heater at 37 ºC during 5 – 8 min, allowing for fast coagulation. The 
clot was subsequently removed by centrifugation at 4000 rpm for 10 min at 4 ºC. 
Supernatant was transferred to a new tube and samples were spin down one more time 
to remove the residual clot. Final supernatant was aliquoted and stored at -20 ºC. 
 
3.2.11 ELISA (enzyme-linked immunosorbent assay) 
To measure the levels of NP-specific IgM and IgG1 antibodies in serum, 96-well plates 
(high binding) were first coated with NP22-BSA (kind gift from Klaus Rajewsky’s lab) 
diluted in 1X BBS (NaCl, H3BO3, NaOH) at a concentration of 2 μg/ml. Following 
overnight incubation at 4 ºC, plates were washed thrice with TPBS (0.05% Tween in 1X 
PBS). To prepare standard curves, NP-IgG1 and NP-IgM stock aliquots (1 mg/ml; kind 
gift from Klaus Rajewsky’s lab) were added to coated plates at a concentration of 20 
μg/mL and serially diluted (4X) in TPBS. 1.63 μl of serum per sample were pipetted into 
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a well containing 80 μl of TPBS (100X dilution) and serial dilutions (8X) were performed. 
Plates were kept overnight at 4 ºC, washed thrice with TPBS and incubated with 
biotinylated anti-IgG1 or IgM biotinylated antibodies (Southern Biotech) at a final 
concentration of 1 μg/ml for at least 2 h at RT or overnight at 4 ºC. Wells were washed 
thrice with TPBS and incubated with Streptavidin conjugated to alkaline phosphatase 
(Streptavidin-AP; 1:6000 v/v; Sigma-Aldrich) for 2 h at RT. An additional washing was 
performed with 1 M diethanolamine buffer (10 mM diethanolamine, 0.5 mM MgCl2, pH 
9.8). Next, samples were treated with 2 mg/mL of 4-nitrophenyl phosphate (Sigma-
Aldrich), which reacts with alkaline phosphatase and produces a yellow solution that 
absorbs light at 405 nm. Reaction was stopped by addition of 1N NaOH and samples 
were measured with SpectraMAX 340PC microplate reader (405 nm). Concentrations of 
NP-specific serum IgG1 and IgM antibodies were quantified relative to NP-binding IgG1 
and IgM standards, respectively.  
The same protocol was followed to measure total IgM and IgG1 levels in serum before 
immunization. In this case, plates were coated with goat anti-lambda and goat anti-kappa 
UNLB (Southern Biotech) and standard curves were prepared with mouse IgM- or IgG1-
UNLB (Southern Biotech).  
 
3.2.12 Retroviral infection and AID overexpression 
In order to produce viral particles, BOSC23 packaging cells (containing gag and pol)191 
were seeded at a concentration of 2x105 cells/ml in complete DMEM in 10 cm plates. On 
the following day, cells were transfected with pMX-IRES-GFP (empty vector)200 or pMX-
AIDER-IRES-GFP (vector containing the coding sequence for AID fused to the estrogen 
receptor; kind gift from Michel Nussenzweig’s lab) and pCL-Eco (vector encoding for a 
murine-specific ecotropic envelope to the virus, so viral particles can only infect murine 
cells). Transfection was carried out by mixing the described vectors with FuGENE HD 
Reagent (Promega) in Opti-MEM medium (ThermoFisher Scientific), inducing the 
generation of viral particles that were released to the supernatant by proliferating 
BOSC23 cells. Splenocytes were isolated, activated with LPS and IL-4 (IgG1) or 
LPS, BAFF and TGF  (IgG2b) and seeded at a concentration of 2.5x105 cells/ml in 6-
well plates. After 16 h, the supernatant of BOSC23 (which were transfected 48 h before) 
was collected with a syringe and filtered through a 0.40 μM filter. Polybrene (homemade) 
was added at a concentration of 10 μg/ml in order to reduce the charge repulsion 
between viral particles and the cell surface, increasing infection efficiency200. B cells tend 
to attach to the bottom of the plate and, therefore, the supernatant could be gently 
removed with a P1000 micropipette and saved. 2 ml of the virus-polybrene mix were 
added to each well and spinoculation was carried out by centrifuging plates at 2350 rpm 
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for 1.5 h at 37 ºC. Splenocytes were subsequently incubated with the virus for 4 h and 
then the previously saved B cell medium containing cytokines was added back to the 
wells. Another round of infection was performed the following day. In order to induce AID 
translocation to the nucleus, 0.05 μM of 4-hydroxytamoxifen (4-HT; Sigma-Aldrich) was 
added to the B cell cultures 72 h post-seeding. Cells were collected 24 h later, stained 
with fluorochrome conjugated antibodies diluted in PBS/FBS (1:400 v/v) to determine the 
surface expression of IgG2b-PE and IgG1-APC. Samples were incubated for 20 min at 
4 ºC, washed and resuspended in PBS/FBS. CSR levels were assessed on GFP+-gated 
populations (i.e. infected cells). 
 
3.2.13 Analysis of B cell development 
For analysis of murine B cell development, spleens were mashed, resuspended in cold 
PBS/FBS and filtered as described above (see primary B cell isolation and culture). To 
obtain cell suspensions from the bone marrow, femurs from mice were flushed in cold 
PBS/FBS and solutions were filtered (50 μM filter). Following centrifugation at 1200 rpm 
for 5 min at 4ºC, supernatants were removed, and cells were incubated with 1 – 3 mL of 
ACK lysis buffer for erythrocytes depletion. The reaction was stopped after 3 min by 
adding 10 – 12 ml of cold PBS/FBS and samples were spin down, resuspended in cold 
PBS/FBS, stained with Trypan Blue and counted with a Neubauer chamber. Next, cells 
were blocked with Fc-block (TruStain FcX, anti-mouse CD16/32; BioLegend) at a 
concentration of 1 μg per 1x106 cells for 10 min at 4 °C. This reduces non-specific binding 
of the subsequently used antibodies to the Fc receptors expressed by different cell types 
in the spleen and bone marrow. Then, cells were labeled with fluorochrome conjugated 
antibodies to determine the surface expression of CD43, IgM (BD Biosciences), and 
CD19 (BioLegend) (bone marrow) and of CD3, CD19, IgM, CD23 (BioLegend), IgD and 
CD21/CD35 (BD Biosciences) (spleen). Antibodies were diluted in PBS/FBS (1:400 v/v) 
and samples were stained for 20 min at 4 °C. Cells were then washed, resuspended in 
PBS/FBS and analyzed.  
 
3.2.14 SHM analysis 
Cell suspensions from Peyer’s patches of 30-31 (ZMYND8 project) and 24-27 (PDAP1 
project) weeks-old mice were obtained following the same approach described above. 
After Fc-blocking, cells were labeled with anti-CD19, anti-B220/CD45R (BioLegend), 
anti-CD38 (ThermoFisher Scientific) and anti-Fas/CD95 (BD Biosciences) conjugated 
antibodies (1:400 v/v) for 20 min at 4 ºC in cold PBS/FBS. Following washing and filtering 
(50 μM filter), suspensions of non-GC (NGC; CD38+ Fas/CD95-) and GC B cells (CD38- 
Fas/CD95+) were sorted directly into proteinase K buffer (1-2x106 NGC and 3-5x105 GC 
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B cells per sample). Proteinase K (Peqlab) was added at a concentration of 0.2 mg/ml 
and samples were incubated overnight at 55 ºC. Genomic DNA was extracted with 
Phenol:Chloroform:Isoamyl alcohol (Roth) (see Genotyping). The 5’ portions of JH4 (Igh) 
and JK5 (Igk) introns were amplified by PCR using Phusion High-Fidelity DNA 
Polymerase (ThermoFisher Scientific) using a forward primer that binds to a degenerate 
VH or VK  family region and a reverse oligo complementary to the 3’ intronic segment of 
JH4 or JK5. 800 bp JH4 and 700 bp JK5 PCR products were run in an agarose gel, 
extracted with NucleoSpin Gel and PCR Clean-up Purification Kit (Macherey-Nagel) and 
cloned into a pCR2.1 vector using the TOPO TA Cloning Kit (ThermoFisher Scientific). 
TOP10 bacteria were transformed, and purified DNA (NucleoSpin DNA Purification Kit, 
Macherey-Nagel) was sent for sanger sequencing. Obtained sequences were aligned to 
unmutated 3’ intronic JH4 or JK5 regions and mutations were quantified over 510 bp 
downstream JH4 and 536 bp downstream JK5 gene segments. Primers used for SHM 
analysis are listed in Table 324,201. 
 
3.2.15 Assessment of GC B cells and CSR in vivo 
In order to measure GC and CSR levels in vivo, Peyer’s patches from the murine 
intestine were isolated and grinded with two glass microscope slides with a back and 
forth motion in cold PBS/FBS. Cell suspensions were filtered (50 μM filter) and 
centrifuged at 1500 rpm for 10 min at 4ºC. Pellets were resuspended in 5 mL of cold 
PBS/FBS and cells were blocked with 5 μg of Fc-block (TruStain FcX, anti-mouse 
CD16/32; BioLegend) to reduce non-specific antibody binding. Following 10 min of 
incubation, cells were stained with fluorochrome-conjugated anti-CD19, anti-
B220/CD45R (BioLegend) anti-CD38 (ThermoFisher Scientific), anti-Fas/CD95 (BD 
Biosciences) and anti-IgA (Southern Bioetch) (1:400 v/v) for 20 min at 4 ºC in cold 
PBS/FBS. Cells were washed, filtered, resuspended in cold PBS/FBS and analyzed by 
flow cytometry. GC B cells are CD19+, B220/CD45R+, CD38- and Fas/CD95+. IgA levels 
were measured on gated GC B cells. 
 
3.2.16 Metaphase analysis 
iMEFs were seeded at a concentration of 3x104 cells/ml (WT, Rc and Zmynd8-KOs) or 
6x104 cells/ml (Brca1-/-) in complete DMEM. PARPi (Olaparib; Selleckchem) was added 
to the cultures on the following day at a final concentration of 2 μM. After 21 h of 
incubation, iMEFs were treated with 5 μg of Colcemid (Sigma-Aldrich) for 1 h to block 
cells in the metaphase stage of mitosis. Cells were collected and gently resuspended in 
pre-warmed 0.075M KCl at 37 ºC while being vortexed in order to avoid the formation of 
clumps. Cell suspensions were incubated at 37 ºC for 20 min to perform a hypotonic 
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shock. Samples were subsequently washed and fixed with a freshly prepared 
methanol/glacial-acetic acid (fixative) solution. Since cells were swollen due to the 
hypotonic shock and in order to prevent cell clumping, this solution was gently added 
while constantly shaking the tubes manually. Samples were incubated for 30 min at room 
temperature (RT) and washed twice, resuspended in fixative and kept at 4 ºC. 
Metaphase spreads were prepared by dropping fixed cells on tilted microscope slides 
with a pasteur pipette from at least 30 cm height distance. Slides were placed on a 
humidifier for 1 – 2 min, air-dried and incubated at 42 ºC for 1 h. Giemsa staining was 
performed by treating slides first with KaryoMAX Giemsa stain solution (ThermoFisher 
Scientific) for 2 min then with Gurr buffer solution (ThermoFisher Scientific) and lastly 
washed with ddH2O. Drying was performed overnight at RT. Metaphases were acquired 
with the Automated Metaphase Finder System Metafer4 at 63X magnification. 
Chromosome radials were manually counted from at least 42 metaphases per sample. 
 
3.2.17 RT-qPCR (quantitative reverse transcription PCR) 
In order to determine Aicda mRNA, germline transcripts and 3’RR hs eRNAs levels in 
primary B cells, splenocytes were isolated and cultured with different cytokine mixes to 
induce CSR to different isotypes (see CSR ex vivo and in vitro). Following 48 h of 
incubation, samples were collected by centrifugation (1500 rpm for 5 min and 4 º C) and 
washed with 1X PBS. Total RNA was extracted using TRIzol (ThermoFisher Scientific) 
or RNeasy Mini Kit (Qiagen) according to manufacturer’s instructions. RNA quality and 
concentration were determined using a NanoDrop spectrophotometer. When using 
TRIzol, genomic DNA (gDNA) was depleted by RapidOUT DNA Removal kit 
(ThermoFisher Scientific). 1 μg of RNA was used to synthesize cDNA with SuperScript 
VILO kit (ThermoFisher Scientific). Luna Universal qPCR Mastermix (SYBBR Green-
based; NEB) was mixed with 6.25 – 12.5 ng (Aicda mRNA and GLTs) or 25 – 50 ng 
(3’RR hs eRNAs) of cDNA and 10 μM of specific forward and reverse primers (listed in 
Table 4)53,202,203. RT-qPCR was carried out in triplicates using a StepOnePlus Real-Time 
PCR System (Applied Biosystems) and non-retrotranscribed and non-template samples 
were used as negative controls. Amplification conditions were: 95 ºC for 2 min and 40 
cycles of 95 ºC for 15 sec and 60 ºC for 1 min, followed by a melting curve). Analysis 
was performed with StepOne software and expression fold change was calculated based 
on double delta Ct value. Data were normalized to Ubc or Gapdh (Aicda mRNA and 





3.2.18 Aicda mRNA decay analysis 
To assess Aicda mRNA decay, Actinomycin D (Sigma-Aldrich) was added at a final 
concentration of 10 μg/ml to the medium of IgG1- and IgG2b-activated splenocytes 
previously cultured for 48 h. Cells were treated for 0.5, 1, 1.5, 2, 3 and 4 h and 
subsequently collected by centrifugation (1500 rpm for 5 min and 4 º C). RNA was 
isolated with TRIzol according to manufacturer’s instructions, gDNA was depleted by 
RapidOUT DNA Removal kit and cDNA was synthesized with SuperScript VILO kit 
(ThermoFisher Scientific). RT-qPCRwas performed as described above. Primers used 
are listed in Table 4150. 
 
3.2.19 RNA-seq and splicing analysis 
The RNA-seq analysis for the ZMYND8 project was performed by Daniel B. Rosen at 
the Rockefeller University (RU) in New York. CH12 cells were cultured in activated (anti-
CD40, TGF and IL-4) and un-activated conditions for 48 h. Samples were subsequently 
collected by centrifugation (1500 rpm for 5 min at 4 ºC) and RNA was isolated with 
AllPrep DNA/RNA Mini Kit (Qiagen). Ribosomal RNA was depleted using Ribo-Zero Gold 
rRNA Removal kit and libraries were prepared with TruSeq Stranded Total RNA Library 
Prep Kit (Illumina) following manufacturer’s instructions. Three biological replicates per 
sample were run in two lanes on the same flow cell on NextSeq High Output 75 SR 
(Illumina). For data analysis (performed by Thiago Y. Oliveira and Joy A. Pai at RU), 
sequences were pseudo-aligned to an index created from the Ensembl mouse 
GRCm38.p5 assembly and custom annotations of Igh locus features. Transcript-level 
abundances were quantified using kallisto v0.43.0204, and subsequently summarized to 
the gene-level using the R package tximport205. Differential gene expression analysis 
was performed using DESeq2206.  
Regarding the PDAP1 project, RNA-seq was performed in primary B cell cultures of 3 
control and 3 Pdap1-deficient mice cultured in LPS and IL-4 (IgG1) and LPS, BAFF and 
TGF (IgG2b) for 48 h. Samples were subsequently collected by centrifugation (1500 
rpm for 5 min at 4 ºC) and RNA was extracted with TRIzol. RNA quality and 
concentrations were determined using Qubit RNA HS Assay Kit (ThermoFisher 
Scientific). Ribosomal RNA was depleted using Ribo-Zero Gold rRNA Removal kit and 
libraries were prepared with TruSeq Stranded Total RNA Library Prep Kit Gold following 
manufacturer’s instructions (Illumina). Samples’ concentration and quality were 
determined using Qubit dsDNA HS Assay Kit (ThermoFisher Scientific) and library size 
was assessed with 4200 TapeStation System (Agilent). Samples were run in one lane 
on a flow cell of HiSeq 4000 (Illumina). Resulted data was analyzed by Robert Altwasser 
using the pigx-rnaseq pipeline207. STAR208 mapped reads to Ensembl mouse 
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GRCm38.p5 assembly and HTSeq209 was used to count transcript abundance. 
Differential gene expression analysis was performed using DESeq2206.  
 
For splicing analysis of Aicda and Pdap1 genes we used the edgeR210 package for R to 
determine differentially expressed exons. The annotation was provided by a filtered 
version of the GRCm38 gene annotation, which contained unique, Havana annotated 
exons. 
 
3.2.20 Mutational analysis (MutPE-seq) 
To determine the frequency of AID-induced mutations at 5’ Sμ, primary B cell cultures 
were activated with LPS and IL-4 (IgG1) for 72 or 96 h. Samples were collected by 
centrifugation (1500 rpm for 5 min at 4 ºC) and gDNA was extracted with phenol-
chloroform-isoamyl alcohol (Roth) (see Genotyping). To amplify 5’ Sμ amplicons, 100 ng 
of gDNA were mixed with Phusion High-Fidelity DNA Polymerase (ThermoFisher 
Scientific or NEB) and locus-specific primers for 5’ Sμ. PCR conditions were: 98 ºC for 
30 sec, 20 cycles of 98 ºC for 10 sec, 64.9 ºC for 15 sec and 72 ºC for 30 sec and a final 
extension step of 72 ºC for 5 min. DNA was gel-extracted (250 bp) and purified by 
NucleoSpin Gel and PCR Clean-up kit (Macherey-Nagel) and 2/3 of the resulting product 
were used as template for a second PCR to introduce sequencing adapters and sample-
specific indexes. Amplification conditions were: 98 ºC for 30 sec, 15 cycles of 98 ºC for 
10 sec, 64.6 ºC for 15 sec and 72 ºC for 30 sec and a final extension step of 72 ºC for 5 
min Gel-extracted and purified amplicons (390 bp) were pooled and sequenced by 
MiSeq (2 x 300 bp paired-end read sequencing). Mutations present in both paired reads 
were considered as AID-induced mutations. Bioinformatic analysis was performed by 
Thiago Y. Oliveira and Joy A. Pai at RU. Primers used are listed in Table 593.  
 
3.2.21 Clonogenic survival assay 
To determine cell survival following DNA damage, iMEFs were plated in 60 mm dishes 
Following 24 h of culture, cells were either irradiated with the indicated doses or treated 
with 0.1, 1 and 5 μM of PARPi (Olaparib; Selleckchem). In the latter case, media and 
PARPi were replenished after 7 days. iMEFs were incubated for a total of 14 days post-
seeding and supernatant was aspirated from the plates. 3 biological and 3 technical 
replicates were performed. Colonies were subsequently fixed with 15% acetic acid-
methanol solution (v/v) for 5 min, stained with 0.5% Crystal Violet (Sigma-Aldrich) for 30 
min and washed twice with 1X PBS. Plates were scanned and colonies were quantified 
with manually with ImageJ software.  
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3.2.22 Switch junction analysis 
To amplify Sμ – Sγ1 junctions, primary B cells were isolated and activated with LPS and 
IL-4 (IgG1). Following 96 h of culturing, gDNA was extracted using 
phenol:chloroform:isoamyl alcohol (Roth) (see Genotyping). Amplification was carried 
out by two rounds of PCR using Phusion High-Fidelity DNA Polymerase (ThermoFisher 
Scientific). Amplification conditions for the first PCR were: 98 ºC for 30 sec, 10 cycles of 
98 ºC for 10 sec and 72 ºC for 2 min and a final extension step of 72 ºC for 10 min. 
Amplification conditions for the second PCR were: 98 ºC for 30 sec, 20 cycles of 98 ºC 
for 10 sec and 72 ºC for 2 min and a final extension step of 72 ºC for 10 min. Amplicons 
were run on agarose gels and 350 – 1000 bp fragments were extracted with NucleoSpin 
Gel and PCR Clean-up Purification Kit (Macherey-Nagel) and cloned into a pCR2.1 
vector using the TOPO TA Cloning Kit (ThermoFisher Scientific). TOP10 bacteria were 
transformed, and purified DNA (NucleoSpin DNA Purification Kit, Macherey-Nagel) was 
sent for sanger sequencing with M13 forward and reverse universal oligos. Primers used 
for this analysis are listed in Table 696. 
 
3.2.23 Cell lysates and immunoblotting  
Frozen cell pellets at -80 ºC were thawed by resuspension in cold lysis buffer (20X 
complete protease inhibitor and 1000X 1 M DTT (ThermoFisher Scientific) in RIPA buffer 
(Sigma-Aldrich)). Samples were incubated for 20 min at 4 ºC and subsequently 
centrifuged at 12700 rpm for 10 min at 4 ºC. Supernatant was used to determine protein 
concentration by Bradford Assay. Standard curve was prepared with different 
concentrations of BSA (10 mg/ml) diluted in lysis buffer. Lysates were mixed with 4X 
NuPAGE LDS Protein Loading buffer (ThermoFisher Scientific) supplemented with 6X 1 
M DTT and boiled at 72 ºC for 10 min. Samples were loaded into precast polyacrylamide 
gradient gels (NuPAGE 3-8% Tris-Acetate or 4-12% Bis-Tris; ThermoFisher Scientific) 
and proteins were separated by electrophoresis in running buffer (NuPAGE MES, MOPS 
or Tris-Acetate  SDS)  at 120 V until the dye reached the front. Proteins were transferred 
to a PVDF (polyvinylidene difluoride, Millipore) membrane using the Mini Trans-Blot Tank 
(ThermoFisher Scientific) containing transfer buffer (25nM Tris, 192 mM glycine, 20% 
methanol) at 200 mA for 1.5 – 2 h. To reduce unspecific antibody binding, membranes 
were incubated in blocking buffer (3% BSA (Albumin IgG-free; Roth) in 1X PBS – 0.1% 
Tween) shaking for 1 h at RT or overnight at 4 ºC. Primary antibodies were diluted in 
blocking buffer and added to membranes that were incubated in sealed pouches for 1 h 
at RT or overnight at 4 ºC (constant shaking): rabbit anti-ZMYND8, mouse anti-Actin, 
anti-PDAP1 (Sigma-Aldrich), rat anti-AID (ThermoFisher Scientific). Membranes were 
subsequently washed 3 times in 1X PBS – 0.1% Tween for 10 min at RT and constant 
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agitation. Horseradish peroxidase (HRP)-tagged secondary antibodies raised against 
mouse, rabbit or rat (kind gift from Fritz Rathjen’s lab) IgG were diluted in blocking buffer 
(1:20000, v/v) and membranes were incubated for 1 h at RT (constant shaking). 
Following 3 additional washes in 1X PBS – 0.1% Tween, membranes were activated 
with freshly prepared chemiluminescence solution (PerkinElmer) and exposed to films 
(Amersham hyperfilm ECL, VWR) that were developed using the OPTIMAX 2010 film 
developer.  
 
3.2.24 I-DIRT and immunoisolation of RIF1FH complexes 
Primary B cells were isolated from the spleen of Rif1FH/FH and wt mice as described 
above. Splenocytes were cultured in complete SILAC-RPMI (-Arg, -Lys) medium 
(ThermoFisher Scientific) supplemented dialized FBS (ThermoFisher Scientific)  and 
with either 13C6 L- arginine and 13C6 L- lysine (heavy medium; Rif1FH/FH; Cambridge 
Isotope Laboratories) or non-labeled L-arginine and L-lysine (light medium; wt; Sigma-
Aldrich), respectively. Cells were treated with LPS and IL-4 to induce CSR to IgG1 and 
also with anti-CD180 (RP/14; BD Biosciences) to promote B cell proliferation. Following 
96 h of incubation, splenocytes were irradiated (20 Gy) to increase the amount of DSBs 
and put back in culture for 45 min to allow for recovery. 2 x109 cells per genotype were 
collected by centrifugation, resuspended in 20 mM HEPES containing 1.2% 
polyvinylpyrrolidone (Sigma-Aldrich), protease and phosphatase inhibitor cocktails 
(Roche), 0.5 mM DTT, and frozen in liquid nitrogen. Rif1FH/FH and wt frozen cells were 
mixed in a 1:1 ratio and cryogenically lysed by wet grinding in a Planetary Ball Mill PM 
100. The resulting frozen product was thawed by resuspension in extraction buffer (20 
mM Tris-Cl pH 8, 150 nM NaCl, 0.5% Igepal CA-630 (Sigma-Aldrich), 1.5 mM MgCl2, 
Benzonase (Sigma-Aldrich) and protease and phosphatase inhibitor cocktails). 
Glutaraldehyde (Sigma-Aldrich) was added to the buffer (2.5 mM) in order to stabilize 
labile interactions while preserving the native composition of protein complexes211. 
Following 5 min incubation, reaction was stopped with 100 mM Tris-Cl pH 8.0 and lysate 
was centrifuged at 13000 rpm at 4 ºC. Supernatant was directly incubated with magnetic 
beads (M-270 Epoxy beads; ThermoFisher Scientific) conjugated to anti-Flag M2 
antibody (Sigma-Aldrich) for 1 h at 4 ºC96. Sample was washed with extraction buffer and 
RIF1FH bait and associated protein were eluted twice under native conditions by two 
rounds of incubation with 2.5 μg/μl 3XFlag peptide (Sigma-Aldrich). Following 45 min of 
incubation at 4 ºC (constant shaking), sample was loaded into a 4 – 12% Bis-Tris precast 
polyacrylamide gradient gel (ThermoFisher Scientific). Proteins were separated by 
electrophoresis and subsequently stained with Coomassie blue. The gel was divided into 
upper and lower parts based on the 39 kDa molecular weight marker. The upper part 
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was cut in 5 portions and all gel pieces were subjected to in-gel tryptic digestion. Peptides 
were extracted and purified, analyzed by LCMS using a Thermo Q Exactive Plus mass 
spectrometer, with a Thermo Easy-nLC 1000 HPLC and a Thermo Easy-Spray 
electrospray source. Identification and quantification of proteins was performed by 
searching against a mouse protein sequence database with the MaxQuant software 
(version 1.2.2.5)212. Dan B. Rosen performed the I-DIRT, immunoisolation of RIF1-
containing complexes and mass spectrometry in collaboration with the laboratory of 
Brian T. Chait at the RU.  
 
3.2.25 Immunofluorescence 
iMEFs were seeded on coverslips placed into 12-well plates that were incubated 
overnight. Cultures were subsequently irradiated (10 Gy) and put back in culture for 
either 90 min or 6 h to allow for recovery. Cells were gently washed with 1X PBS 
and fixed with 2 ml of freshly prepared 4% paraformaldehyde solution in 1X PBS (Sigma-
Aldrich) for 10 min at RT. After three washings, permeabilization was performed with 2 
ml of 0.5% Triton X-100 for 5 min at RT. Plates were additionally rinsed 3 times with 1X 
PBS and incubated with blocking solution (2.5% goat serum and 1% BSA in 1X PBS) 
shaking for 1 h at RT or overnight at 4 ºC. Primary antibodies were diluted in blocking 
solution and cells were stained with mouse anti-γH2AX (1:500 v/v; Millipore), rabbit anti-
RIF1 serum96, mouse anti-53BP1 (Millipore), mouse anti-Flag M2 or rabbit anti-ZMYND8 
(Sigma-Aldrich) for 1 h at RT. Coverslips were washed once with 2 ml of 0.1% Triton X-
100 (in 1X PBS) for 5 min at RT and subsequently rinsed twice with 1X PBS. Samples 
were incubated with fluorochrome-conjugated secondary antibodies goat anti-rabbit 
Alexa546 and goat anti-mouse Alexa488 (1:500 v/v; ThermoFisher Scientific) together 
with DAPI (1:1000 v/v) for 1 h at RT. Coverslips were rinsed three times with 1X PBS 
and placed on microscope slides using mounting medium (Prolong Gold Antifade 
Mountant, ThermoFisher Scientific). Images were acquired with an inverted LSM700 
laser scanning confocal microscope (Zeiss) and processed with Fiji software. These 
experiments and analyses were performed by Devakumar Sundaravinayagam.  
 
3.2.26 ChIP-seq (chromatin immunoprecipitation coupled with sequencing) 
ChIP-seq analysis for ZMYND8 in CH12 was performed by Qiao Wang. ChIP-seq 
analysis for ZMYND8 and RNAPII in primary B cells were conducted by me (splenocytes 
isolation, culture and fixing) and Daniel B. Rosen (libraries preparation). Computational 
analysis was done by Thiago Y. Oliveira and Joy A. Pai. Primary B cells were extracted 
and stimulated with LPS and IL-4 for 72 h. CH12 cells were cultured in activating (anti-
CD40, TGF and IL-4) or non-activating conditions for 48 h. Samples were counted, 
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collected by centrifugation (1500 rpm for 5 min at 4 ºC) and fixed with 1% of 16% 
Formaldehyde Methanol-free (ThermoFisher Scientific) for 10 min at 37 ºC. Reaction 
was quenched by adding 1/20 volume of 2.5M glycine dissolved in 1X PBS pH 7.4 (final 
concentration 0.125 M) and swirling. Fixed cells were washed with cold 1X PBS, 
centrifuged (1500 rpm for 5 min at 4 ºC), aliquoted (20 x106 cells/aliquot), frozen in liquid 
nitrogen and stored at -80 ºC. Frozen pellets were resuspended in 100 μl of 1% SDS of 
RIPA buffer supplemented with Complete-EDTA free protease inhibitor (Roche) and 
incubated for 20 min at 4 ºC. Sonication was performed with a Covaris S220 Focused 
Ultrasonicator at peak value 105, duty factor 5, cycle/burst 200 for 10 min. Next, SDS 
concentration was adjusted to 0.1% by diluting samples with non-SDS containing RIPA 
buffer and tubes were centrifuged at 14000 rpm for 10 min at 4 ºC. Chromatin fragments 
were pre-cleared by incubation with Dynabeads Protein A (ThermoFisher Scientific) with 
rotation at 4 ºC for 1 h. Samples were subsequently mixed with 10 μg of antibody specific 
for ZMYND8 (Sigma-Aldrich) or RNAPII (phospho-S5; 4H8, Abcam) previously bound to 
Dynabeads. This allowed for immunoprecipitation of cross-linked DNA fragments 
associated with either ZMYND8 or RNAPII. Samples were incubated with Proteinase K 
(Peqlab) for 4 h at 65 ºC and DNA was extracted with phenol:chloroform:isoamyl alcohol 
(Roth). DNA libraries were prepared using Illumina compatible adaptors (Bio Scientific) 
and sequenced on an Illumina NextSeq 500 sequencer (Illumina). FASTQ files were 
aligned against mouse genome (mm10) using Burrows-Wheeler Alignment tool213. 
Processing and peak-calling of ChIP-seq data were accomplished with HOMER ChIP-



















4.1 Identification of novel CSR factors 
 
4.1.1 Functional loss-of-CSR screen 
To identify bona-fide effectors involved in CSR, a robust functional screen was 
established in the B cell lymphoma line CH12F13 (CH12) that can be induced to express 
AID and undergo class switching to IgA with high efficiency upon in vitro cytokine 
treatment189,216. B cells cannot be transfected via classical methods (calcium phosphate, 
lipofectamin, etc.), and the efficiency of retroviral transduction is drastically affected by 
the size of the Cas9-containing vectors (>10 Kb). Therefore, as a first step, the conditions 
for efficient expression of Cas9 and guide RNAs (gRNAs) targeting were set up by 
electroporating a pX330 variant vector that contains GFP co-translationally expressed 
with Cas9 (pX330-T2A-GFP)197,217. Different electroporation parameters (voltage, width 
and pulse) were tested in order to find the optimal conditions for efficient transfection of 
CH12 cells, being 1600 volts, 20 milliseconds and 1 pulse the best combination (data 
not shown). Subsequently, the loss-of-CSR assay was set up by targeting Aicda gene, 
which encodes for AID and it is an essential factor for antibody isotype differentiation53. 
Positively nucleofected cells somatically targeted with 3 independent gRNAs against 
Aicda showed an 80-90% decrease in CSR when compared to control (cells 
electroporated with an empty pX330-T2A-GFP vector, EV) (Figure 4.1A). Next, several 
gRNAs were designed to disrupt Trp53bp1 gene that encode for the DSB repair factor 
53BP1, since 53BP1-deficient primary mouse B cells exhibit a dramatic reduction of CSR 
efficiency (more than 90%)218,219. Surprisingly, no major reduction in the percentage of 
IgA positive cells was observed when employing the same conditions that resulted in a 
drastic CSR deficiency of Aicda-targeted CH12 cells (Figure 4.1B, left panel). This could 
be due to a protein turnover issue, since AID expression is induced only upon activation 
for CSR and 53BP1 is constitutively expressed. Therefore, even if Trp53bp1 had been 
correctly disrupted following Cas9-gRNA electroporation, it is possible that the previously 
translated protein was still available when cells were stimulated to undergo CSR. To test 
this, the time in culture in between nucleofection and cytokine treatment was extended 
by sorting the positively electroporated GFP positive cells, allowing the cells to undergo 
more cell divisions and 53BP1 proteasomal degradation. Accordingly, the residual CSR 
levels dropped to 40-50%, which ensured a large dynamic range to further perform the 
screen (Figure 4.1B, right panel). These experimental conditions (Figure 4.1C) were 
further validated by targeting Rif1, since deletion of this factor in primary B cells leads to 
a 80-85% decrease in CSR96. In line with Trp53bp1 disruption in CH12 and the fact that 
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53BP1-deficiency affects CSR more dramatically than Rif1 absence in primary B cell 
cultures, Rif1-targeted cells showed a 50-60% reduction in the percentage of IgA positive 
cells (Figure 1D). Altogether, a robust loss-of-CSR assay was set up for the functional 
screening of potential candidates involved in CSR.  
 
 
Figure 4.1. Loss-of-CSR CRISPR/Cas9 in CH12 cells. 
A. Left: flow cytometry plots measuring the percentage of nucleofected CH12 cells (GFP+; top) 
and CSR to IgA (bottom) after CRISPR/Cas9 somatic targeting of Aicda with three different 
gRNAs. Right: summary graph representing CSR to IgA relative to the empty vector (EV) value. 
N.E., non-electroporated. B. Dot plots showing CSR to IgA in Cas9/gAicda- and Cas9/gTrp53bp1-
nucleofected CH12 cells activated subsequently to electroporation (left) or after sorting and 
culturing the positively targeted cells (right). Data were normalized to the mean value of the control 
samples (Ctrl: EV or gRandom), which was set to 100%. C. Scheme representing the 
experimental conditions for the loss-of-CSR screen by CRISPR/Cas9 in CH12 cells. D. Graph 
summarizing the validation of the loss-of-CSR screen in CH12 by somatic targeting of Aicda, 
Trp53bp1 and Rif1 genes following the scheme in (C). Graph summarizes three independent 
experiments where either Aicda, Rif1 or Trp53bp1 was targeted with different gRNAs. CSR is 






4.1.2 Identification of potential factors involved in CSR 
The RIF1 protein interactome in primary B-lymphocytes undergoing CSR was studied in 
order to define the pool of novel factors that could be regulating antibody isotype 
differentiation. A SILAC-based (Stable Isotype Labeling by Amino acids in Cell culture) 
approach was optimized for the targeted identification of bona-fide, and likely transient, 
RIF1 interactors (Isotopic Differentiation of Interactors as Random or Targeted, I-
DIRT)220. This method consists on culturing cells expressing a tagged protein of interest 
and un-tagged cells in media that are differentially isotopically labeled, allowing for 
identification of specific interactors of the tagged factor. For this purpose, mice bearing 
a homozygous 1X Flag – 2X hemagglutinin (HA) – tagged knocked-in version of RIF1 
that can still support CSR to wild-type (WT) levels were used (Rif1FH/FH). WT cells 
expressing endogenous RIF1 were isolated in parallel and cultured in isotopically labeled 
light medium whereas RIF1FLAG-HA splenocytes were cultured in isotopically labeled 
heavy medium. Both cell populations were irradiated (20 Gy) to increase DSB formation 
and processed for anti-FLAG immunoprecipitation (Figure 4.2A). A collaboration was 
established with Brian Chait’s laboratory at the Rockefeller University (RU) to optimize 
the experimental conditions in order to identify RIF1 weak, transient or rapidly 
exchanging interactions221. Specifically, cells were frozen in liquid nitrogen to preserve 
native interactions and subsequently subjected to cryomilling to generate frozen cell 
micron fragments that can be rapidly deepen in a solvent. Lastly, glutaraldehyde was 
added to chemically stabilize protein complexes before cell lysis. This cross-linking 
reagent had been previously shown to have a high reactivity and stabilizing properties 
at low temperatures222,223.  
Upon immuno-isolation of RIF1-interacting complexes, the vast majority of identified 
proteins displayed a SILAC ratio characteristic of pull-down contaminant, with several 
proteins exhibiting a ratio significantly higher than the mean of the distribution, being 
RIF1 bait and 53BP1 the top hits (Figure 4.2B). To increase the confidence selecting 
potential new RIF1-interacting candidates, the subsequent functional loss-of-CSR 
analysis was limited to candidates that: 1) exhibited a SILAC ratio more than 2 standard 
deviations (SD) (0.095) above the mean of the distribution (0.49); 2) have been identified 
with at least 4 peptides; and 3) exhibited an overall PEP (Posterior Error Probability)224 
≤1x10-4. Moreover, the resulting candidates were shortlisted based on previous literature 
suggesting a role in DNA repair, leading to a final list of fourteen potential RIF1 
interactors. The loss-of-CSR assay was performed on these factors and IgA levels were 
measured after targeting each of them with three to six different pooled gRNAs. 
“Random” gRNAs (sequences not present in the mouse genome), and gRNAs against 
Aicda, Rif1 and Trp53bp were used in parallel as negative and positive controls for the 
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assay, respectively. gRNAs were designed using a robust online tool 
(www.crispr.mit.edu)194 that predicted sequence-specific gRNAs and off-target effects. 
For each candidate, a literature search was done in order to look for available KO (knock-
out) mouse models or cell lines that gave information about which exon to target. 
ZMYND8 (Zinc Finger MYND-type [myeloid, Nervy, and DEAF-1] containing 8), also 
known as RACK7 and PRKCBP1, was one of the top potential RIF1 interacting 
candidates and was identified as a hit. Consequently, its genomic disruption led to a 
clear CSR decrease in CH12 (Figure 4.2C). This factor had been previously shown to 
be a chromatin reader that binds to enhancers and super-enhancers to regulate 
transcription, acting mostly as a repressor225–228. Moreover, it had been described to act 
at sites of DNA damaged within transcriptionally active chromatin to repress transcription 
and promote HR-dependent repair229–233. Considering that transcription, DNA repair and 
enhancer activity are crucial steps in CSR, ZMYND8 was selected for further studying 
its role in regulating antibody isotype differentiation. 
 
 
Figure 4.2. Screening for novel RIF1-interacting CSR factors in B-lymphocytes. 
A. Experimental scheme of the identification of RIF1-interactome in stimulated primary B-
lymphocytes by I-DIRT (Isotopic Differentiation of Interactions as Random or Targeted). FH: 
FLAG-HA tag; IR: ionizing radiation; GA: glutaraldehyde; LC-MS/MS: liquid chromatography-
tandem mass spectrometry. B. Top: graph depicting the RIF1-interacting proteins identified by I-
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DIRT following the scheme in (A) and plotted based on their H/(H+L) ratio. Data was filtered to 
show factors with a peptide count ≥ 4 and a posterior error probability ≤ 10-4. Each candidate’s 
error bar indicates the standard error of its H/(H+L) mean value. Bottom: table specifying the 
peptide count and H/(H+L) mean for 53BP1 and ZMYND8. C. Graph showing CSR to IgA in 
activated CH12 cells after CRISPR/Cas9 somatic targeting of the indicated candidates resulting 
from the RIF1 I-DIRT. At least three independent experiments were performed for each candidate. 
Error bars indicate SD.  
 
An independent list of potential phospho-dependent 53BP1 interactors identified by 
SILAC-based approach that was previously published was used for the functional screen 
of loss-of-CSR96. Briefly, Trp53bp1-deficient primary B cultures undergoing CSR were 
infected with a retrovirus containing either the cDNA for a WT or for a phospho-deficient 
version of 53BP1 fused to a FLAG tag (53BP1PM-FLAG). After isotopic labeling, cells were 
irradiated to increase the load of DSBs, and 53BP1-interacting factors were 
immunoprecipitated with an anti-FLAG antibody (Figure 4.3A). Since 53BP1 depends 
on ATM-mediated phosphorylation to function in CSR during DSB repair98,99,147,148, 
potential candidates that specifically interacted with WT 53BP1 (that can undergo 
phosphorylation) were selected. The SD, peptide number and PEP cut-off values 
described above were also employed here to increase the confidence in the selection of 
potential interactors. In this case, a list of thirty-three potential phospho-53BP1 
interactors were assessed for their function in CSR. In this case, gRNAs were designed 
with CrispRGold, which predicts off-target effects and provides sequences that hit the 
maximum number of isoforms195. Upon genomic targeting by CRISPR/Cas9, Mrpl14, 
Eif4g2 and Pdap1 showed the most dramatic reduction in IgA levels compared to 
“Random” controls (Figure 4.3B). MRPL14 is a component of the mitochondrial large 
ribosomal subunit234–236, which seemed to be important for B cell viability (data not 
shown). EIF4G2 (eukaryotic translation initiation factor 4 gamma 2) is a cap-binding 
factor that plays a role in translation initiation237–239. PDAP1 (platelet-derived growth 
factor-associated protein 1) is a protein of 181 amino acids highly conserved in 
vertebrates initially identified as a casein kinase II substrate240,241.  It has been described 
to putatively bind RNA in human cell lines in several RNA-protein interactome studies242–
246. An additional study showed that PDAP1 is overexpressed in glioma cells and it is 
related to malignant proliferation through up-regulation of PDGF-B/Akt/PDK1 
signaling247. Lastly, a recent publication suggested a potential role of PDAP1 in STAT6 
– ERK – NF-κB network248. Given the limited information available in literature about the 
function in PDAP1 and its degree of conservation, this candidate was selected for further 




Figure 4.3. Screening for novel phospho-53BP1-interacting CSR factors in B-lymphocytes. 
A. Experimental scheme of the identification of 53BP1-interactome in stimulated primary B-
lymphocytes by SILAC (Stable Isotope Labeling by Amino acids in Cell culture)96. 53BP1WT-FLAG: 
53BP1Wild-Type-FLAG; 53BP1PM-FLAG: 53BP1Phospho-Mutant-FLAG. LC-MS/MS: liquid chromatography-
tandem mass spectrometry. IR: ionized radiation. B. Graph showing the percentage of IgA 
positive cells in activated CH12 after CRISPR/Cas9 somatic targeting of the indicated candidates 
resulting from the 53BP1 SILAC. At least three independent experiments were performed for each 
candidate where error bars depicting the SD are shown. Significance was calculated with the 
Mann-Whitney U test. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. 
 
4.2 The chromatin reader ZMYND8 regulates the 3’ Igh enhancer to promote CSR 
 
4.2.1 ZMYND8 is essential for efficient CSR 
In agreement with the loss-of-CSR screen results showed above, somatic targeting of 
Zmynd8 in CH12 cells led to a significant decrease in the percentage of IgA positive cells 
and ZMYND8 protein expression, compared to control (cells electroporated with an EV 
or with a “random” gRNA that does not target any region in the mouse genome) (Figure 
4.4A-B). To further dissect the role of this factor in CSR, Zmynd8- KO clonal derivatives 
were generated by using the nickase version of Cas9 (Nickase-Cas9D10A), which exhibits 
reduced off-target effects197. This mutant version of the protein generates a nick instead 
of a DSB. Therefore, only when using two gRNAs that target close regions in opposite 
strands, the two nicks are converted into a DSB. As expected, these KO clones were 




Figure 4.4. Deletion of Zmynd8 in CH12 causes loss of CSR. 
A. Representation of the murine Zmynd8 locus and the genomic location of the gRNAs used in 
this study. Single gRNAs that guide a WT-Cas9 are shown in red, whereas gRNA pairs that guide 
a Nickase-Cas9D10A are depicted in blue. B. Flow cytometry plots representing the percentage of 
IgA positive cells (left top) and Western Blot (WB) analysis of WCE (whole-cell-extracts) (left 
bottom) from somatically targeted CH12 cells with CRISPR/Cas9 and the indicated gRNAs. Ctrl 
(control) stands for cells electroporated with an EV or with a gRandom. Right: graph summarizing 
the CSR data to IgA of three independent experiments after normalizing data to the control value 
that is set to 100%. C. Left: summary dot plot of IgA levels in Random Aicda- and Zmynd8-KO 
activated CH12 cells (clonal derivatives). Values of control cell lines were averaged and set to 
100% for normalization. Data is representative of two independent experiments. Right: WB 
analysis of WCE from WT CH12 cells and two independent Zmynd8-KO clonal derivatives. 
Significance in (B) and (C) was calculated with the Mann-Whitney U test. *p ≤ 0.05.  
 
To confirm the results in CH12 and dive into the mechanistic aspects of ZMYND8 in 
antibody isotype differentiation, a conditional Zmynd8-KO mouse model was generated. 
Specifically, the KO-first allele with conditional potential Zmynd8tm1a(EUCOMM)Wtsi mouse 
was purchased and crossed to a flippase-expressing mouse line (Rosa26Flpo). Next, 
Zmynd8F/+ mice, exhibiting two LoxP sites flanking exon 4, were backcrossed to a 
C57BL/6 (wt) mouse to confirm germline transmission. Positive Zmynd8F/+ heterozygous 
pups were intercrossed to get a homozygous Zmynd8F/F allele. Finally, these mice were 
crossed to a Cd19Cre/+ mouse to conditionally delete Zmynd8 in B-lymphocytes 
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(Zmynd8F/F Cd19Cre/+) (Figure 4.5A). Of note, CD19 is a B cell marker that is expressed 
early on during development, specifically at the pro-B cell stage (see section 1.3)37,188. 
This implies that Zmynd8 is deleted at the initial stages of B cell differentiation when 
expressing Cre under the control of CD19. As expected, primary B-lymphocytes from the 
newly generated mouse model Zmynd8F/F-Cd19Cre/+ showed a major reduction of 
ZMYND8 protein expression as determined by WB analysis (Figure 4.5B).  
 
 
Figure 4.5. Generation of a conditional Zmynd8 knock-out mouse model. 
A. Top: representation of the KO-first allele with conditional potential Zmynd8tm1a mouse model. 
Bottom: scheme of the same locus after flippase (FLP) recombination.  FRT: flippase recognition 
target; LoxP: lox site. B. WB analysis of WCE from splenocytes of the indicated genotypes 
cultured for 72 h in the presence of LPS and IL-4. Triangles represent threefold dilution.  
 
B cells present different markers on their surface depending on their developmental 
stage, which can be used as a tool to determine distinctive B cell populations by flow 
cytometry (see section 1.3)36. This approach was used to study B cell development in 
ZMYND8-deficient cells collected from the spleen and the bone marrow (BM). B-
lymphocytes seemed to differentiate comparably to control, evidencing that ZMYND8 
does not play a role in B cell development or V(D)J recombination (Figure 4.6A-B). 
Moreover, ZMYND8 protein expression was not induced upon cytokine stimulation and 
levels did not vary during CSR induction as assessed by WB analysis of Cd19Cre/+ 




Figure 4.6. ZMYND8 is dispensable for B cell development. 
A. Representative flow cytometry plots of the indicated surface markers in the bone marrow (BM) 
and spleen of Zmynd8F/F Cd19Cre/+ and Zmynd8+/+ Cd19Cre/+ mice. B. Summary graphs for three 
independent experiments of the data shown in (B). C. WB analysis of WCE from un-activated (0h) 
mature Zmynd8+/+ Cd19Cre/+ B lymphocytes and after CSR induction in the presence of LPS and 
IL-4 for 48 and 72 h. 
 
CSR of IgM to other isotypes can be induced in vitro by different cytokine treatments. 
Specifically, LPS and IL-4 stimulates switching to IgG1; LPS, TGFβ and BAFF promote 
IgG2b CSR; and LPS alone induces the expression of IgG3 in the surface of B cells (see 
section 1.5.1). WT and ZMYND8-deficient splenocytes were cultured in the presence of 
these different cytokine cocktail mixes to study the requirement of ZMYND8 for CSR in 
primary B cells. ZMYND8 deficiency lead to a significant and consistent reduction of all 




Figure 4.7. ZMYND8 is a novel factor required for CSR ex vivo. 
A-C. Top: representative flow cytometry plots indicating the percentage of IgG1 (LPS and IL-4) 
(A), IgG2b (LPS, TGFβ and BAFF) (B) and IgG3 (LPS) (C) positive cells of Zmynd8F/F Cd19Cre/+ 
and Zmynd8+/+ Cd19Cre/+ splenocytes stimulated for the indicated time points. Bottom: graph 
summarizing the data of at least five mice per time point and per genotype. Significance was 
calculated with the Mann-Whitney U test and error bars represent SD. *p ≤ 0.05, **p ≤ 0.01, ***p 
≤ 0.001, ****p ≤ 0.0001. 
 
To further understand if the CSR defect observed in cultured splenocytes is a reflect of 
a defective immune response in vivo, control and Zmynd8 conditional KO mice were 
immunized. Antibody titers present in the serum 7 days (peak of germinal center 
formation) and 20 days post-immunization were determined by ELISA (enzyme-linked 
immunosorbent assay). Specifically, NP-CGG antigen (4-Hydroxy-3-nitrophenylacetyl 
hapten conjugated to chicken gamma globulin) was used to induce a T cell-dependent 
response that promotes B cell activation, GC formation and, therefore, SHM and CSR249. 
As shown in Figure 4.8, ZMYND8 deficiency lead to a significant decrease in NP-specific 
IgG1 antibodies compared to control, both at day 7 and day 20 after immunization. NP-
specific IgM titers were slightly decreased at the immunization day (day 0) and merely 
increased at day 7, which correlates with the reduced ability of ZMYND8-deficient cells 
to undergo CSR. Altogether, these data evidenced that ZMYND8 is required for efficient 




Figure 4.8. ZMYND8 is a novel factor required for CSR in vivo. 
Summary plots for the titers of NP-reacting IgM (left) and IgG1 (right) antibodies in the serum of 
Zmynd8F/F Cd19Cre/+ and Zmynd8+/+ Cd19Cre/+ before (Day 0) and after 7- and 20-days post-
immunization with NP-CGG antigen. Graph summarizing the data of at least five mice per time 
point and per genotype. Significance was calculated with the Mann-Whitney U test and error bars 
represent SD. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001. 
 
4.2.2 ZMYND8 is dispensable for B cell proliferation 
B cell proliferation and cell cycle progression is a limiting step for CSR to happen, since 
undivided B-lymphocytes do not undergo antibody isotype differentiation and AID 
expression is cell-division dependent (see section 1.5.5)93,107,111.To assess if ZMYND8 
plays a role in cell cycle progression, WT and ZMYND8-deficient splenocytes were 
labeled with Cell Trace Violet (CTV). This fluorescent dye can permeate the plasma 
membrane and form covalent bonds to free amines that are present on the cellular 
surface and intracellularly. Upon cell division, the dye content gets diluted by half and 
changes can be tracked daily by flow cytometry, allowing the comparison of cells from 
different genotypes250. Splenocytes were isolated, labeled with CTV and stimulated with 
different cytokines to undergo CSR to IgG1, IgG2b and IgG3. CTV dilution profiles from 
ZMYND8-deficient B cells were comparable to those from WT at all time points measured 
(Figure 4.9A-C) and CSR was reduced in all cell cycle divisions upon ZMYND8 deletion 
(Figure 4.9D). Moreover, no significant changes in cell growth were observed upon CSR 
induction of splenocytes from the two genotypes (Figure 4.9E), leading to the conclusion 




Figure 4.9. ZMYND8 is dispensable for B cell proliferation. 
A-C. Representative histogram flow cytometry plots showing Cell Trace Violet (CTV) dilution of 
labeled splenocytes of the indicated genotypes stimulated for 48, 72 and 96 h in the presence of 
LPS and IL-4 (A), LPS, TGFβ and BAFF (B) and LPS (C). Data were derived from at least two 
mice per genotype. D. Flow cytometry analysis indicating the percentage of IgG1 positive cells in 
each cell division as measured by CFSE dye dilution. Primary B lymphocytes were isolated from 
Zmynd8F/F Cd19Cre/+ and Zmynd8+/+ Cd19Cre/+ mice and cultured for 72h with LPS and IL-4. Data 
are representative of two independent experiments with at least four mice per genotype.  E. Graph 
summarizing the number of cells per milliliter of splenocytes from the indicated genotypes cultured 
for 48, 72 and 96 h in the presence of LPS and IL-4. Data are representative of two independent 
experiments with at least four mice per genotype.   
 
4.2.3 ZMYND8 does not regulate the repair of DSBs  
Upon AID-mediated DSB formation within the S regions, the DDR is activated, and DNA 
repair factors mediate c-NHEJ, leading to productive CSR events. Alternatively, these 
DSBs can be internally re-joined preferentially with the use of microhomologies that are 
exposed by limited resection within the S regions, which are internally repetitive94,95. By 
protecting DNA ends against resection, phosphorylated 53BP194,95,98,101,147,148 and its 
downstream effector RIF196,97,100,137 counteract this unproductive micro-homology-
mediated intra-switch region repair and favor classical end-joining of distal S breaks (see 
section 1.5.4 and 1.7). To determine the consequences of ZMYND8 ablation in DNA 
damage-induced signaling cascade and DNA repair, Zmynd8-/- immortalized mouse 
embryonic fibroblasts (iMEFs) were generated by CRISPR/Cas9 gene targeting (Figure 
4.10A-B). Of note, a “random” clone (Rc), was generated in parallel as a control by using 
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a gRNA not present in the mouse genome. iMEFs constitute an ideal model system for 
performing assays that require adherent cells and for determining the recruitment of DNA 
repair factors to sites of ionizing radiation (IR)-induced DNA damage, that can be 
observed microscopically as foci (in the majority of cases). Although ZMYND8 localized 
into the nucleus, it did not seem to be a focus forming protein (Figure 4.10A).  
 
 
Figure 4.10. Generation of Zmynd8-KO iMEFs. 
A-B. Representative immunofluorescent staining images (A) and western blot analysis (B) of WT 
and Zmynd8-/- immortalized mouse embryonic fibroblasts (iMEFs). Three different Zmynd8-/- 
clones derived from CRISPR/Cas9 somatic targeting (KO1, KO2 and KO3) were compared to 
control cell lines generated in parallel: WTc, a WT clonal derivative; R-1 and R-2, two independent 
WT clones nucleofected with a gRNA not present in the mouse genome.   
 
Importantly, ZMYND8 deficiency did not affect the DNA-damage induced signaling 
cascade, as measured by immunofluorescence staining of H2AX phosphorylation 




Figure 4.11. ZMYND8 is dispensable for the signaling of stochastic DNA damage. 
Representative immunofluorescent staining images for the indicated factors of irradiation-induced 
foci (10 Gy) in WT and Zmynd8-/- iMEFs following 90 min and 6 h of recovery. Data derive from 
two independent experiments.   
 
Since ZMYND8 had been previously suggested to play a role in DSB by HR229–233, 
clonogenic survival assays following IR and PARP inhibition were performed. IR leads 
to breaks preferentially repaired by NHEJ, while PARPi induces DNA replication 
associated breaks that are physiologically repaired by HR251,252. ZMYND8-deficient 
iMEFs cell survival was similar to controls (WT and Rc) in both treatment scenarios 
(Figure 4.12A-B). In agreement with the lack of sensitivity to PARPi, Zmynd8-/- iMEFs 
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did not show any significant difference in chromosomal aberrations compared to 
ZMYND8-proficient cells in the presence of PARPi. Brca1-/- iMEFs were used as a 
positive control, since this gene is a major component of HR and KO cells die when 
treated with PARPi due to their inability to repair breaks that occur during DNA replication 
(Figure 4.12C)253.  
 
 
Figure 4.12. ZMYND8 is dispensable for the repair of IR- and PARPi-induced DSBs. 
A-B. Graphs representing the percentage of cell survival as determined by colony formation 
assay of iMEFs cell lines of the indicated genotypes following ionized radiation (IR) (A) or PARP 
inhibition treatment (PARPi) (B). Each condition was performed in triplicates and error bars 
represent the mean. Data of two independent experiments per graph are shown.  C. 
Representative metaphase images (left) and graph summarizing the number of radials per cell 
observed in iMEFs clones of the indicated genotypes in the presence or absence of 2 μM of 
PARPi for 24 h (right). Data of at least 42 metaphases per condition are shown. Red arrows 
indicate radials. 
 
To determine if ZMYND8 is affecting the repair of DSBs in the context of antibody isotype 
differentiation, CSR was induced via CRISPR/Cas9 by targeting the Sμ (donor) and Sα 
(acceptor) regions in CH12 cells254. In this case, no cytokines were added to prevent the 
induction of AID-mediated DSBs. The percentage of IgA positive cells in ZMYND8-
deficient cells was comparable to WT and also to Aicda-/- cells, which were used as a 
positive control. Lig4-, Trp53bp1- and Rif1-KO cells were unable to rescue CSR due to 
their role in c-NHEJ. In these cases, residual IgA levels could be explained by the activity 
of the alt-NHEJ pathway that can join the DNA ends by using microhomology regions 
when c-NHEJ is defective (Figure 4.13)94,101,102. Furthermore, the consequence of 
ZMYND8 ablation in the repair of AID-induced DSBs at the S regions was determined 
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by amplifying the Sμ-Sγ1 junctions of IgG1 switched primary B-lymphocytes. Specifically, 
the frequency of blunt-joined DNA ends together with nucleotides insertions or deletions 
and microhomology at the junction was analyzed. No significance differences were 
observed when comparing Zmynd8F/F-Cd19Cre/+ to Cd19Cre/+ control splenocytes, 
indicating that ZMYND8 does not regulate microhomology mediated-end joining (MMEJ) 
of AID-induced breaks at the Igh locus (Figure S1). Altogether, these results 
demonstrated that ZMYND8 is dispensable for DSB-induced signaling and repair. 
 
 
Figure 4.13. ZMYND8 is dispensable for the repair of Cas9-induced DSBs. 
Left: experimental scheme of CSR assay induced via CRISPR/Cas9. Right: graph summarizing 
the percentage of IgA positive cells in un-activated CH12 cell lines of the indicated genotypes 
following somatic targeting of Switch-μ (gSμ) and Switch-α (gSα) regions. Data are representative 
of three independent experiments.     
 
4.2.4 ZMYND8 is not essential for AID expression and function 
In order for antibody isotype differentiation to efficiently occur, the two copies of the Aicda 
gene need to be expressed and the resulting AID protein has to target the S regions at 
the Igh locus. Therefore, Aicda haploinsufficiency and reduced AID expression or 
targeting result in CSR deficiency255,256. To first exclude the possibility that ZMYND8 is 
involved in Aicda transcription, Aicda mRNA levels in primary B cells were quantified by 
RT-qPCR (quantitative reverse transcription PCR). Differently to Aicda-KO cells that 
were used as a positive control, ZMYND8-deficient primary B-lymphocytes showed no 
apparent reduction in Aicda transcript levels compared to control (Figure 4.14A). To 
determine if ZMYND8 is regulating AID-dependent formation of DSBs, mutation rates at 
the 5’Sμ region were measured by paired-end next generation sequencing (MutPE-
seq)93,257. This assay allows for the detection of mutations introduced by AID. Since the 
S regions are highly repetitive, deep sequencing was carried at the 5’ extreme of Sμ, 
where a “footprint” of AID-mutations can be detected (Figure 4.14B, left). Moreover, 
amplification with low number of PCR cycles, the use of a proof-reading polymerase and 
the fact of having the information about the two strands of the DNA by pair-end 
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sequencing ensured the exclusive detection of AID-dependent introduced mutations. 
This assay was performed in splenocytes cultured in the presence of LPS and IL-4 for 
72 or 96 h and no differences were observed in any of the cases when comparing 
ZMYND8-deficient and -proficient cells (Figure 4.14B, right). Altogether, these data 
support the conclusion that ZMYND8 is not required for efficient Aicda gene expression 
and that ZMYND8 deficiency does not regulate AID function.  
 
 
Figure 4.14. ZMYND8 is dispensable for AID expression and induction of DSBs. 
A. RT-qPCR analysis of Aicda mRNA levels in splenocytes of the indicated genotypes stimulated 
to undergo CSR to IgG1 (LPS and IL-4), IgG2b (LPS, TGFβ and BAFF) and IgG3 (LPS) for 48 h. 
Data were normalized to a Cd19Cre/+ control within each experiment and error bars indicate SD.  
B. Left: scheme representing the mutations generated by AID in the region of the Igh locus 
confined in between JH4 and Cμ. Right: graph showing the relative mutation rates measured by 
MutPE-seq at 5’Sμ region in splenocytes of the indicated genotypes cultured in the presence of 
LPS and IL-4 for 72 or 96 h. Three independent experiments were performed, each column 
representing one mouse.  
 
4.2.5  ZMYND8 promotes efficient transcription of acceptor S regions 
AID targeting to the S regions depends on the noncoding transcription across the donor 
(Sμ) and acceptor S elements and the following constant genes (GLT)51,52,62. Sμ region 
is constitutively transcribed in naïve B cells and increases upon stimulation. On the other 
hand, GLT across the acceptor region(s) is induced in a cytokine dependent manner due 
to the accumulation of histone modifications that determine an open chromatin status 
(H3K4me3 and H3K9ac) at the same time the repressive marks H3K9me3 and 
H3K27me3 are removed10,82–84. Moreover, splicing of primary GLTs has been shown to 
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be required for efficient AID targeting to the S regions, although there are different 
models and still controversy in literature understanding the reason for it (see section 
1.5.3)58. To determine if ZMYND8 deficiency is regulating GLT or playing a role in 
splicing, Sμ and pre- and post-spliced Igγ1, Igγ2b and Igγ3 transcripts were amplified by 
RT-qPCR analysis on splenocytes stimulated to undergo CSR to IgG1, IgG2b and IgG3, 
respectively (Figure 4.15). Of note, cells were collected 48 h post-activation because 
GLT is an early event during antibody isotype differentiation.  
 
 
Figure 4.15. ZMYND8 is dispensable for Sμ (donor) GLT. 
Left: schematic representation of the position of the primers used to amplify post-spliced Sμ GLTs. 
Right: graphs representing the GLT levels of post-spliced Sμ in primary B-lymphocytes stimulated 
with LPS and IL-4 (IgG1), LPS, TGFβ and BAFF (IgG2b) and LPS (IgG3) for 48 h. Data were 
normalized to a Cd19Cre/+ control within each experiment.  
 
Whereas Sμ GLT in Zmynd8-KO cells was undistinguishable from control, pre- and post-
spliced acceptor GLT were significantly reduced in all isotypes tested upon Zmynd8 
deletion (Figure 4.16A-B). Conclusively, ZMYND8 is required for efficient transcription 




Figure 4.16. ZMYND8 supports GLT of acceptor S regions. 
Left: schematic representation of the position of the primers used to amplify pre- and post-spliced 
acceptor GLTs. Right: graphs representing the GLT levels of pre and post-spliced Sγ1, Sγ2b and 
Sγ3 in primary B lymphocytes stimulated with LPS and IL-4 (IgG1), LPS, TGFβ and BAFF (IgG2b) 
and LPS (IgG3) for 48 h. Data were normalized to a Cd19Cre/+ control within each experiment. 
Significance was calculated with the Mann-Whitney U test and error bars represent SD. **p ≤ 
0.01, ***p ≤ 0.001. 
 
4.2.6 ZMYND8 associates to the 3’ Igh enhancer and regulates its transcriptional 
activity 
ZMYND8 is a chromatin reader that associates with enhancers and super-enhancers 
through its interaction with H3K4me0, H3K4me1, H3K14Ac and H3K27Ac histone 
marks, promoting transcriptional repression and, in some cases, activation225,227–230,232. 
To further dissect the role of ZMYND8 in CSR, its association with the Igh locus was 
determined by chromatin immunoprecipitation coupled with high-throughput sequencing 
(ChIP-seq). Consistent with previous literature findings, ZMYND8 binding to the 
chromatin was enriched in the two major Igh super-enhancer regions: Eμ, located 5’ of 
Sμ; the uncharacterized enhancer in between Cγ1 and Sγ2b; and the 3’ regulatory region 
(3’RR), found at the 3’ end of the Igh locus and composed of four transcriptional 
enhancers (DNase 1 hypersensitive sites hs3a, hs1,2, hs3b and hs4) (see section 1.6) 
(Fig. 13A)17–19,25,27. Since ZMYND8 binding to chromatin was reported to have an effect 
on transcription, RNA polymerase II (RNAPII) loading at the Igh locus was measured by 
ChIP-seq analysis in stimulated ZMYND8-deficient and -proficient B cells. Importantly, 
the C-terminal domain of RNAPII is phosphorylated at different sites to modulate its 
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activity during transcription. Consequently, phosphorylation at Serine5 (RNAPII-S5) is 
enriched at promoters and transcription start sites of genes, signifying that the 
polymerase has been loaded. As transcription elongation takes place, S5 
phosphorylation is progressively removed at the same time S2 is phosphorylated258. 
Specifically, ZMYND8-deficient primary B-lymphocytes and CH12 cells showed a 
significant increase in RNAPII-S5 at the 3’RR compared to control, being the effect more 
prominent in hs1,2 and hs3b core enhancer regions (Figure 4.17A-B and Figure S3).  
 
 
Figure 4.17. ZMYND8 binds to Igh enhancers and regulates RNAPII loading at the 3’RR. 
A. Top: ZMYND8 and RNA polymerase II phosphorylated on serine 5 (RNAPII-S5) loading at the 
Igh locus as measured by ChIP-seq analysis in naïve B cells stimulated to undergo CSR to IgG1 
for 72 h. Bottom: overlaid RNAPII-S5 ChIP-seq tracks of Zmynd8F/F Cd19Cre/+ and 
Zmynd8+/+Cd19Cre/+ mice at Eμ and 3’RR enhancer regions. B. Quantification of RNAPII-S5 
occupancy at the 3’RR core enhancer regions hs4, hs3b, hs1,2 and hs3a (left) and at Eμ and 
3’RR enhancers (right). Data derived from 3 independent mice per genotype and error bars 
indicate SD. Significance was calculated with Welch 2 sample unpaired t-test. 
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RT-qPCR analysis of hs1,2 and hs3b in Zmynd8F/F-Cd19Cre/+ and Cd19Cre/+ splenocytes 
stimulated to undergo CSR to IgG1 and IgG3 confirmed that the increase in RNAPII 
loading at the 3’RR upon Zmynd8 deletion corresponded to increased transcription levels 
of eRNAs (enhancer RNAs) (Figure 4.18). Furthermore, RNA-seq analysis of two 
independent Zmynd8-KO CH12 clones provided the same results (Figure S2). 
Therefore, ZMYND8 binds to the 3’RR and modulates its transcriptional status by 
preventing its overexpression.  
 
 
Figure 4.18. ZMYND8 represses hs1,2 and hs3b transcription. 
A-B. RT-qPCR analysis of hs1,2 and hs3b eRNA levels in splenocytes stimulated to undergo 
CSR to IgG1 (A) or to IgG3 (B). Two different primer pairs located at the 5’ (5’hs3b) and at the 3’ 
(3’hs3b) regions of the hs3b core enhancer were used. Data were normalized to a Cd19Cre/+ 
control within each experiment. Significance was calculated with the Mann-Whitney U test and 
error bars represent SD. **p ≤ 0.01.   
 
4.2.7 ZMYND8 regulates SHM of the heavy chain locus 
The 3’RR has been shown to be required for efficient GLT as well as for SHM of the 
heavy chain locus (see section 1.6)22,24–27,128,129,134. SHM is the responsible process for 
increasing antigen affinity of antibodies and it is also dependent on AID, which introduces 
mutations in the variable regions of the heavy and light chain locus (see section 1.4)55,56. 
To further characterize the role of ZMYND8 in the 3’RR activity, the number of AID-
induced mutations in the variable regions of heavy and light chains were quantified. This 
experiment was performed in aged mice because Peyer’s Patches (accumulations of 
lymphoid follicles located in the intestine) contain activated B-lymphocytes that undergo 
SHM due to their continue exposure to food and exogenous antigens259–261. Specifically, 
this process happens in the so-called germinal centers (GCs), which are microanatomic 
structures of secondary lymphoid organs where SHM and CSR take place upon antigen 
encountering43. There are two possible light chains that can be rearranged and form a B 
cell receptor (BCR) together with the heavy chain during B cell development, Igκ and 
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Igλ. While human B cells present a ratio of 1.5:1 of Igκ to Igλ, murine B cells have a ratio 
of 19:1, which explains why the Igκ is considered over the Igλ when studying SHM in 
mice (see section 1.2.2)32. Genomic DNA was extracted from sorted GC and non-GC 
(NGC) B cells and the intronic regions located immediately downstream the recombined 
V(D)J in the heavy (Igh) and in the light (Igκ) loci were amplified and sequenced259,262,263. 
Amplicons were aligned to un-mutated JH4 and Jκ5 sequences and the number of point 
mutations were quantified. As expected, only GC B cells contained mutations, as SHM 
does not take place outside the GC (Figure 4.19A and 4.19D). Surprisingly, ZMYND8-
deficient GC B cells showed a decreased number of mutated sequences and mutation 
frequency as compared to Cd19Cre/+ cells at the 3’JH4 region (Figure 4.19A-B and 
4.19E). Moreover, GC B cells presented a bias towards low-mutated sequences and a 
significant decrease in high rate of mutations in this region upon Zmynd8 deletion. 
However, similar number and distribution of mutations were found in Zmynd8F/F-Cd19Cre/+ 
and Cd19Cre/+ GC B lymphocytes at the 3’JK5 region, which is not regulated by the 3’RR 
(Figure 4.19D and 4.19E). Altogether, these data indicated that ZMYND8 is exclusively 
required for efficient SHM at the heavy chain locus, supporting the hypothesis that this 




Figure 4.19. ZMYND8 is required for efficient SHM at the Igh locus. 
Genomic DNA from non-germinal center (NGC) and germinal center (GC) B cells from the Peyer’s 
Patches of un-immunized aged Zmynd8F/F Cd19Cre/+ and Cd19Cre/+ mice was amplified, cloned and 
analyzed (four mice per genotype). A. Cumulative pie charts representing the percentage of 
mutations in the 3’JH4 intronic region over 510bp sequence. B-C. Pie charts showing the 
percentage of mutations in the 3’JH4 intronic region of GC B cells from 4 independent Cd19Cre/+ 
(B) and aged Zmynd8F/F Cd19Cre/+ (C) mice. D. Cumulative pie charts representing the percentage 
of mutations in the 3’JK5 intronic region over 510bp sequence. E. Table specifying the number of 
sequences (N. seq), total bp analyzed, number of mutations (N. mut) and mutation frequency (per 
bp) in the 3’JH4 and 3’JK5 intronic regions of GC B cells shown in (A) and (D). Significance was 





4.3 PDAP1 is a novel CSR factor required for efficient AID expression and 
suppression of the integrated stress response 
 
4.3.1. PDAP1 required for CSR  
Since PDAP1 resulted a candidate of interest from the loss-of-CSR screen (Figure 
4.3B), Pdap1-/- CH12 clones were generated to validate the observed phenotype and 
further characterize the role of this factor in antibody isotype differentiation. To do so,  
three independent paired gRNAs were designed and cloned into a plasmid containing 
the nickase version of Cas9 (Cas9D10A) (Figure 4.20A). As expected, genomic Pdap1 
targeting led to a significant reduction of CSR (Figure 4.20B). Three clonal derivatives 
that showed a decrease in IgA levels were picked and their genomic scar and PDAP1 
protein expression were analyzed. Two of these clones, P1 and P2, showed frameshift 
and premature termination codons in both alleles, resulting in lack of PDAP1 protein. P3 
presented a 27 bp internal deletion within exon 4 that caused a decreased but still 
detectable PDAP1 protein (Figure 4.20C).  
 
 
Figure 4.20. Generation of PDAP1-deficient CH12 clones. 
A. Schematic representation of the murine Pdap1 locus. The location of 3 different gRNA pairs 
used in this study that guide a Nickase-Cas9D10A is indicated. B. Graphs showing the percentage 
IgA positive cells after somatic targeting of CH12 with gCtrl (paired random gRNAs) and three 
independent gRNAs pairs targeting the Pdap1 locus (Nickase-a, -b and -c). Each dot indicates a 
single CH12 clone. C. Left: table listing the genomic conformation of 2 independent Pdap1-/- (P1, 
P2 and P2) and 1 mutant Pdap1 (P3: Pdap1m) CH12 clones selected from analysis shown in (B). 
PCT: premature termination codon; fs: frameshift; het: heterozygous; homo: homozygous; Δ: 
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deletion. Right: WB analysis of WCE from two random (R1 and R2) and the 3 Pdap1 clones 
described on top. Asterisk marks an unspecific band. Significance was calculated with the Mann-
Whitney U test and error bars represent SD. **p ≤ 0.01, ***p ≤ 0.001. 
 
Moreover, these CH12 clones exhibited a significant reduction in CSR compared to 
controls when activated in vitro (Figure 4.21), indicating that the deletion observed in P3 
is not responsible for the loss of CSR caused by PDAP1. Altogether, these data confirm 
that PDAP1 is required for efficient antibody isotype differentiation in CH12 cells. 
 
 
Figure 4.21. PDAP1 is a novel factor required for CSR in CH12. 
Left: Representative flow cytometry plots showing the percentage of IgA+ cells from WT (parental 
cell line, R1 and R2), Pdap1-/- and Pdap1m CH12 cells following 48 h of stimulation with αCD40, 
TGFβ and IL-4. Right: Graph summarizing 4 independent experiments. Significance was 
calculated with the Mann-Whitney U test and error bars represent SD. *p ≤ 0.05. 
 
To validate the results obtained in CH12 and study the mechanistic aspects of PDAP1 
in CSR, a conditional Pdap1-KO mouse model was generated. Specifically, two LoxP 
sites flaking the exon 2 were introduced by CRISPR-Cas9 targeting and subsequent 
repair by HR. Importantly, the targeting vector contained silent mutations at the gRNA 
sequence site in order for Cas9 not to cut it (represented with an asterisk in the figure) 
(Figure 4.22A). The resulted Pdap1F/+ mouse was bred to get a homozygous Pdap1F/F 
allele, which was then crossed to a Cd19Cre/+ mouse to conditionally delete Pdap1 in B-
lymphocytes at early stages of B cell differentiation188. The conditional deletion of Pdap1 
and the lack of protein levels were assessed by PCR and WB analysis, respectively 




Figure 4.22. Generation of a conditional Pdap1-KO mouse model. 
A. Representation of the murine Pdap1 locus before and after CRISPR/Cas9 somatic targeting. 
Asterisk indicates silent mutations introduced within Cas9 target sites to exclude cutting of the 
targeting vector. HA: homology harm; LoxP: lox site. B. Top: schematic representation of the WT, 
Flox and deleted (Δ) Pdap1 alleles and the location of primers to detect these alleles. Bottom: 
PCR analysis of gDNA extracted from splenocytes of the specified genotypes and amplified with 
the primers indicated on (top). C. WB analysis of WCE from splenocytes of the indicated 
genotypes cultured for 96 h in the presence of LPS and IL-4. Triangles represent threefold dilution. 
Asterisk indicates an unspecific band. 
 
To understand if PDAP1 has any role in B cell development, surface expression of 
different markers that are expressed during B cell maturation in the bone marrow and 
spleen were determined by flow cytometry. PDAP1-deficient B-lymphocytes 
differentiated comparably to control, indicating that this factor does not play a role in 
V(D)J recombination or early B cell maturation (Figure 4.23A-B). However, a significant 
decreased number of mature B-lymphocytes (CD43-) was observed in the absence of 





Figure 4.23. PDAP1 is largely dispensable for B cell development. 
A. Representative flow cytometry plots of the indicated surface markers in the bone marrow (BM) 
and spleen of Pdap1F/F Cd19Cre/+ and Pdap1+/+ Cd19Cre/+ mice. Pdap1F/F Cd19+/+ were also used 
as a control. B. Summary graphs for 2 independent experiments of the data shown in (A). C. 
Number of resting B (CD43-) cells isolated from spleens of the genotypes indicated in (B). Each 
dot represents a different mouse. Significance was calculated with the Mann-Whitney U test and 
error bars represent SD. ***p ≤ 0.001. 
 
To study the requirement of PDAP1 for CSR in primary B cells, WT and PDAP1-deficient 
splenocytes were cultured in the presence of different cytokine cocktail mixes and IgG1, 
IgG3, IgG2b and IgA levels were measured over time. The resulted data indicated that 





Figure 4.24. PDAP1 is required for efficient CSR ex vivo. 
A-D. Left: Representative flow cytometry plots indicating the percentage of IgG1 (LPS and IL-4) 
(A), IgG3 (LPS) (B), IgG2b (LPS, BAFF, TGFβ) (C) and IgA (LPS, BAFF, TGFβ, IL-5) (D) positive 
cells of Pdap1F/F Cd19Cre/+, Pdap1+/+ Cd19Cre/+ and Pdap1F/F Cd19+/+ splenocytes stimulated for 
the indicated time points. Right: Graph summarizing the data of at least six mice per time point 
and per genotype. Significance was calculated with the Mann-Whitney U test and error bars 
represent SD. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001. 
To further understand if the CSR defect shown in PDAP1-deficient cultured splenocytes 
was a reflect of a defective immune response in vivo, the percentage of IgA positive cells 
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was determined in the Peyer’s Patches of control and PDAP1-deficient B-lymphocytes. 
As a result of continuous exposure to food, Peyer’s Patches (located in the intestine) 
exhibit GC formation, thus containing B cells that undergo SHM and CSR to IgA261. In 
agreement with the data obtained ex vivo, B-lymphocytes displayed a significant 
reduction in IgA in the absence of PDAP1 as compared to control. Surprisingly, PDAP1-
deficient mice also showed a decrease in the percentage of GC B cells. Conclusively, 
these data evidenced that PDAP1 is required for effective CSR in vivo (Figure 4.25).    
 
 
Figure 4.25. PDAP1 is required for efficient CSR in vivo. 
A-D. Left: Representative flow cytometry plots showing the percentage of germinal center (GC) 
B cells (CD19+ B220+ CD38- Fas+) and IgA positive splenocytes in Peyer’s Patches (PP) of 
unimmunized mice. Right: Graph summarizing the data of at least five mice per genotype in two 
independent experiments. Significance was calculated with the Mann-Whitney U test and error 
bars represent SD. *p ≤ 0.05, **p ≤ 0.01. 
 
4.3.2. PDAP1 is largely dispensable for B cell proliferation 
To determine if the CSR reduction observed in PDAP1-deficient cells is due to a defect 
in B cell proliferation, splenocytes were labeled with Cell Trace Violet (CTV) and cultured 
in the presence of different cytokine mixes. The CTV dilution profiles of Pdap1F/FCd19Cre/+ 
B cells were comparable to those from WT at all time points measured under all 
stimulation conditions (Figure 4.26A-D). Furthermore, CSR was reduced in all cell cycle 
divisions upon PDAP1 deletion (Figure 4.26E). Therefore, these data proved that 




Figure 4.26. PDAP1 is dispensable for B cell proliferation. 
A-D. Representative histogram flow cytometry plots showing Cell Trace Violet (CTV) dilution of 
labeled splenocytes of the indicated genotypes stimulated for 48, 72 and 96 h in the presence of 
LPS and IL-4 (A), LPS, (B) LPS, TGFβ and BAFF (C) and LPS, TGFβ, BAFF and IL-5 (D). Data 
were derived from at least two mice per genotype. E. Flow cytometry analysis indicating the 
percentage of IgG1 positive cells in each cell division as measured by CTV dye dilution. Primary 
B-lymphocytes were isolated from mice of the indicated genotypes and cultured for 72 h with LPS 
and IL-4. Data are representative of two independent experiments with at least three mice per 
genotype.   
 
4.3.3. PDAP1 is required for efficient AID expression 
Transcription across the donor (Sμ) and acceptor S regions together with the 
transcription and expression of the two Aicda copies are a requisite for productive 
CSR70,255,256. To determine if PDAP1 regulates any of these processes, GLT and Aicda 
levels were measured by RT-qPCR analysis in splenocytes activated in vitro to undergo 
CSR to different isotypes. Whereas GLT of the donor Sμ region was unaffected, 
Pdap1F/F-Cd19Cre/+ B cells exhibited a differential post-spliced germline transcript 
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expression depending on the switching conditions: Igγ1 and Igα GLT were significantly 
reduced in the absence of PDAP1; Igγ3 transcript was also decreased, although the 
effect was not as pronounced as in Igγ1 and Igα; and, lastly, Igγ2b GLT levels were 
comparable to control cells (Figure 4.27A-B). Moreover, a consistent two-fold reduction 
of Aicda mRNA levels were observed in PDAP1-deficient splenocytes switching to all 
isotypes tested (IgG1, IgG3, IgG2b and IgA) (Figure 4.27C). Notably, this decrease in 
AID upon PDAP1 deficiency was also observed at the protein level (Figure 4.27D). 
 
 
Figure 4.27. PDAP1 is required for efficient AID expression. 
A-C. Graphs summarizing RT-qPCR analysis for GLT levels of post-spliced Igμ (A) and Igγ1, 
Igγ3, Igγ2b and Igα (B) and Aicda mRNA levels (A) in primary B-lymphocytes stimulated to 
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undergo CSR to IgG1 (LPS and IL-4), IgG3 (LPS), IgG2b (LPS, TGFβ and BAFF) and IgA (LPS, 
TGFβ, BAFF and IL-5) for 48 h. Significance was calculated with the Mann-Whitney U test and 
error bars represent SD. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. D. WB analysis of WCE of splenocytes 
of the indicated genotypes cultured in the presence of LPS and IL-4 for 48 h. Triangles represent 
threefold dilution.   
 
In order to confirm that the CSR defect of Pdap1F/FCd19Cre/+ B cells is due to reduced 
AID expression, AID was overexpressed in these cells to assess if CSR levels could be 
rescued. Specifically, primary B cell cultures were infected with a plasmid containing the 
cDNA of Aicda fused to the hormone-binding domain of the modified estrogen receptor 
(AID-ER). Upon tamoxifen treatment (4-hydroxytamoxifen, 4-HT), AID translocates into 
the nucleus to mediate CSR84. Considering that AID targeting is dependent on GLT, this 
experiment was performed both in IgG1 (where a decrease in Igγ1 transcription was 
observed) and IgG2b (where GLT was not affected) conditions (Figure 4.27B). 
Moreover, AID-deficient primary B cells were included as a positive control, which 
underwent CSR only when infected with the AID-ER plasmid and treated with tamoxifen 
(Figure 4.28). The CSR defect in Pdap1F/F-Cd19Cre/+ cells was rescued to similar levels 
as in AID-ER-reconstituted Aicda-/- splenocytes when inducing AID overexpression in the 
nucleus of IgG2b- but not of IgG1-activated cells. This result could be explained by the 
differential effect of PDAP1-deficiency in Igγ1 and Igγ2b GLT (Figure 4.27B). Altogether, 
these data indicated that PDAP1 deficiency impairs AID expression and, consequently, 
antibody isotype differentiation. 
 
 
Figure 4.28. AID overexpression rescues IgG2b CSR. 
A-C. Graph summarizing the percentage of IgG2b (left) and IgG1 (right) positive cells after 
retroviral infection of splenocytes of the indicated genotypes with empty vector (EV) or AID-ER 
(AID cDNA fused to the estrogen receptor) constructs. Cells were stimulated to undergo CSR to 
for 96 h. Tamoxifen (4-HT) treatment was done for 24 h. Data are representative of four 
independent experiments with at least four mice per genotype.  Significance was calculated with 





4.3.4. PDAP1 supports efficient SHM of Ig loci 
SHM is a physiological process that is also dependent on AID and Aicda+/- mice exhibit 
defects in both, CSR and SHM255,256. In order to assess if the reduction in AID expression 
observed in PDAP1-deficient cells also leads to a decrease in SHM, the number of 
mutations in the Igh and Igk loci were quantified. Specifically, GC B cells from Peyer’s 
Patches of Pdap1F/FCd19Cre/+ and control aged mice were isolated and the intronic 
regions downstream JH4 and Jκ5 were amplified by PCR and sequenced259,260. Pdap1F/F-
Cd19Cre/+ cells showed a significant reduction in the number of mutated sequences and 
mutation frequency as compared to controls, both in the JH4 and Jκ5 downstream intronic 
regions. PDAP1-deficient GC B cells presented an increase in low-mutated sequences 
and a decrease in high mutation rates (more than 20) (Figure 4.29A-D). Furthermore, 
PDAP1 did not affect the distribution of nucleotide substitutions that result from AID 
function, confirming the role of PDAP1 in supporting AID expression rather than 
processing the processing of AID-induced lesions (Fig. 21E-F). These data evidenced 
that PDAP1 supports physiological levels of SHM of heavy and light chain Ig loci. 
Conclusively, PDAP1 is required for efficient antibody diversification by SHM and CSR 




Figure 4.29. AID is required for efficient SHM at Ig loci. 
A-B. Up: Graphs summarizing the number of mutations in the 3’JH4 intronic region over 510bp 
sequence (A) and in the 3’JK5 intronic region over 536bp sequence (B). Genomic DNA from non-
germinal center (NGC) and germinal center (GC) B cells from the Peyer’s Patches of un-
immunized aged mice was amplified, cloned and analyzed (four mice per genotype). Significance 
was calculated with the Mann-Whitney U test. **p ≤ 0.01, ****p ≤ 0.0001. Bottom: Tables listing 
the total number and length of analyzed sequences, as well as the number of mutations and 
mutation frequency at 3’JH4 (left) and 3’JK5 (right) intronic regions. (C-D) Graphs summarizing 
the percentage of sequences from panels (A) and (B) presenting the indicated number of 
mutations in 3’JH4 (C) and 3’JK5 (D). (E-F) Profiles of nucleotide substitutions at 3’JH4 (E) and 





4.3.5. PDAP1 is dispensable for the post-transcriptional regulation of Aicda 
mRNA 
AID expression is tightly regulated at the level of transcription, post-transcription, post-
translational modifications, cellular localization, and targeting to the S regions in order to 
prevent oncogenic chromosomal translocations (see section 1.8.2)20,168. Indeed, only a 
minimum amount of AID protein enters the nucleus upon activating conditions178–180. 
PDAP1 locates in the cytoplasm in primary B cells (data not shown) and, therefore, it 
might exert a post-transcriptional effect on Aicda mRNA. Moreover, since PDAP1 has 
been recently identified as an RNA binding protein, it could be associating to Aicda 
transcript, modulating AID expression242–246. To test this hypothesis, PDAP1-deficient 
and control splenocytes were isolated and cultured in the presence of Actinomycin D to 
inhibit de novo transcription. Alterations in mRNA capping, adenylation and stability 
would result in an accelerated mRNA decay, which can be quantified by qRT-PCR264. 
Cells were activated to undergo CSR to IgG1 and IgG2b for 48 h and then collected after 
1, 2, 3 and 4 h post-Actinomycin D treatment. Although PDAP1-deficient cells showed a 
~50% reduction in Aicda mRNA consistent with previous results (Figure 4.27), its decay 
rate was comparable to control cells (Figure 4.30A-B). This result suggested that 
PDAP1 is dispensable for Aicda mRNA stability, capping and adenylation. 
 
 
Figure 4.30. PDAP1 is dispensable for Aicda mRNA stability. 
A-B. Left: Graphs summarizing RT-qPCR analysis for Aicda mRNA levels in splenocytes cultured 
in the presence of LPS and IL-4 (A) or LPS, TGFβ and BAFF (B) for 48 h and treated with 
Actinomycin-D over the indicated times. Bottom: Linear regression analysis of data shown on the 
left panel as ln [RNA] versus time of Actinomycin-D treatment. 
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Importantly, several non-functional AID isoforms have been described in literature, being 
the full-length transcript the only splice form encoding a functional AID protein169,174,175. 
Consequently, PDAP1 could be regulating AID splicing, affecting its expression. To test 
this, RNA-sequencing was performed in splenocytes stimulated to undergo CSR to IgG1 
and IgG2b for 48 h and the differential exon usage of Aicda mRNA in PDAP1-deficient 
cells was compared to control cells. This method allows for the quantification of exon 
expression and identification of different isoforms in RNA-seq samples206. As an example 
and positive control of this analysis, the exon usage of Pdap1 mRNA was also 
determined. Pdap1 exon 2 expression was decreased in Pdap1F/F-Cd19Cre/+ cells, which 
agreed with the conditional mouse model strategy (Figure 4.22 and Figure 4.31A). 
Contrary, no difference in Aicda exon usage was observed upon PDAP1 deficiency, 
independently of the stimulation conditions (Figure 4.31B). Moreover, the unspliced 
Aicda mRNA was also quantified by RT-qPCR, comparing PDAP1-deficient and control 
cells. As for the spliced Aicda mRNA, Pdap1F/F-Cd19Cre/+ cells exhibited a significant 
reduction in the primary transcript (Figure 4.31C). Therefore, these data proved that 
PDAP1 is dispensable for the post-transcriptional regulation of Aicda mRNA. 
 
 
Figure 4.31. PDAP1 is dispensable for Aicda mRNA splicing. 
A-B. Analysis of exon usage of Pdap1 (A) and Aicda (B) genes in splenocytes activated to 
undergo CSR to IgG1 (LPS and IL-4) and to IgG2b (LPS, TGFβ and BAFF) for 48 h. A schematic 
 88 
representation of each locus is provided above. logFC, log fold change. C. RT-qPCR analysis for 
Aicda primary/unspliced transcript in splenocytes of the indicated genotypes stimulated with LPS 
for 48 h. Data is representative of at least four mice per genotype. One Cd19Cre/+ mouse within 
each experiment was assigned an arbitrary value of 1.  
 
4.3.6. PDAP1 deficiency leads to activation of the integrated stress response in 
primary B cells 
To further characterize the molecular mechanism of PDAP1 in antibody isotype 
differentiation, the transcriptome of Pdap1F/F-Cd19Cre/+ splenocytes was compared to 
Cd19Cre/+ control. Since a differential effect in the acceptor GLT was observed in PDAP1-
deficient cells depending on the activating conditions, RNA-seq was performed on 
primary B cell cultures treated with LPS and IL-4 (IgG1) and LPS, BAFF and TGFβ 
(IgG2b). Importantly, cells were collected 48 h post activation because most of the 
changes in the transcriptome happen early after CSR induction and before the BCR is 
expressed in the cell surface265. To identify the differentially expressed genes, the 
significance level of false discovery rate (FDR) was set to < 0.05. The number of 
differentially regulated genes was higher in LPS-IL-4-stimulated cultures than in LPS-
BAFF-TGF-activated cells (1227 versus 173). Furthermore, the number of genes up-
regulated in Pdap1F/FCd19Cre/+ was considerably higher than the down-regulated ones in 
LPS-BAFF-TGF-stimulated cultures (124 up- versus 49 down-regulated), but was 
evenly distributed among the two categories in the LPS-IL-4 stimulation condition (561 
up- versus 666 down-regulated) (Figure 4.32).  
 
 
Figure 4.32. Transcriptome analysis of PDAP1-deficient cells. 
Scatterplots of gene expression in Pdap1F/FCd19Cre/+ versus control (Cd19Cre/+) mature B cells 
stimulated with LPS and IL-4 (left) or LPS, BAFF, and TGF (right). Genes with an adjusted p-
value (FDR) < 0.05 that are up- or down-regulated in Pdap1F/FCd19Cre/+ cells are highlighted in 
red or purple, respectively. Data summarizes results from three mice per genotype per stimulation 
condition and is presented as log2(RPM) (reads per gene per million mapped sequence reads) 
values. 
 
PDAP1-deficient cells showed a reduction in Aicda and Ighg3 genes in both stimulation 
conditions, which is in agreement with previous RT-qPCR results (Figure 4.27B and 
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Figure 4.33B). Moreover, pathway enrichment analysis of the upregulated genes in 
Pdap1F/FCd19Cre/+ B cells in both conditions were related to metabolic pathways of amino 
acid and aminoacyl-tRNA biosynthesis. Indeed Asns, Cth, and Psat1 and Psph (required 
for the synthesis of asparagine, cysteine and serine, respectively) were found among the 
top upregulated genes together with several amino acid transporters (Slc1a4, Slc7a3 
and Slc6a9) upon PDAP1-deficiency (Figure 4.33A). These “metabolic signature” is 
characteristic of cells that undergo amino acid deprivation and activate the integrated 
stress response (ISR). Accordingly, ATF4, which is a main effector of the ISR, was also 
significantly upregulated in Pdap1F/FCd19Cre/+ B cells, both at the transcript and protein 
level (Figure 4.33B-C). Importantly, the ATF4 pathway has been shown to be 
suppressed in B-lymphocytes and induced only after activation. This was also observed 
in Cd19Cre/+ cells after 72 and 96 h of cytokine stimulation. In contrast, Pdap1F/FCd19Cre/+ 
splenocytes exhibited an increased ATF4 expression even in resting (unstimulating) 
conditions. Therefore, all these data indicated that PDAP1 deficiency causes activation 
of the ISR in B cells. What are the implications of this activated ISR and whether its 
induction is a direct consequence of PDAP1 depletion or if this factor is exerting an 





Figure 4.33. PDAP1 deficiency activates the integrated stress response. 
A. Pathway enrichment analysis (KEGG pathways) of the differentially regulated genes (FDR < 
0.05) from Figure 4.32. The number of differentially regulated genes in each category is indicated. 
B. Volcano plots displaying differentially expressed genes between control and Pdap1-deficient 
splenocytes activated with LPS and IL-4 or (left) or LPS, BAFF, and TGF (right). The red and 
purple dots represent transcripts up- and down-regulated in Pdap1F/FCd19Cre/+ cells, respectively, 
with FDR < 0.05 and expression fold change > 2 (up-regulated) or 1.7 (down-regulated) in both 
stimulation conditions. The names of the down-regulated and the 30 most significantly up-
regulated genes within each stimulation condition are indicated in each graph. The fold change 
threshold for down-regulated genes was set to 1.7 to include genes yielding a biologically relevant 
effect even with less pronounced variations in expression levels (e.g. Aicda, haploinsufficient 
gene). C. Representative WB analysis of splenocytes of the indicated genotypes before (resting 




5. DISCUSSION  
 
Upon antigen encounter in the secondary lymphoid organs, mature naïve B cells 
undergo SHM and CSR in order to produce antibodies that have high specificity for the 
antigen and different effector properties. These two processes are therefore essential for 
the establishment of an effective immune response and alterations in any of the two 
could cause immunodeficiency and/or cancerous genomic rearrangements. Although 
the molecular aspects of SHM and CSR have been extensively studied, the full picture 
of factors regulating antibody diversification in mature B cells is still missing. The loss-
of-CSR assay developed in this study represents a useful tool for the identification of 
novel players that contribute to mediate an effective immune response in B-lymphocytes. 
By applying this screening method, ZMYND8 and PDAP1 have been identified as novel 
CSR factors. Their contribution to Igh gene diversification has been dissected, thus 
providing new insights in the mechanisms that contribute to the generation of the 
antibody diversity.  
 
5.1 Advantages and caveats of the loss-of-CSR assay 
 
The setup of the loss-of-CSR assay allowed for rapid, robust and functional screening of 
potential candidates involved in antibody isotype differentiation. The characterization of 
multiple negative and positive controls ensured the establishment of a large dynamic 
range to perform the screen. Moreover, CH12 cells are an ideal model system for this 
purpose not just because it is the only available cell line that undergoes CSR with high 
efficiency, but also because these cells divide every 8-12 h189,216. The optimized 
conditions led to the identification of ZMYND8 and PDAP1 as positive hits in two 
independent screening rounds. Their role in CSR was later validated in CH12 KO clonal 
derivatives (ZMYND8-KO and PDAP1-KO) and in conditional mouse models (Zmynd8F/F-
Cd19Cre/+ and Pdap1F/F-Cd19Cre/+), which prove the robustness of the screen. 
Furthermore, ZMYND8 and PDAP1 were shown in this study to have different functions 
during CSR, evidencing the potential of the screen to reveal novel factors involved in 
different steps of antibody isotype differentiation. Of note, the majority of the tested 
candidates did not show any reduction in CSR and this could be due to several reasons. 
Firstly, the gRNAs used were designed using robust software tools that predicted off-
target effects and generated gene/sequence-specific gRNAs (www.crispr.mit.edu194 and 
CrispRGold195). However, these gRNAs were not experimentally tested for their targeting 
efficiency or off-target effects. To increase the chances of causing indels at the desired 
locus, 3-6 gRNAs per candidate were designed and electroporated together as a pool in 
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equal ratio. Nevertheless, this does not exclude the option that a negative result in the 
screen could be due to inefficient gRNA targeting. Secondly, it is possible that 
CRISPR/Cas9 mediated the deletion or truncation of a factor that is required for B cell 
proliferation. Consequently, positively targeted cells would have died, and the non-
targeted cells would have proliferated and led to physiological levels of CSR. Lastly, each 
factor displays its own turnover ratio. This implies that, even if the desired locus was 
efficiently targeted, the previously translated protein might had not been fully degraded 
when cells were activated to undergo CSR. Therefore, all these considerations imply that 
the negative hits in the screen could still be factors involved in antibody isotype 
differentiation.   
 
5.2 ZMYND8 function in Igh gene diversification 
 
5.2.1 ZMYND8-RIF1 interaction 
RIF1 has been shown to play a role in the repair phase of CSR by preventing DNA end 
resection and, therefore, supporting NHEJ. Consequently, Rif1-/- B-lymphocytes are 
unable to repair AID-induced breaks at the Igh locus. This leads to a major reduction in 
productive CSR (80-85%) but also to the accumulation of chromosome breaks, 
translocations and genomic instability96,97,100,137,138. Considering the relevance of RIF1 
function in CSR, a SILAC-based approach was set up in splenocytes stimulated ex vivo 
for the identification of novel interactors that could be regulating antibody isotype 
differentiation (Figure 4.2). In this context, ZMYND8 was found to be a RIF1 interacting 
partner and later shown to be required for efficient CSR (Figure 4.4, 4.7 and 4.8). 
Importantly, co-immunoprecipitation studies proved that, unlike phosphorylated 53BP1-
RIF1 association, this interaction is DNA-damage-independent (data not shown). 
ZMYND8 was dispensable for DSB repair, independently of the model system used 
(CH12, primary B-lymphocytes or iMEFs) and the source of DNA breaks (AID, Cas9, IR 
or PARPi) (Figure 4.11-13). Furthermore, RIF1-deficiency did not lead to an increase of 
RNAPII loading at the 3’ regulatory region as it was observed in Zmynd8-/- cells (Figure 
S3). Altogether, these findings indicate that ZMYND8 and RIF1 clearly have independent 
functions during antibody isotype differentiation. Consequently, it is possible that their 
interaction could be stochastic or not have any implication during CSR. On the other 
hand, RIF1 and ZMYND8 could potentially function together in CSR or other 
physiological processes independently from their role in DSB repair and 3’RR 
transcriptional regulation, respectively. In this context, it has been recently shown that 
53BP1-dependent RIF1 protection of DSB DNA ends is required but not essential for 
CSR to happen. Specifically, Trp53bp1-/- splenocytes complemented with a mutant 
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version of 53BP1 that is unable to recruit RIF1 and prevent DNA end resection upon 
DSB formation can undergo CSR to a considerable extent266. Also, an independent study 
showed that inhibition of CtIP, an endonuclease that resects DNA ends, does not rescue 
the CSR defect observed upon RIF1 deficiency96. Lastly, several articles have pointed 
out the role of RIF1 in transcriptional regulation, both in mammals and yeast152–155,267–271. 
Altogether, these data support the interesting and novel idea that RIF1 presents an 
additional function in antibody isotype differentiation prior to DSB formation. In this 
regard, there might be other potential RIF1 interactors identified in the I-DIRT that may 
contribute to RIF1 additional function(s) in CSR. Moreover, it would be interesting to 
elucidate if RIF1-deficient splenocytes show a decrease in the number of AID-induced 
mutations. Another interesting approach to further study RIF1-ZMYND8 interaction 
would be to reconstitute ZMYND8-deficient primary B cells with the full length ZMYND8 
protein together with an array of mutant forms, measuring CSR levels and performing 
co-immunoprecipitation. This would characterize the domain of ZMYND8 that is required 
for its interaction with RIF1. Furthermore, this experiment would determine if any of the 
ZMYND8 mutants is able to rescue CSR. Of note, RIF1 is a large protein (2426 amino 
acids) compared to ZMYND8 (1235 amino acids), impeding the packaging of RIF1 
coding sequence into a retroviral vector and its transduction efficiency in B cells.   
 
5.2.2 ZMYND8 role in DNA repair 
Human ZMYND8 has been previously reported to support the recruitment of the NuRD 
complex to sites of DNA damage within transcriptionally active chromatin to promote 
transcriptional repression and subsequent repair by HR229–233. CSR is mediated by c-
NHEJ, so it is not surprising that ZMYND8 did not play a role in DSB repair in this context. 
However, no significant defect in cell survival or increased chromosomal aberrations 
were observed when comparing Zmynd8-/- to wt cells upon PARPi treatment (Figure 
4.12B-C). Importantly, the reduction in HR upon ZMYND8 deficiency previously 
described was partial and only observed upon simultaneous laser micro-irradiation 
(which induces massive DNA damage in a specific location) and PARP inhibition229,232. 
Indeed, the NuRD complex can still associate to target genes in the absence of 
ZMYND8. Recruitment of the different NuRD complex subunits to sites of DNA damage 
and subsequently DSB repair by HR are only partially reduced in ZMYND8-deficient 
cells232. Therefore, ZMYND8 seems to have a minor role in DNA repair that may not be 





5.2.3 Transcriptional regulation of the Igh 3’ RR 
This study evidences that increased transcription of the 3’RR has a negative effect in 
CSR. The murine 3’RR is a palindromic super-enhancer of 28 kb composed of four core 
enhancers. The 3’RR is involved in late B cell development and during the early steps of 
antibody isotype differentiation, specifically in GLT, chromatin accessibility, RNAPII 
loading and pausing and AID recruitment134. Moreover, this super-enhancer also 
promotes SHM at the variable region of the Igh locus (see section 1.6)24. Interestingly, 
ZMYND8 binds to the 3’RR and regulates its transcriptional status, acting as a repressor. 
ZMYND8-deficient mice showed increased RNAPII loading and enhancer transcription 
of the 3’RR (Figure 4.17-18), decreased CSR and GLT of acceptor S regions (Figure 
4.7, 4.8 and 4.16), and reduced SHM exclusively in the heavy chain locus (Figure 4.19). 
Therefore, some key aspects of previously published work about the 3’RR functions 
correlate with the described observations upon ZMYND8 deficiency and will be 
discussed more in more detail below.  
 
B cell development 
The 3’RR and specifically the hs4 core enhancer have been shown to regulate late B cell 
development, promoting the transition from immature to mature B cells and, supporting 
efficient Ig expression and B cell differentiation into the marginal zone compartment22–
25,129,132. ZMYND8 associates with the 3’RR and significantly represses RNAPII loading 
and transcription of hs1,2 and hs3b core enhancers (Figure 4.17-18 and S2). 
Zmynd8F/F-Cd19Cre/+ mice did not show any major defect in B cell development, which is 
in agreement with the fact that the hs4 region (crucial for B cell development) is 
unaffected in these mice (Figure 4.6). However, it is important to consider that Cre-
mediated Zmynd8 deletion is not fully efficient and this may impede to observe a 
phenotype in B cell development. Since Zmynd8-/- mice are likely lethal, this hypothesis 




The palindromic module of the 3’RR (hs3a-hs1,2-hs3b) regulates SHM of the heavy but 
not of the light chain129. Consequently, SHM of the Igh locus is severly defective in mice 
bearing the following mutations: Δ3’RR (complete absence of the super-enhancer),  
Δhs3a-hs1,2, Δhs3a-hs1,2-hs3b, ΔIRIS (altered palindromic structure of hs3a and hs1,2) 
and core-3’RR (lack of the packaging DNA that links the 4 core enhancers) (Figure 1.7) 
(see section 1.6)24,128,129,135. Likewise, ZMYND8 promotes SHM exclusively in the heavy 
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chain locus, supporting the idea that this factor plays a central role in the regulation of 
the 3’RR function in mature B-lymphocytes (Figure 4.19).  
 
Germline transcription of S regions 
While deletion of individual core enhancers does not affect CSR, removal of the entire 
3’RR completely abrogates GLT and antibody isotype differentiation to all isotypes22–
24,26,132–134. Δ3’RR partially reduces transcription of the donor Sμ region and totally 
abolishes the expression of acceptor S regions. Thus, it has been hypothesized that this 
super-enhancer regulates GLT and accessibility of the acceptor S regions, being Sμ less 
3’RR dependent134. ZMYND8 deficiency leads to decreased GLT of acceptor S regions, 
while transcription of the donor Sμ region is unaffected (Figure 4.15). This phenotype 
was also observed in cells presenting a combined deletion of hs3b and hs4 core 
enhancers (Δhs3b-hs4) or a replacement of hs1,2 with an actively transcribed neomycin 
cassette. In both cases, splenocytes showed diminished GLT of several acceptor S 
regions while preserving WT levels of Sμ transcription. However, these mutations did not 
affect IgG1 surface expression or γ1 GLT, which were significantly reduced in ZMYND8-
deficient cells (Figure 4.7A and 4.16)25,26.  
Importantly, the reduced GLT observed in 3’RR-deleted splenocytes correlated with a 
decrease in both, paused and elongating phosphorylated RNAPII (RNAPII-S5 and 
RNAPII-S2, respectively) at acceptor S regions134. This phenotype was different in 
ZMYND8-deficient cells, which showed reduced levels of γ1 GLT but not of RNAPII-S5 
at Igγ1 region. Of note, the decrease in γ1 GLT was determined by RT-qPCR (Figure 
4.16) and by GRO-seq analysis (global run-on sequencing), which measures nascent 
RNA species in isolated nuclei (data not shown). These two assays also confirmed the 
increased enhancer transcription of the 3’RR in ZMYND8-deficient splenocytes, which 
correlated with an increase in RNAPII-S5, compared to control cells. Therefore, 
transcription of acceptor S regions is reduced upon Zmynd8 deletion but RNAPII loading 
in these regions is unaffected. One possible explanation is that the increase in RNAPII 
loading at the 3’RR in ZMYND8-deficient cells leads to local competition of Igh 
transcription factors, biasing the positioning of the transcriptional machinery towards the 
3’RR and reducing its activity at the acceptor S regions. Alternatively, the rate of 
elongating RNAPII (RNAPII-S2) at acceptor S regions upon ZMYND8 deficiency could 
be reduced, explaining the decrease in GLT while preserving the amount of loaded 
polymerase (RNAPII-S5). In agreement with this idea, ZMYND8 has been shown to 
interact and recruit P-TEFb (positive transcription elongation factor b) that facilitates the 
release of paused RNAPII by mediating its phosphorylation at Ser2. Accordingly, 
ZMYND8-deficient cells present a decrease in p-TEFb recruitment to target genes226. 
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Therefore, it would be necessary to perform a RNAPII-S2 ChIP-seq to further dissect the 
molecular mechanism by which ZMYND8 mediates its function in GLT regulation and 
CSR.  
 
Igh chromatin architecture    
Chromatin organization of the heavy chain is crucial for efficient GLT and CSR to 
happen. Mature resting B cells exhibit a looped Igh locus, characterized by the contact 
of Eμ and the 3’RR. Cytokine stimulation leads to inducible transcription of a specific 
GLT promoter that is recruited to the Eμ-3’RR loop base, allowing transcription of the S 
region, AID targeting and CSR114,115. This architectural configuration is dependent on the 
3’RR, as combined deletion of core enhancers hs3b and hs4 impairs the loop formation 
in between Eμ and the 3’RR115. ZMYND8-deficiency leads to transcriptional de-
regulation of the 3’RR, which could lead to inefficient Igh looping. This would explain why 
increased transcription of this super-enhancer has a negative effect on GLT of acceptor 
S regions. Circularized chromosome conformation capture combined with sequencing 
(4C-seq) of ZMYND8-deficient splenocytes in resting conditions and also stimulated with 
LPS and IL-4 for 48 h did not show any difference in the interactions within the Igh locus 
compared to WT cells (data not shown). This result indicates that ZMYND8 is 
dispensable for the chromatin architecture of the Igh locus. Therefore, the transcriptional 
de-regulation of the 3’RR and GLT reduction caused by ZMYND8 deficiency does not 
correlate with a defect in Igh looping. Of note, the 4C-seq experiment was performed by 
using a region within the 3’RR as an anchor, and it has been previously discussed that 
the resolution of this assay can vary depending on the bait used272. Consequently, it 
would be interesting to repeat this analysis, using different bait locations in parallel and 
compare the results. An alternative could be anchoring Eμ, which has been widely used 
in previous studies to analyze the chromatin configuration of the Igh locus115,118,273. 
Additionally, it is possible that ZMYND8-deficiency leads to subtle chromatin 
architectural changes that may not be detectable by 4C but still able to disrupt the 3’RR 
function.  
 
5.2.4 ZMYND8 as a transcriptional repressor and activator 
Apart from being a transcriptional repressor, human ZMYND8 has been also shown to 
bind and recruit P-TEFb to transcription start sties (TSS) of active genes226. P-TEFb 
function is crucial to promote the transition from paused to elongating state of RNAPII 
and, therefore, reduced P-TEFb recruitment correlates with decreased transcription of 
target genes274. Moreover, human ZMYND8 can be found as a monomer or a dimer and 
it has been suggested to have different roles in transcription depending on its 
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configuration226. Specifically, monomeric ZMYND8 has been suggested to bind CHD4 to 
allow the NuRD complex recruitment to enhancers and promoters and transiently 
repress transcription during DNA repair of active genes. On the other hand, human 
ZMYND8 can also form homodimers, which preferentially associates to P-TEFb and 
positively regulates transcription226. Importantly, human ZMYND8 has been also 
reported to repress transcription at enhancers and super-enhancers through its 
interaction with KDM5C and independently of the NuRD complex in human cells227. 
Consequently, it is likely that ZMYND8 role in transcriptional regulation could be different 
depending on the chromatin element it binds and the different factors that is associating 
to. This implies that ZMYND8 could mediate transcriptional activation of the acceptor S 
regions while independently repressing the transcription of the 3’RR region. Therefore, 
it would be interesting to study if murine ZMYND8 binds to DNA elements (promoters 
and enhancers) within the Igh locus in distinctive mono-/oligomeric states and if it is 
interacting with different partners to promote transcriptional repression or activation. 
Moreover, in this study ZMYND8 was found to bind the putative enhancer element in 
between Cγ1 and Sγ2b, E. Although the function of this regulatory element is still 
elusive, it has been recently shown to be required for efficient CSR to some isotypes31. 
It would be then interesting to further characterize the role of this putative enhancer in 
mature B cells and the consequences of ZMYND8 binding to this region.  
 
5.2.5 Molecular mechanism of ZMYND8 function in CSR 
Taking into account all the phenotypical variances shown by the different mutants of the 
3’RR described in the literature and the fact that ZMYND8 preferentially represses the 
transcription of hs1,2 and hs3b core enhancers, it is not surprising that ZMYND8-
deficiency does not completely phenocopy all the aspects characteristic of 3’RR-deleted 
cells. In this study, a novel function for the chromatin reader ZMYND8 has been 
described as the first modulator of the 3’RR transcriptional activity. Specifically, ZMYND8 
supports GLT of acceptor S regions and CSR in vivo as well as efficient SHM of the Igh 
locus, which, as CSR, is also under the control of the 3’RR. ZMYND8 deficiency leads 
to increased transcription of this super-enhancer and the data favors the hypothesis that 
this de-regulation is responsible for the decreased transcription of acceptor S regions, 
CSR and SHM and the of the Igh locus (Figure 5.1) In agreement with this idea, 
replacement of single hs1,2 or hs3a or paired hs3b-hs4 core enhancers with a neomycin 
cassette that is actively transcribed affected GLT and CSR. On the other hand, individual 
deletion of the same modules did not have any effect on CSR and hs3b-hs4 abrogation 
resulted in a less severe defect in GLT and CSR than its replacement with a neomycin 
cassette25–27. However, further analyses need to be performed to support this link. A 
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possibility would be to use a catalytically inactive Cas9 (dCas9) fused to transcriptional 
effectors that can be guided to the chromatin for silencing or activating the 3’RR. 
Specifically, dCas9-KRAB could be targeted to the hs1,2 and hs3b regions to repress 
their overexpression in order to assess whether this would rescue the GLT and CSR 
defect of ZMYND8-deficient splenocytes. Alternatively, WT cells could be infected with 
dCas9-VP64 to overexpress the 3’RR and test if this causes a decrease in GLT and CSR 
as in Zmynd8 deleted B lymphocytes.  
 
 
Figure 5.1. Model for ZMYND8 function at the Igh locus. 
ZMYND8 binds to and regulates the activity of the 3’RR, controlling CSR and SHM. GLT and CSR 
to IgG1 are exemplified. Asterisks indicate mutations at the VDJ region as a consequence of 
SHM. 
 
5.3 PDAP1 role in B cell physiology  
 
5.3.1 PDAP1 regulation of Aicda expression and GLT 
In this study, PDAP1 was found to support efficient Aicda expression since PDAP1-
deficient splenocytes showed a ~50% reduction in Aicda mRNA levels (Figure 4.27C-
D). Consequently, CSR and SHM were significantly decreased upon Pdap1 deletion. 
These results are in agreement with previously published data revealing that Aicda is 
haploinsufficient. Accordingly, mice harboring only one functional Aicda allele show a 
defect in CSR and SHM255,256. Moreover, exogenous induction of AID expression in the 
nucleus of Pdap1-/- cells restored the decreased IgG2b surface expression to 
physiological levels (Figure 4.28). PDAP1 has been previously reported to bind RNA in 
human cell lines242–246 and, therefore, it may associate to Aicda transcript and regulate 
its splicing or stability. However, data resulted from this study conclusively indicated that 
PDAP1 is dispensable for the post-transcriptional regulation of Aicda mRNA (Figure 
4.30). Considering that PDAP1 localizes in the cytoplasm (Human Protein Atlas and data 
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not shown), it is likely that this factor is indirectly modulating Aicda transcription, rather 
than acting as a transcription factor. In support of this idea, RNA-seq analysis of primary 
B cell cultures undergoing CSR showed a significant increase of Trib3 transcript levels 
upon PDAP1 deficiency (Figure 4.33B). TRIB3 has been shown to act as an inhibitor of 
NF-κB dependent transcription, which is required for efficient AID expression (see 
section 1.8.2)275–278. Furthermore, PDAP1-deficient splenocytes displayed reduced Batf 
expression, and Batf has been reported to support Aicda and GLT of acceptor S regions 
(Figure 4.33B)279. This result is in agreement with the fact that Pdap1 deletion also leads 
to a decrease in GLT of several acceptor regions compared to control, although 
transcription of Igγ2b was unaffected (Figure 4.27B). These differential effect of PDAP1 
in GLT could explain why AID overexpression in PDAP1-deficient cells rescued the CSR 
defect to IgG2b but not to IgG1 (Figure 4.28).  Importantly, activation of germline 
promoters with different cytokine cocktail mixes leads to the recruitment of independent 
and distinct transcription factors to the Igh locus280,281. Consistently with this idea, IL-4 
activates STAT6 that associates with the Igγ1 and Igγ3 promoters whereas 
TGFβ stimulates SMADs and RUNX proteins, which promote Igγ2b transcription63,65. 
This implies that PDAP1 could be directly or indirectly regulating GLT of Igγ1 but not of 
Igγ2b. Although the currently available data suggests that PDAP1 is not a transcription 
factor, it would be interesting to determine its chromatin association profile in activated 
primary B cells to confirm this hypothesis. Moreover, it would be helpful to perform PAR-
CLIP (Photoactivatable-Ribonucleoside-Enhanced Crosslinking and 
Immunoprecipitation) in switching splenocytes in order to identify PDAP1 RNA binding 
sites and RNA interactome. This analysis would determine if PDAP1 is directly 
associating to Aicda mRNA and/or germline transcripts and would provide new insights 
to further characterize the role of PDAP1 in antibody isotype differentiation.  
 
5.3.2 PDAP1 and the integrated stress response 
PDAP1-deficiency is accompanied by the activation of the integrated stress response 
(ISR), as determined by RNA-seq signature of activated mature B-lymphocytes (Figure 
4.33). Importantly, ATF4 expression is induced as a consequence of amino-acid 
deprivation, oxidative stress and the unfolded protein response (UPR). ATF4 plays a 
major role supporting the transcription of stress-related genes and factors required for 
amino acid synthesis and transport, regulating the cell metabolism282–285. The UPR is 
crucial during an immune response for the differentiation of B-lymphocytes into antibody-
secreting plasma cells. Specifically, the immunoglobulin heavy and light chains are 
translocated into the endoplasmic reticulum (ER), where they are assembled to form 
functional molecules. As antibody production increases, the ER activates the UPR to 
 100 
augment its protein folding capacity286–289. The UPR comprises three branches that 
involve the activity of independent transducing factors during ER stress, promoting the 
transcription of UPR target genes. Upon stress, ATF6 translocates into the Golgi 
apparatus, where it is cleaved and, thus, is able to move to the nucleus and activate 
genes involved in protein folding. Independently, PERK dimerizes and is phosphorylated, 
allowing the subsequent phosphorylation of eIF2α and global translation inhibition. As a 
consequence of PERK and eIF2α phosphorylation, ATF4 translation is increased, which 
promotes the transcription of CHOP that is involved in apoptosis. Lastly, IRE1 undergoes 
oligomerization upon stress and cleaves a 26-nucleotide segment from the mRNA of 
Xbp1, a UPR-specific transcription factor. As a result, there is a shift in the reading frame 
of Xbp1 and this spliced version of the protein is translocated into the nucleus, where it 
induces the expression of target genes283. Importantly XBP1 is crucial for the expansion 
of the secretory pathway in plasma cells and Xbp1 deleted B-lymphocytes show reduced 
levels of antibody secretion compared to control cells. Moreover, BLIMP-1, encoded by 
Prdm1, has been reported to act upstream of XBP1 during plasma cell 
differentiation290,291. Interestingly, both Atf4 and Prdm1 transcripts were upregulated 
upon PDAP1 deficiency, indicating the potential role of PDAP1 in activating the stress 
response and plasma cell differentiation. PDAP1-deficient cells might over-activate the 
UPR, leading to an increase in the number of plasma cells and the levels of secreted 
antibodies. In agreement with this idea, there was a decrease in the percentage of 
germinal center (GC) B cells compared to control upon Pdap1 deletion (Figure 4.25). 
Therefore, it would be interesting to determine the levels of plasma cells in the bone 
marrow and spleen of PDAP1-deficient splenocytes as well as measuring the percentage 
of plasmablasts in activated primary B cell cultures. In this context, it would be also 
necessary to quantify the number of antibody secreting cells by ELISpot (enzyme-linked 
immunospot) and antibody titers in serum by ELISA. Furthermore, it would be interesting 
to assess the levels of spliced Xbp1 transcript and protein in PDAP1-deficient and control 
cells undergoing CSR. These analyses would elucidate if PDAP1 is playing a role during 
plasma cell differentiation. 
 
Recent literature show that B cells suffer broad metabolic changes during activation, 
including the upregulation of oxidative phosphorylation (OXPHOS), tricaboxylic acid 
cycle (TCA) and nucleotide biosynthesis292–297. Stimulated B cells also modify their 
mitochondrial mass, membrane potential and architecture, changing from few elongated 
mitochondria with multiple nucleoids to multiple rounded mitochondria with a single 
nucleoid296,298.  Moreover, mitochondrial stress has been shown to inhibit components 
necessary for OXPHOS and to promote the induction of ATF4 together with its 
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downstream targets, which mediate the ISR. Specifically, ATF4 supports the expression 
of several amino-acid transporters (SLC6A9, SLC1A4, SLC7A3, SLC1A5, SLC7A11), 
enzymes involved in the synthesis of amino-acids (ASNS, PSPH, PHGDH, GPT2, PCK2) 
and enzymes required for mitochondrial one-carbon metabolism and glutathione 
degradation (ALDH1L2 and CHAC1). This leads to metabolic reprogramming of the cell 
that ensures adaptation to stress299. In agreement to this, ATF4 has been reported to 
play a major role in metabolic remodeling of activated CD4+ T cells300. Importantly, ATF4 
also promotes cell death during persistent ISR by activating downstream pro-apoptotic 
targets, such as CHOP and TRIB3301–304. Considering that ATF4 and the majority of 
these factors are upregulated in stimulated PDAP1-deficient splenocytes, it is possible 
that PDAP1 supports mitochondrial function, ensuring survival and activity of mature B 
cells. This hypothesis could explain the decrease in the number of mature splenocytes 
and the reduction in GC B cells upon Pdap1 deletion (Figure 4.23C and 4.25). However, 
further studies need to be performed to confirm this hypothesis. Specifically, it would be 
necessary to determine the rate of mitochondrial respiration (oxygen consumption rate, 
OCR) and the level of glycolysis (extracellular acidification rate, ECAR) in naïve and 
activated PDAP1-deficient cells. These parameters, together with an additional array of 
measurements that can be obtained by using the Seahorse Analyzer could provide an 
insight into the mitochondrial functioning of Pdap1 deleted B cells, compared to control. 
Furthermore, it would be worth quantifying the level of apoptosis and cell number of 
PDAP1-deficient and control splenocytes following activation to undergo CSR as well as 
characterizing the expression and signaling of the effectors of the ISR.  
 
Conclusively, activation of the ISR in PDAP1-deficient cells could have different 
outcomes in B cell fate and function. Further analyses need to be performed to determine 
what are the cause/s and consequences of the induction of this stress response and 
what is the link to the reduced number of GC B cells, Aicda mRNA expression, CSR and 











CONCLUSION AND FUTURE OUTLOOK 
 
Altogether, the identification and characterization of novel CSR factors provide valuable 
information about the requirements for the establishment of an efficient immune 
response and further increase our knowledge about B cell development and functioning. 
Apart from the points discussed above, this study opened several questions and new 
lines of research: 
- Investigating the potential novel role of RIF1 in CSR before DSB repair. 
- Further defining the mechanism of ZMYND8 function in the Igh locus 
transcription. 
- Studying the implications of the 3’RR overactivation in B cell development and 
function. 
- Understanding the role of PDAP1 in CSR. 
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Figure S1. Sµ-Sγ1 junction recombination analysis in Zmynd8F/FCd19Cre/+ and control B 
cells. 
Blunt junctions are indicated with “:”, micro-homology in bold, mutations in italics, and nucleotide 
additions are underlined. Micro-homology at the junction was determined by identifying the 
longest region at the switch junction of perfect uninterrupted donor/acceptor identity. INS: 







Figure S2. RNA-seq analysis of ZMYND8-deficient CH12 cells. 
A. Heatmap showing Aicda, Zmynd8 and Igh 3’RR enhancers differential transcript expression 
as determined by RNA-seq in two control (WT bulk and a clonal derivative, WTc) and two 
Zmynd8-KO CH12 clones (KO1 and KO2). Expression counts are row-normalized by Z score. 
Data results from three replicates per sample. B. Graphs representing relative transcript levels of 
hs3a, hs3b, hs1,2 and hs4 in ZMYND8-deficient CH12 cells (blue) compared to controls (black). 
The adjusted p values were calculated with the Wald test and corrected for multiple testing with 


















Figure S3. RNAPII-S5 is increased at the 3’RR in ZMYND8- but not in RIF1-deficient 
CH12 cells. 
A. RNAPII-S5 ChIP-seq analysis at the Igh locus in WT, Zmynd8-/- and Rif1-/- CH12 cells. Cells 
were kept in complete RPMI (un-activated) or cultured in the presence of anti-CD40, TGF and 
IL4 (activated). B. Overlay of ChIP-seq tracks at Eμ and 3’RR enhancers. Regions were defined 
based on the location of ZMYND8 peaks from ZMYND8 ChIP-seq. C. RNAPII-S5 quantification 














Table 1. Genotyping primers 
 
Table 2. gRNA sequences 
 
gRNA Sequence (5’→3’) Reference 
Optimization loss-of-CSR screen 
gRandom GCGAGGTATTCGGCTCCGCG GeCKO (196)  
gRandom ATGTTGCAGTTCGGCTCGAT GeCKO (196) 
gRandom ACGTGTAAGGCGAACGCCTT  GeCKO (196) 
gAicda-1 CATGCCGTCCCTTGGCCCAG This study 
gAicda-2 TCCTCTTCACCACGTAGCAG This study 
gAicda-3 ACCTCCTGCTCACTGGACTT This study 
gAicda-4 GTGACGCGGTAACACCGGCC This study 
gAicda-5 CTATGACTGTGCCCGGCACG This study 
gAicda-6 TTCACAGAAGTAGAGGCGCG This study 
gAicda-7 TGCGGAGACTGCACCGCGCT This study 
gTrp53bp1-1 TGACGCGGGTGACGAGTGTA This study 
gTrp53bp1-2 CAGATGTTTATTATGTGGAT This study 
gTrp53bp1-3 GAGTGTACGGACTTCTCGAA This study 
gRif1-1 CTCCAGGGGGCTGCGACCTG This study 
gRif1-2 GGAAGACCCCTCGGTGCCTC This study 
gRif1-3 AAGTCTCCAGAAGCGGCTCC This study 
gRif1-4 GAAGACCCCTCGGTGCCTCC This study 
gRif1-5 ACTCTTAATGATACCATTCA This study 
gRif1-6 TGTGTGTACCAGGGCACTGT This study 








MDV_p240 (Fw) GTGCAAACGTGTTCAGTGG This study 
Pdap1F/F 
MDV_p223 (Fw) CTGGGGAAAAGGAGGCTCTG This study 
MDV_p313 (Fw) GTCCTATGATTGGACCAAC This study 
MDV_p226 (Rev) AACATACAGCCTGCCTTCCC This study 
Cd19Cre/+ 
p881 AACCAGTCAACACCCTTCC 193 
p882 CCAGACTAGATACAGACCAG 193 
p883 TCAGCTACACCAGAGACCGG 193 
Zmynd8-KO (Exon 4) 
MDV_p100 CCTTCTGAACTGCCCTTTATG This study 
MDV_p101 GAAGGAAGAGACAGGTAGATTC This study 
Zmynd8-KO (Exon 5) 
MDV_p102 GGAAGAAAAGAGAAAGGAGAGG This study 
MDV_p103 GCAAATGACTGCTCAGAAAC This study 
Pdap1-KO (Exon 4) 
MDV_p228 ATGGGCTGTCGGTGGCTTG This study 
MDV_p229 GCTGTATGTGTAGCTGGGAG This study 
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gRif1-7 TAGGCGTCCGTCTGCTCTCC This study 
Loss-of-CSR screen (potential RIF1 interactors) 
gAhnak-1 AACTCCCCTGCGGCCCGCAC This study 
gAhnak-2 ACTCCCCTGCGGCCCGCACT This study 
gAhnak-3 GGCTTGAAGTTGCACCGTAA This study 
gAhnak-4 AACTCCCCTGCGGCCCGCAC This study 
gAhnak-5 ACCACCCCAGTGCGGGCCGC This study 
gAhnak-6 CTGGGCAATGGTCAGCCCGT This study 
gCcdc124-1 GTTCTCGCCCTGGAACTTCT This study 
gCcdc124-2 AGTCGGCAGCTGCCCGAGCA This study 
gCcdc124-3 CCTTGGCGGGCGCCACACGT This study 
gCcdc124-4 CACAGATCGAGGACTCGCTG This study 
gCcdc124-5 GGACAAACACGTGATGCGGA This study 
gCcdc124-6 CCCACGTGTGGCGCCCGCCA This study 
gDynll1-1 GGAGAAGTACAACATCGAGA This study 
gDynll1-2 CATGTCGGAAGAGATGCAAC This study 
gDynll1-3 CATTTTTGATCACCGCCTTC This study 
gDynll1-4 ACAAGAAGTACAACCCTACC This study 
gDynll1-5 CAACATCGAGAAGGATATTG This study 
gDynll1-6 TGCATTGTGGGCCGAAACTT This study 
gLas1l-1 TGGATCGCGTGTGGCGTGCG This study 
gLas1l-2 CCAAGAGACGACGATACCCC This study 
gLas1l-3 CGCTGAACCGAATTACAGTA This study 
gLas1l-4 CATCGATGCAGCCGGTACCT This study 
gLas1l-5 CGATGAGCTTGCATCTTACC This study 
gLas1l-6 GATGAACTTAGACTGCTCTA This study 
gMga-1 CCTTCCGGCTGATTGTACTG This study 
gMga-2 CTTCCGGCTGATTGTACTGT This study 
gMga-3 TCCTCACCATCAAACCCGAA This study 
gMga-4 AAGTTTCCATTCGGGTTTGA This study 
gMga-5 TCCATTCGGGTTTGATGGTG This study 
gNaa50-1 TCACATCTCCCAGCTCGATC This study 
gNaa50-2 ACAGTTGAAGAGACTGAACC This study 
gNaa50-3 CTTGCACCTTACCGAAGACT This study 
gNaa50-4 CTAGTCTTCGGTAAGGTGCA This study 
gNaa50-5 ATTCTACAAGGATGTGCTAG This study 
gNaa50-6 CTGTAGGTGCAGTGTGCTGC This study 
gPyhin1-1 AAAGGACACGGACAGGGAAA This study 
gPyhin1-2 CATTTGTGGTGGACATAGGT This study 
gPyhin1-3 GGTGTACTCCTCCCTGATTC This study 
gPyhin1-4 ATACTGCTGGACGGTCTTTT This study 
gPyhin1-5 AAGACCGTCCAGCAGTATTC This study 
gPyhin1-6 CTAGAGGAACTCCTAGTGCC This study 
gRnf2-1 AGTTCCCATGTTTTGCTTAA This study 
gRnf2-2 GTGTTTACATCGGTTTTGCG This study 
gRnf2-3 AGTGCATCAAAGTTCGGGTC This study 
gRnf2-4 TGATGAGTATGAAGCGCATC This study 
gRnf2-5 CTAGTCTTCGGTAAGGTGCA This study 
gRnf2-6 CTGTAGGTGCAGTGTGCTGC This study 
gTex10-1 CTATCCTCTTTAAGTTGTTC This study 
gTex10-2 GCTGTAGCATTTTCTAACTT This study 
gTex10-3 TTTGCCTGAACAACTTAAAG This study 
gTex10-4 AATGTGTTCAGTTCGTATTT This study 
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gTex10-5 TGAGAAGTGACTCTCCGATT This study 
gTex10-6 GCAACTCCATTTTTATCAAC This study 
gTlk2-1 CAGTTAGCGCCACGGGGAGC This study 
gTlk2-2 CACAGAGCAGTTAGCGCCAC This study 
gTlk2-3 TAAAGTGGCCTAATCGCAAT This study 
gTlk2-4 GAGCCTCGTTTACTGAGCAG This study 
gTlk2-5 CGAGCAGAACAGCCTCTGTA This study 
gTlk2-6 ATGCAGGACCGATTGCGATT This study 
gZmynd8-1 AGAAAACGGCCCCGAAACGG This study 
gZmynd8-2 AAGTCATTCCGTCCGTCCTG This study 
gZmynd8-3 GCTGGGGAACCTCCGTTTCG This study 
gZmynd8-4 TTGGGGCGAATGGCCATTGG This study 
gZmynd8-5 TGGGGCTCGTGGATGAGTCT This study 
gZmynd8-6 GACACTTAGCGTGATAAACC This study 
gZfp592-1 TTCAAACGACTCTTGGCGGC This study 
gZfp592-2 ACTTGTGTGCATGGATCCGC This study 
gZfp592-3 CCATGGTGTTCCCCGGAACG This study 
gZranb2-1 TCCGAGTCAGTGACGGGGAC This study 
gZranb2-2 AATTTCCGAGTCAGTGACG This study 
gZranb2-3 TCGACCACATCTGTTACAGC This study 
gZranb2-4 GTGGAAATGTAAACTTTGCT This study 
gZranb2-5 CATTGGCACTAAATAAGCCC This study 
gZranb2-6 GCTTATTTAGTGCCAATGAT This study 
Loss-of-CSR screen (potential 53BP1 interactors) 
gPdap1-1 AGTGAGGCAGTATACGAGCC This study 
gPdap1-2 CATTGAGAACCCCAACCGCG This study 
gPdap1-3 ACTGGATCTGGACGGGCCAA This study 
gMrpl14-1 GATGACTCGGGTCCGAGTAG This study 
gMrpl14-2 CACCGGGGTGGCCGATGGTA This study 
gMrpl14-3 TTATAGACGTGGATGCACCG This study 
gEif4g2-1 TAGAGTTGCGAGAGCACCAT This study 
gEif4g2-2 TGCTCAGCTATGTCTGCGAT This study 
gEif4g2-3 CATTTCTGAGCGTTTTGCCC This study 
gDdx18-1 TGCAATACTAAGGGACCTTC This study 
gDdx18-2 TTTGTGTCTTTTTAGCCCGT This study 
gDdx18-3 GCCATCACCTGTCAGTCCTA This study 
gSec61a1-1 CAGGTGGAATAGCGCTATGA This study 
gSec61a1-2 ATAAGACCGGAGGTGACAAT This study 
gSec61a1-3 ATCAAGTCGGCGCGTTACCG This study 
gDdx47-1 GGACCAGGGCGAACAGTCGC This study 
gDdx47-2 AAGTGGTCAATCAGTCGGCC This study 
gDdx47-3 GACTCACCTATTACTATATG This study 
gChtop-1 TCCCCCACGTAGTCCTCCTC This study 
gChtop-2 CAGAGAGGCTTGCCCCGAGG This study 
gChtop-3 GTCCCCCACGTAGTCCTCCT This study 
gPa2g4-1 CCCAGGGGTGCTTCGATCTT This study 
gPa2g4-2 GCCTTACGACTGGTCAAACC This study 
gPa2g4-3 TCCAGGTTTGACCAGTCGTA This study 
gRsl1d1-1 TTACTGATGCGAGAATTCGA This study 
gRsl1d1-2 CAGCTGTAAAAGAGCGGTCG This study 
gRsl1d1-3 TCCAGCTGTAAAAGAGCGGT This study 
gTopbp1-1 GAGATTATGATGACGACGTG This study 
gTopbp1-2 GACTCTACAGTTCGTGAAGA This study 
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gTopbp1-3 CGTGCTTAGCCGTGAGTTGC This study 
gUsp10-1 GCAGAACTGCACACCGACGA This study 
gUsp10-2 TGCCGGCGGCCTTGGTCAGA This study 
gUsp10-3 GGCATGGCCGTTGACCAGGG This study 
gFus-1 TCTGTTTTCTTGTAGCTACG This study 
gFus-2 TCCAGCGGAAGTGACCGCGG This study 
gFus-3 TTCTCCAGCGGAAGTGACCG This study 
gG3bp1-1 GCACACCTGTGCAACATGTC This study 
gG3bp1-2 CAGACCCTTACCTGTGACGC This study 
gG3bp1-3 AGCAACATACCTCAGGAGCA This study 
gFam76b-1 CACGCAGCGCTACCCCTTCG This study 
gFam76b-2 CCCTGCGAGAGCTCCTCGAA This study 
gFam76b-3 CCCTTCGAGGAGCTCTCGCA This study 
gTaf15-1 CAAACGACTGATTCTTCGTA This study 
gTaf15-2 ATGACCGTCGTGATGTGAGT This study 
gTaf15-3 CATACCTACTCACATCACGA This study 
gSnd1-1 GGTGCGCCATAATTGTCCGA This study 
gSnd1-2 GGTCAATTGCAGTTTACACC This study 
gSnd1-3 ACGATGCCCCGCTGCACGGT This study 
gPabpc1l-1 TACAATGAACATGGATCGCG This study 
gPabpc1l-2 GGAAAGGATATTGCCGATCG This study 
gPabpc1l-3 TGCCCATACCAGACTTCCGA This study 
gGtf2h2-1 GTAGATGCGCCACCTGTATG This study 
gGtf2h2-2 CTTAAGGAATTATAGAGCGA This study 
gGtf2h2-3 GGTGGATGGATCGAGAACAA This study 
gInts10-1 CACACTGGACCCGACCGGGA This study 
gInts10-2 ATCCCACATCGTCGACCCCT This study 
gInts10-3 GAATTTCCCGGACCAGCCGG This study 
gNaca-1 CACCTACCTGTCTCAGCCTG This study 
gNaca-2 TTATTCCCTTCAGAAATGCC This study 
gNaca-3 TGTAGCAGGGACGGTTTCTG This study 
gRpl22-1 ATACTCCTAGAAAAAGCTTG This study 
gRpl22-2 CAGAATGTCACTTACAAAAT This study 
gRpl22-3 CTAGAAAAAGCTTGTGGCGA This study 
gSec61a2-1 GCTACAGAAGGGTTACGGCT This study 
gSec61a2-2 ATTTCCCCAATTGTAACGTC This study 
gSec61a2-3 ATTAAGTCGGCACGGTATCG This study 
gCcdc124-1 CTCACGGCTCAAAGGCGGCA This study 
gCcdc124-2 CTTCCTGCAGGCGCCGGTTA This study 
gCcdc124-3 CACAGATCGAGGACTCGCTG This study 
gMtdh1-1 GAAGGAGCCCGCCCCGCAAA This study 
gMtdh1-2 ACGGACTGTTGAAGTACCCG This study 
gMtdh1-3 ACCCAGCCCGGGTACCGCTT This study 
gSub1-1 GTCAGTGTTCGGGACTTCAA This study 
gSub1-2 TTGCCTGTTTTAAGTTAAAG This study 
gSub1-3 TGCTTCTTCACGGGCTTCTC This study 
gTrip12-1 AGTATAAACTCGTCCCAGAG This study 
gTrip12-2 CTACAACAGCAGATGACCGG This study 
gTrip12-3 TGTTACAGTCGGCGAGGCTC This study 
gAbcf2-1 GCCCGACAGCGACCCAGAAA This study 
gAbcf2-2 TCCATGCTGCTCTCGGCTAT This study 
gAbcf2-3 TCTGGGTCGCTGTCGGGCTT This study 
gRrbp1-1 GCCACAGCGGATACACGCAC This study 
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gRrbp1-2 ACCAGTGCGTGTATCCGCTG This study 
gRrbp1-3 TTCATACGACGTCTCCTTCA This study 
gG3bp2-1 GCTAGCTAGCCTTACGTCAC This study 
gG3bp2-2 TCATACCAAAATTCGTCATG This study 
gG3bp2-3 GGTCGCTGTTCCCGTACACG This study 
gLarp4-1 CCATCAATGCTCACCTCTAC This study 
gLarp4-2 TTTGATCTTACCGATTTTTT This study 
gLarp4-3 ATGTTGGCAACCGTCCATAT This study 
gHnrnpa2b-1 GGCCCCATTCCATTGATGGC This study 
gHnrnpa2b-2 ACCCTGCCATCAATGGAATG This study 
gHnrnpa2b-3 AGCCACCAATAAAGAGCTTT This study 
gCaprin-1 CAGCATCCGGCAACCGGCAC This study 
gCaprin-2 GCGTAATCGACAAGAAACTT This study 
gCaprin-3 GCTTCTCAGCATCCGGCAAC This study 
gHnrnpa1-1 AATTAACGCACCTCTCTGAC This study 
gHnrnpa1-2 AATCTCTTTTAAGGTCGCAG This study 
gHnrnpa1-3 TTTTAAGGTCGCAGTGGTTC This study 
CH12 KO clonal derivatives 
gZmynd8-1 AGAAAACGGCCCCGAAACGG This study 
gZmynd8-2 AAGTCATTCCGTCCGTCCTG This study 
gZmynd8  



















gPdap1-1 AGTGAGGCAGTATACGAGCC  This study 
gPdap1-2 CATTGAGAACCCCAACCGCG  This study 
gPdap1-3 ACTGGATCTGGACGGGCCAA  This study 
gPdap1-4 GAAGGTCACGCAACTGGATC  This study 
gPdap1-5 TTGTCTGTGCCACGCGGTTG  This study 
gPdap1-6 GTTGTCTGTGCCACGCGGTT  This study 
 
Table 3. SHM primers 
 
Name Sequence (5’→3’) Reference 
JH4 
VHA (Fw) ARGCCTGGGRCTTCAGTGAAG 201 
VHE (Fw) GTGGAGTCTGGGGGAGGCTTA 201 
JH4_intron (Rev) CTCCACCAGACCTCTCTAGACAGC 201 
JK5 
VK (Fw) GGCTGCAGSTTCAGTGGCAGTGGRTCWGGRAC 
24 











Table 4. RT-qPCR primers 
 
Name Sequence (5’→3’) Reference 
Aicda 
AID-F (Fw) GAAAGTCACGCTGGAGACCG 203 
AID-R (Rev) TCTCATGCCGTCCCTTGG 203 
pre-spliced GLT γ1  
MDV_g1-3b (Fw) CAGGATCAATCCCAGCATTGGG  This study 
MDV_g1-1 (Rev) CTGTGCTTGGATCACCACACTTCC 202 
pre-spliced GLT γ3  
MDV_g3-3 (Fw) GTGGAACTCTAAGGTTTAGGAGTCAA 202 
MDV_g3-1 (Rev) CTGTGGCTGCTCAACTTGGTACCTT  This study 
pre-spliced GLT γ2b  
MDV_g2b-3 (Fw) GTTGACCTGACCTAGAGACTGGTGGAC 202 
MDV_g2b-1 (Rev) CTTTCTTTCAGCTTCATTCATGGAAC 202 
post-spliced GLT γ1   
Ig1 (Fw) GGCCCTTCCAGATCTTTGAG 53 
Cg1R (Rev) GGATCCAGAGTTCCAGGTCACT 53 
post-spliced GLT γ3  
Ig3F (Fw) TGGGCAAGTGGATCTGAACA 53 
Cg3R (Rev) CTCAGGGAAGTAGCCTTTGACA 53 
post-spliced GLT γ2b  
MDV_p243 (Fw) CACTGGGCCTTTCCAGAACTA 53 
MDV_p244 (Rev) CACTGAGCTGCTCATAGTGTAGAGTC 53 
post-spliced GLT μ  
ImF (Fw) CTCTGGCCCTGCTTATTGTTG 53 
CmR (Rev) GAAGACATTTGGGAAGGACTGACT 53 
post-spliced GLT α 
IaF (Fw)  CCTGGCTGTTCCCCTATGAA  53 
CaR (Rev)  GAGCTGGTGGGAGTGTCAGTG  53 
3’RR hs1,2 
MDV_p324 (Fw) CATTGAGCTCCGGCTCTAAC This study 
MDV_p325 (Rev) CAAGAGGACATGACAGGAGATG This study 
3’RR 5’ hs3b 
MDV_p314 (Fw) CATTGAGCTCCGGCTCTAAC This study 
MDV_p315 (Rev) CCCCTGTAGGGATCCTCCTAAT This study 
3’RR 3’ hs3b 
MDV_p316 (Fw) CATCCAGAGTCAAGGGGTGTC This study 
MDV_p317 (Rev) CTAGAACCACATGCTATCTAAGGGA This study 
Housekeeping 
Ubc_Fw GCCCAGTGTTACCACCAAGA  305  
Ubc_Rev CCCATCACACCCAAGAACA  305 
Gapdh_Fw TGTGTCCGTCGTGGATCTGA  305 
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Gapdh_Rev TTGCTGTTGAAGTCGCAGGAG  305 
 
Table 5. MutPE-seq primers 
 
Name Sequence (5’→3’) Reference 
First PCR 
QW_506 (Fw) TCTACACTCTTTCCCTACACGACGCTCTTCCGATCTTCTCTGAGTGCTTCTAAAATGCG 
93 
QW_507 (Rev) GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTTCACCCCAACACAGCGTAGC 
93 
Second PCR 








Table 6. Switch junction analysis primers 
 
Name Sequence (5’→3’) Reference 
First PCR 
5m3 (Fw) AATGGATACCTCAGTGGTTTTTAATGGTGGGTTTAATATAG 
96 
gamma1R (Rev) TGCCAATTAGCTCCTGCTCTTCTGTGG 96 
Second PCR 
5m3-1 (Fw) GGCTAAGAAGGCAATCCTGGGATTCTGG 96 
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3’Eκ   3’ kappa enhancer 
3’RR   3‘ regulatory region 
4-HT  4-hydroxytamoxifen 
4C-se circularized chromosome conformation capture combined with 
sequencing 
53BP1   p53-binding protein 1 
A   adenine 
ACK   ammonium-chloride-potassium 
AID   activation-induced deaminase   
alt-NHEJ  alternative non-homologous end-joining 
APE1/2  apurinic/apyrimidinic endonuclease 1/2 
ATM   ataxia telangiectasia mutated 
BAFF   B-cell activator of the TNF-α family 
BAFF-R  BAFF-receptor 
BCR   B cell receptor 
BER   base excision repair 
BLIMP-1  B-lymphocyte-induced maturation protein-1 
BM   bone marrow 
BRCA1  breast cancer 1 
BSA bovine serum albumin 
C   cytosine 
c-NHEJ  classical non-homologous end-joining 
CD40L   CD40 ligand 
CFSE   carboxyfluorescein succinimidyl ester 
ChIP-seq  chromatin immunoprecipitation combined with sequencing 
CLP   common lymphoid progenitor  
CMP   common myeloid progenitor  
CRISPR  clustered regularly interspaced short palindromic repeats 
CSR   class switch recombination 
CtIP   C-terminal-binding protein interacting protein 
Ctrl   control   
CTV   cell trace violet 
DDR   DNA damage response 
DMEM   Dulbecco’s modified eagle medium 
DNA-PKcs  DNA-PK catalytic subunit 
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DSB   double strand break 
ECAR extracellular acidification rate 
EDTA   ethylenediaminetetraacetic acid 
EIF4G2 eukaryotic translation initiation factor 4 gamma 2 
Eiκ   intronic kappa enhancer 
ELISA enzyme-linked immunosorbent assay 
ELISpot enzyme-linked immunospot 
ER endoplasmic reticulum 
eRNA   enhancer RNA 
EXO-1   exonuclease-1 
Eλ2-4   lambda 2-4 enhancer 
Eλ3-1   lambda 3-1 enhancer 
Eμ   enhancer μ region 
Fab   antigen binding fragment 
FBS   fetal bovine serum 
Fc   crystallizable fragment 
FDR   false discovery rate 
FL   full-length 
FO   follicular 
G   guanine 
GC   germinal center 
gDNA   genomic DNA 
GFP  green fluorescent protein 
GLT   germline transcription 
gRNA  guide RNA 
GRO-seq global run-on sequencing 
H2AX   H2A histone family member X 
HA hemagglutinin 
HEPES  4-(2-hydroxylethyl)-1-piperazineethanesulfonic acid 
HP1γ   heterochromatin protein 1 
HR   homologous recombination 
HRP horseradish peroxidase 
hs   DNase hypersensitive sites 
HSC   hematopoietic stem cell 
I-DIRT isotopic differentiation of interactions as random or targeted 
IFN-γ   interferon-γ 
Ig   immunoglobulin 
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IgH   immunoglobulin heavy chain 
IgL   immunoglobulin light chain 
IL-4   interleukin-4 
IL-5   interleukin-5 
iMEFs  immortalized mouse embryonic fibroblasts 
IR   ionized radiation 
IRES internal ribosome entry site 
ISR integrated stress response 
KAP1   KRAB domain-associated protein 1 
KO   knock-out 
LIG4   DNA ligase 4 
LLPC   long-lived plasma cell 
Log2FC  Log 2 fold change 
LPS   lipopolysaccharide 
MAD2L2  mitotic arrest deficient-like 2 
MDC1   mediator of DNA damage checkpoint 1 
MLL   mixed-lineage leukemia-like 
MMP   multipotent progenitor  
MMR   mismatch repair pathway 
MRE11  meiotic recombination 11 homolog A 
mRNA messenger RNA 
MSH2/MSH6  homologue of bacterial MutS 2/6 
MZ   marginal zone 
NBS1   Nijmegen breakage syndrome 1 
NES   nuclear export signal 
NF-κB   nuclear factor kappa beta 
NK   natural killer 
NLS   nuclear localization signal 
NP-CGG 4-Hydroxy-3-nitrophenylacetyl hapten conjugated to chicken 
gamma globulin 
OCR oxygen consumption rate 
OXPHOS oxidative phosphorylation 
P-TEFb positive transcription elongation factor b 
PAD   primary antibody deficiency 
PAMPs  pathogen-associated molecular patterns 
PARC-CLIP photoactivatable-ribonucleoside-enhanced crosslinking and 
immunoprecipitation 
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PARPi PARP inhibitor 
PB   plasmablast 
PBS   phosphate-buffered saline 
PCR  polymerase chain reaction 
PDAP1 platelet-derived growth factor-associated protein 1 
pre-B   precursor B cell 
pre-BCR  pre-B cell receptor 
pre-pro B cell  pre-progenitor B cell 
pro-B   progenitor B cell 
PTIP   pax interaction with transcription-activation domain protein 1 
RAG   recombination activating gene 
RIF1   replication timing regulatory factor 1 
RMP   reads per gene per million mapped sequence reads 
RNAPII  RNA polymerase II 
RNAPII-S2  RNA polymerase II – phosphorylated on serine 2 
RNAPII-S5  RNA polymerase II – phosphorylated on serine 5 
RNF168  ring finger protein 168 
RNF8   ring finger protein 8 
RPMI   Roswell Park Memorial Institute 
RS   recombining segment 
RSS   recombination signal sequence 
RT room temperature 
RT-qPCR quantitative reverse transcription PCR 
S3   serine-3 
S38   serine-38 
SDS   sodium dodecyl sulfate 
SHM   somatic hypermutation 
SILAC stable isotope labeling with amino acids in cell culture 
SLC   surrogate light chain 
SLPC   short-lived plasma cell 
SPF   specific pathogen-free 
SPT5   suppressor of Ty 5 homolog 
SSB   single strand break 
ssDNA   single-stranded DNA 
T   timine 
T1, T2 and T3  Transitional B cell populations 1, 2 and 3 
T140   threonine-140 
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TCA tricaboxylic acid cycle 
TD   T cell-dependent 
TGFβ   transforming growth factor β 
TI   T cell-independent 
TLR   toll-like receptors 
TSS transcription start sties 
UDR   ubiquitination-dependent recruitment 
UNG   uracil DNA-glycosilase 
UPR unfolded protein response 
V(D)J   variable, (diversity), joining 
WB   Western Blot 
WCE whole-cell-extracts  
WT   wild-type 
XLF   XRCC4-like factor 
XRCC4  X-ray repair cross complementing 4 
ZMYND8 zinc finger MYND-type (myeloid, nervy, and DEAF-1) containing 
8 
Κ   Kappa 
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